Nothing Special   »   [go: up one dir, main page]

US20070254299A1 - Fungal delta 12 desaturase and delta 15 desaturase motifs - Google Patents

Fungal delta 12 desaturase and delta 15 desaturase motifs Download PDF

Info

Publication number
US20070254299A1
US20070254299A1 US11/740,298 US74029807A US2007254299A1 US 20070254299 A1 US20070254299 A1 US 20070254299A1 US 74029807 A US74029807 A US 74029807A US 2007254299 A1 US2007254299 A1 US 2007254299A1
Authority
US
United States
Prior art keywords
desaturase
fungal
seq
polypeptide
motif
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/740,298
Inventor
Narendra S. Yadav
Hongxiang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/740,298 priority Critical patent/US20070254299A1/en
Assigned to E. I. DU PONT DE NEMOURS AND COMPANY reassignment E. I. DU PONT DE NEMOURS AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YADAV, NARENDRA S., ZHANG, HONGXIANG
Publication of US20070254299A1 publication Critical patent/US20070254299A1/en
Priority to US12/396,845 priority patent/US9057083B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6431—Linoleic acids [18:2[n-6]]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/001—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Definitions

  • This invention is in the field of biotechnology. More specifically, this invention pertains to the identification of nucleic acid fragments encoding fungal motifs indicative of ⁇ 15 fatty acid desaturase enzymes and ⁇ 12 fatty acid desaturase enzymes.
  • PUFAs long chain polyunsaturated fatty acids
  • certain PUFAs are important biological components of healthy cells and are recognized as: “essential” fatty acids that cannot be synthesized de novo in mammals and instead must be obtained either in the diet or derived by further desaturation and elongation of linoleic acid (LA;18:2 ⁇ -6) or ⁇ -linolenic acid (ALA; 18:3 ⁇ -3); constituents of plasma membranes of cells, where they may be found in such forms as phospholipids or triacylglycerols; necessary for proper development (particularly in the developing infant brain) and for tissue formation and repair; and, precursors to several biologically active eicosanoids of importance in mammals (e.g., prostacyclins, eicosanoids, leukotrienes, prostaglandins).
  • a variety of different hosts including plants, algae, fungi and yeast are being investigated as means for commercial PUFA production. Genetic engineering has demonstrated that the natural abilities of some hosts (even those natively limited to LA and ALA fatty acid production) can be substantially altered to result in high level production of e.g., arachidonic acid (ARA; 20:4 ⁇ -6), eicosapentaenoic acid (EPA; 20:5 ⁇ -3) and docosahexaenoic acid (DHA; 22:6 ⁇ -3) PUFAs.
  • ARA arachidonic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • both strategies may require conversion of oleic acid (18:1) to LA by the action of a ⁇ 12 desaturase; ⁇ -3 PUFA production is typically enhanced by the conversion of LA to ALA by the action of a ⁇ 15 desaturase.
  • Subsequent longer-chain PUFAs are generally synthesized via either the ⁇ 6 desaturase/ ⁇ 6 elongase pathway (which is predominantly found in algae, mosses, fungi, nematodes and humans and which is characterized by production of ⁇ -linoleic acid (GLA; 18:3 ⁇ -6) and/or stearidonic acid (STA; 18:4 ⁇ -3)) or the ⁇ 9 elongase/ ⁇ 8 desaturase pathway (which operates in some organisms, such as euglenoid species and which is characterized by production of eicosadienoic acid (EDA; 20:2 ⁇ -6) and/or eicosatrienoic acid (ETrA; 20:3 ⁇ -3)) ( FIG. 1 ).
  • GLA ⁇ -linoleic acid
  • STA stearidonic acid
  • EDA eicosadienoic acid
  • EDA eicosatrienoic acid
  • PCT Publication No. WO 2003/099216 (Monsanto Technology, LLC) teaches fungal sequences and their expression, and specifically includes data supporting the functional characterization of desaturases having ⁇ 15 activity from Neurospora crassa and Aspergillus nidulans, as well as some amino acid motifs derived thereof; a putative “ ⁇ 15 desaturase” sequence from Botrytis cinerea is also disclosed.
  • PCT Publication No. WO 2006/019192 describes the ⁇ 15 desaturase of Mortierella alpina. Additionally, Kainou et al. ( Yeast, 23(8):605-612 (2006)) and Murayama et al.
  • Applicants have solved the stated problem via a sequence of empirical steps comprising: (1) isolating a pool of ⁇ 12/ ⁇ 15 desaturase-like polypeptides of fungal origin; (2) developing a sequence-based means to distinguish fungal ⁇ 12 desaturases from fungal ⁇ 15 desaturases; and, (3) identifying a specific amino acid residue(s) that enables one to alter fungal desaturase enzyme activity, substrate specificity and ⁇ 12/ ⁇ 15 regiospecificity.
  • the invention relates to the discovery of motifs present in desaturases enzymes having either ⁇ 12 or ⁇ 15 desaturase activity.
  • the ⁇ 12 desaturase motifs are diagnostic for ⁇ 12 desaturase activity; and conversely, the ⁇ 15 desaturase motifs are diagnostic for ⁇ 15 desaturase activity.
  • the invention describes specific amino acid residues that, when altered, have the effect of altering the ⁇ 12 or ⁇ 15 desaturase specificity.
  • the invention provides a fungal ⁇ 12 desaturase motif having an amino acid sequence as set forth in SEQ ID NO:5.
  • Other preferred ⁇ 12 desaturase motifs are encompassed by the amino acid sequences of SEQ ID NOs:3 and 4.
  • the invention provides a fungal ⁇ 15 desaturase motif having an amino acid sequence as set forth in SEQ ID NO:48, where other preferred motifs have the amino acid motifs set forth in SEQ ID NOs:46 and 47.
  • the invention provides a method for identifying a fungal polypeptide having ⁇ 12 desaturase activity from a pool of ⁇ 12/ ⁇ 15 desaturase-like polypeptides comprising:
  • the invention provides a method for identifying a fungal polypeptide having ⁇ 15 desaturase activity from a pool of ⁇ 12/ ⁇ 15 desaturase-like polypeptides comprising:
  • the invention provides a fungal polypeptide having ⁇ 12 desaturase activity isolated by the methods of the invention, excluding ⁇ 12 desaturase polypeptides isolated from the following species: Saccharomyces kluyveri, Mortierella alpina, Fusarium graminearum, Fusarium moniliforme, Magnaporthe grisea, Neurospora crassa, Aspergillus nidulans, Mortierella isabellina, Pichia pastoris, Aspergillus parasiticus, Cryptococcus curvatus, Saprolegnia diclina, Yarrowia lipolytica, Lentinula edodes, Mucor circinelloides, Mucor rouxii, Rhizopus oryzae, Botrytis cinerea and Aspergillus flavus.
  • the invention provides an isolated fungal polypeptide having ⁇ 15 desaturase activity isolated by the methods of the invention, excluding ⁇ 15 desaturase polypeptides isolated from the following species: Saccharomyces kluyveri, Mortierella alpina, Aspergillus nidulans, Neurospora crassa, Fusarium graminearum, Fusarium moniliforme and Magnaporthe grisea.
  • the invention provides methods for obtaining nucleic acid molecules encoding the ⁇ 12 and ⁇ 15 desaturase polypeptides of the invention using primer directed amplification protocols or nucleic acid hybridization methods in combination with primers or probes having sequence homology based on the motifs disclosed herein against fungal libraries or genomic DNA.
  • the invention provides a method for increasing the ability of a bifunctional fungal ⁇ 12 desaturase enzyme to act on a ⁇ 15 desaturase substrate comprising:
  • the invention provides a method for the production of ⁇ -linolenic acid comprising:
  • the invention provides a method for identifying a polynucleotide sequence encoding a fungal polypeptide having ⁇ 15 desaturase activity comprising:
  • the invention provides a method for identifying an amino acid sequence of fungal polypeptide having ⁇ 12 desaturase activity comprising:
  • FIG. 1 illustrates the ⁇ -3/ ⁇ -6 fatty acid biosynthetic pathway.
  • FIG. 2 shows a phylogenetic tree of fungal ⁇ 12 desaturase and fungal ⁇ 15 desaturase proteins, created using the MegAlignTM program of DNASTAR software.
  • FIG. 4 provides plasmid maps for the following: (A) pY137; and, (B) pY117.
  • SEQ ID Nos:1-30 and 46-95 are motifs, regions of conserved amino acids or proteins encoding desaturases, as identified in Table 1.
  • XP_455402 Kluyveromyces lactis ⁇ 15 desaturase (GenBank 64 (415 AA) Accession No. XP_451551) Candida albicans SC5314 ⁇ 12 desaturase 65 (436 AA) (GenBank Accession No. EAK94955) Candida albicans SC5314 ⁇ 15 desaturase 66 (433 AA) (GenBank Accession No.
  • Candida guilliermondii ⁇ 12 desaturase 67 (417 AA)
  • Candida guilliermondii ⁇ 15 desaturase 68 (370 AA)
  • Candida tropicalis ⁇ 12 desaturase 69 (340 AA)
  • Candida tropicalis ⁇ 15 desaturase 70 (349 AA)
  • Candida lusitaniae ⁇ 12 desaturase 71 (418 AA)
  • Candida lusitaniae ⁇ 15 desaturase 72 (346 AA)
  • Debaryomyces hansenii CBS767 ⁇ 12 desaturase 73 (416 AA) (GenBank Accession No. CAG90237)
  • Debaryomyces hansenii CBS767 ⁇ 15 desaturase 74 (435 AA) (GenBank Accession No.
  • SEQ ID NOs:33-34 correspond to primers 519 and 520, respectively, used to PCR amplify Sk.d15 from Saccharomyces kluyveri.
  • SEQ ID NOs:35-36 correspond to primers 521 and 522, respectively, used to PCR amplify Dh.d15 from Debaryomyces hansenii CBS767.
  • SEQ ID NO:37 provides the amino acid sequence of the Saccharomyces kluyveri ⁇ 15 desaturase (i.e., Sk.d15) in plasmid pY107 Skd15.
  • SEQ ID NO:40 shows the DNA sequence of the Fusarium moniliforme ⁇ 12 desaturase gene, while SEQ ID NO:41 shows the corresponding amino acid sequence of the F. moniliforme ⁇ 12 desaturase (i.e., Fm.d12).
  • SEQ ID NOs:99 and 100 correspond to primers 633 and 634, respectively, used during site-directed mutagenesis of Yl.d12.
  • SEQ ID NO:101 provides the 6,267 bp nucleotide sequence of plasmid pY137.
  • SEQ ID NO:102 provides the 9,570 bp nucleotide sequence of plasmid pY117.
  • SEQ ID NO:103 provides the nucleic acid sequence of the Saccharomyces kluyveri ⁇ 15 desaturase (i.e., Sk.d15) in plasmid pY107 Skd15.
  • Patent Application No. 60/853,563 (filed Oct. 23, 2006), U.S. Patent Application No. 60/855,177 (filed Oct. 30, 2006), U.S. patent application Ser. No. 11/601,563 and Ser. No. 11/601,564 (filed Nov. 16, 2006), U.S. patent application Ser. No. 11/635,258 (filed Dec. 7, 2006) and U.S. patent application Ser. No. 11/613,420 (filed Dec. 20, 2006).
  • ⁇ 15 desaturases from Kluyveromyces lactis, Candida albicans, C. guilliermondii, C. tropicalis, C. lusitaniae, Debaryomyces hansenii CBS767, Aspergillus fumigatus, A. oryzae and Chaetomium globosum. Methods are also provided to readily distinguish fungal protein sequences having ⁇ 15 desaturase activity as opposed to ⁇ 12 desaturase activity, based on a single isoleucine/valine amino acid. Mutation of this specific residue has proven an effective means to alter enzyme substrate specificity or regioselectivity, such as towards ⁇ 12 desaturation or towards ⁇ 15 desaturation.
  • the invention relates to novel fungal ⁇ 12 and ⁇ 15 desaturase enzymes and genes encoding the same that may be used for the manipulation of biochemical pathways for the production of healthful PUFAs.
  • PUFAs, or derivatives thereof, made by the methodology disclosed herein can be used as dietary substitutes, or supplements, particularly infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition.
  • the purified PUFAs (or derivatives thereof) may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount for dietary supplementation.
  • the PUFAs may also be incorporated into infant formulas, nutritional supplements or other food products and may find use as anti-inflammatory or cholesterol lowering agents.
  • the compositions may be used for pharmaceutical use (human or veterinary).
  • Supplementation of humans or animals with PUFAs produced by recombinant means can result in increased levels of the added PUFAs, as well as their metabolic progeny.
  • treatment with EPA can result not only in increased levels of EPA, but also downstream products of EPA such as eicosanoids (i.e., prostaglandins, leukotrienes, thromboxanes).
  • eicosanoids i.e., prostaglandins, leukotrienes, thromboxanes.
  • Complex regulatory mechanisms can make it desirable to combine various PUFAs, or add different conjugates of PUFAs, in order to prevent, control or overcome such mechanisms to achieve the desired levels of specific PUFAs in an individual.
  • Fusarium moniliforme is synonymous with “ Fusarium verticillioides ” and is also synonymous with “ Gibberella fujikuroi ”. More specifically, the Fusarium moniliforme ⁇ 12 desaturase described herein as SEQ ID NO:41 (Fm.d12) is identical to the Gibberella fujikuroi ⁇ 12 desaturase described as GenBank Accession No. DQ272515 (SEQ ID NO:49 herein). Similarly, the Fusarium moniliforme ⁇ 15 desaturase described herein as SEQ ID NO:39 (Fm.d15) is identical to the Gibberella fujikuroi ⁇ 15 desaturase described as GenBank Accession No. DQ272516 (SEQ ID NO:50 herein).
  • Fusarium graminearium is synonymous with “ Gibberella zeae ”. More specifically, the Fusarium graminearium ⁇ 12 desaturase described herein as Fg.d12 is identical to the Gibberella zeae ⁇ 12 desaturase described as GenBank Accession No. EAA75859 (SEQ ID NO:57 herein). Similarly, the Fusarium graminearium ⁇ 15 desaturase described herein as Fg.d15 is identical to the partial Gibberella zeae ⁇ 15 desaturase fragment described as GenBank Accession No. BAA33772 (SEQ ID NO:58 herein).
  • invention or “present invention” as used herein is not meant to be limiting to any one specific embodiment of the invention but applies generally to any and all embodiments of the invention as described in the claims and specification.
  • fatty acids refers to long chain aliphatic acids (alkanoic acids) of varying chain lengths, from about C 12 to C 22 (although both longer and shorter chain-length acids are known). The predominant chain lengths are between C 16 and C 22 .
  • the structure of a fatty acid is represented by a simple notation system of “X:Y”, where X is the total number of carbon (C) atoms in the particular fatty acid and Y is the number of double bonds.
  • Nomenclature used to describe PUFAs in the present disclosure is shown below in Table 2.
  • the omega-reference system is used to indicate the number of carbons, the number of double bonds and the position of the double bond closest to the omega carbon, counting from the omega carbon (which is numbered 1 for this purpose).
  • the remainder of the Table summarizes the common names of ⁇ -3 and ⁇ -6 fatty acids and their precursors, the abbreviations that will be used throughout the specification and each compounds' chemical name.
  • triacylglycerol refers to neutral lipids composed of three fatty acyl residues esterified to a glycerol molecule (and such terms will be used interchangeably throughout the present disclosure herein).
  • oils can contain long chain PUFAs, as well as shorter saturated and unsaturated fatty acids and longer chain saturated fatty acids.
  • oil biosynthesis generically refers to the synthesis of TAGs in the cell.
  • Percent (%) PUFAs in the total lipid and oil fractions refers to the percent of PUFAs relative to the total fatty acids in those fractions.
  • PC phosphatidylcholine
  • PE phosphatidyletanolamine
  • TAG or oil triacylglycerol
  • a metabolic pathway, or biosynthetic pathway, in a biochemical sense can be regarded as a series of chemical reactions occurring within a cell, catalyzed by enzymes, to achieve either the formation of a metabolic product to be used or stored by the cell, or the initiation of another metabolic pathway (then called a flux generating step). Many of these pathways are elaborate, and involve a step by step modification of the initial substance to shape it into a product having the exact chemical structure desired.
  • PUFA biosynthetic pathway refers to a metabolic process that converts oleic acid to LA, EDA, GLA, DGLA, ARA, ALA, STA, ETrA, ETA, EPA, DPA and DHA. This process is well described in the literature (e.g., see PCT Publication No. WO2006/052870). Briefly, this process involves elongation of the carbon chain through the addition of carbon atoms and desaturation of the molecule through the addition of double bonds, via a series of special desaturation and elongation enzymes (i.e., “PUFA biosynthetic pathway enzymes”) present in the endoplasmic reticulim membrane.
  • PUFA biosynthetic pathway enzymes refer to any of the following enzymes (and genes which encode said enzymes) associated with the biosynthesis of a PUFA, including: a ⁇ 4 desaturase, a ⁇ 5 desaturase, a ⁇ 6 desaturase, a ⁇ 12 desaturase, a ⁇ 15 desaturase, a ⁇ 17 desaturase, a ⁇ 9 desaturase, a ⁇ 8 desaturase, a ⁇ 9 elongase, a C 14/16 elongase, a C 16/18 elongase, a C 18/20 elongase and/or a C 20/22 elongase.
  • ⁇ -3/ ⁇ -6 fatty acid biosynthetic pathway refers to a set of genes which, when expressed under the appropriate conditions encode enzymes that catalyze the production of either or both ⁇ -3 and ⁇ -6 fatty acids.
  • genes involved in the ⁇ -3/ ⁇ -6 fatty acid biosynthetic pathway encode PUFA biosynthetic pathway enzymes.
  • FIG. 1 A representative pathway is illustrated in FIG. 1 , providing for the conversion of myristic acid through various intermediates to DHA, which demonstrates how both ⁇ -3 and ⁇ -6 fatty acids may be produced from a common source. The pathway is naturally divided into two portions where one portion will generate ⁇ -3 fatty acids and the other portion, only ⁇ -6 fatty acids.
  • That portion that only generates ⁇ -3 fatty acids will be referred to herein as the ⁇ -3 fatty acid biosynthetic pathway, whereas that portion that generates only ⁇ -6 fatty acids will be referred to herein as the ⁇ -6 fatty acid biosynthetic pathway.
  • amplification refers to the process in which “replication” is repeated in cyclic process such that the number of copies of the nucleic acid sequence is increased in either a linear or logarithmic fashion.
  • replication processes may include but are not limited to, for example, Polymerase Chain Reaction (PCR) [(see, Thein and Wallace, “The use of oligonucleotide as specific hybridization probes in the Diagnosis of Genetic Disorders”, in Human Genetic Diseases: A Practical Approach, K. E. Davis Ed., (1986) pp 33-50, IRL: Herndon, Va.); and Rychlik, W. In, Methods in Molecular Biology, PCR Protocols: Current Methods and Applications. White, B. A., Ed. (1993), Vol.
  • PCR Polymerase Chain Reaction
  • primer directed nucleic acid amplification refers to any method known in the art wherein primers are used to sponsor replication of nucleic acid sequences in the linear or logarithmic amplification of nucleic acid molecules. Applicants contemplate that primer-directed amplification may be accomplished by any of several schemes known in this art, including but not limited to the polymerase chain reaction (PCR), ligase chain reaction (LCR) or strand-displacement amplification (SDA).
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • SDA strand-displacement amplification
  • amplification product refers to portions of nucleic acid fragments that are produced during a primer directed amplification reaction.
  • Typical methods of primer directed amplification include polymerase chain reaction (PCR), ligase chain reaction (LCR) or Strand displacement Amplification (SDA).
  • PCR polymerase chain reaction
  • LCR ligase chain reaction
  • SDA Strand displacement Amplification
  • the replication composition would include for example, nucleotide triphosphates, two primers with appropriate sequences, DNA or RNA polymerase and proteins.
  • the nucleic acid replication compositions would comprise, for example, a thermostable ligase, e.g., T. aquaticus ligase, two sets of adjacent oligonucleotides wherein one member of each set is complementary to each of the target strands, Tris HCl buffer, KCl, EDTA, NAD, dithiothreitol and salmon sperm DNA. See, for example, Tabor et al., Proc. Acad. Sci. U.S.A., 82, 1074-1078 (1985)).
  • ⁇ -3/ ⁇ -6 fatty acid biosynthetic pathway means that some (or all of) the genes in the pathway express active enzymes, resulting in in vivo catalysis or substrate conversion. It should be understood that “ ⁇ -3/ ⁇ -6 fatty acid biosynthetic pathway” or “functional ⁇ -3/ ⁇ -6 fatty acid biosynthetic pathway” does not imply that all the genes listed in the above paragraph are required, as a number of fatty acid products will only require the expression of a subset of the genes of this pathway.
  • omega-reference system refers to a polypeptide that can desaturate, i.e., introduce a double bond, in one or more fatty acids to produce a fatty acid or precursor of interest.
  • ⁇ 17 desaturases that desaturate a fatty acid between the 17 th and 18 th carbon atom numbered from the carboxyl-terminal end of the molecule and which, for example, catalyze the conversion of ARA to EPA and/or DGLA to ETA; 2.) ⁇ 6 desaturases that catalyze the conversion of LA to GLA and/or ALA to STA; 3.) ⁇ 5 desaturases that catalyze the conversion of DGLA to ARA and/or ETA to EPA; 4.) ⁇ 4 desaturases that catalyze the conversion of DPA to DHA; 5.) ⁇ 8 desaturases that catalyze the conversion of EDA to DGLA and/or ETrA to ETA; 6.) ⁇ 9 desaturases that catalyze the conversion of palmitate to palmitoleic acid (16:1) and/or stearate to oleic acid; 7.) ⁇ 12 desaturases that catalyze the conversion of oleic acid
  • ⁇ 15 and ⁇ 17 desaturases are also occasionally referred to as “omega-3 desaturases”, “w-3 desaturases” and/or “ ⁇ -3 desaturases”, based on their ability to convert ⁇ -6 fatty acids into their ⁇ -3 counterparts (e.g., conversion of LA into ALA and ARA into EPA, respectively).
  • ⁇ 12 desaturases and ⁇ 15 desaturases are further classified with respect to only ⁇ 12 and ⁇ 15 desaturase activities as being either “monofunctional” or “bifunctional” ⁇ 12 or ⁇ 15 desaturases.
  • ⁇ 12 desaturases are defined as those fatty acid desaturases having monofunctional or bifunctional ⁇ 12 desaturase activity, wherein ⁇ 12 desaturase activity is the conversion of oleic acid to LA.
  • the term “monofunctional ⁇ 12 desaturase”, “monofunctional ⁇ 12 desaturase activity” or “exclusive ⁇ 12 desaturase activity” refers to a ⁇ 12 desaturase that is capable of converting oleic acid to LA but that is not capable of converting LA to ALA.
  • bifunctional ⁇ 12 desaturase refers to a ⁇ 12 desaturase that preferentially converts oleic acid to LA but additionally has limited ability to convert LA into ALA.
  • a bifunctional ⁇ 12 desaturase is the Fusarium moniliforme ⁇ 12 desaturase, Fm.d12 (SEQ ID NOs:41 and 49; PCT Publications No. WO 2005/047485 and No. WO 2005/047480).
  • ⁇ 15 desaturases are defined as those fatty acid desaturases having monofunctional or bifunctional ⁇ 15 desaturase activity, wherein ⁇ 15 desaturase activity is the conversion of LA to ALA.
  • the term “monofunctional ⁇ 15 desaturase”, “monofunctional ⁇ 15 desaturase activity” or “exclusive ⁇ 15 desaturase activity” refers to a ⁇ 15 desaturase that is capable of converting LA to ALA but that is not capable of converting oleic acid to LA.
  • bifunctional ⁇ 15 desaturase refers to a ⁇ 15 desaturase that preferentially converts LA into ALA but additionally has limited ability to convert oleic acid to LA;
  • a bifunctional ⁇ 15 desaturase is the Fusarium moniliforme ⁇ 15 desaturase, Fm.d15 (SEQ ID NOs:39 and 50; PCT Publications No. WO 2005/047485 and No. WO 2005/047480).
  • ⁇ 12 and ⁇ 15 desaturases can have specificities other than ⁇ 12 and ⁇ 15 desaturation that are not relevant in the present classification. It should also be noted that the distinction between monofunctional and bifunctional ⁇ 12 or ⁇ 15 desaturases is a practical one and not absolute in fungi; the same enzyme can function with e.g., either monofunctional or bifunctional ⁇ 12 desaturase activity, depending on the level of its expression, growth condition, etc..
  • the native ⁇ 12 desaturases appear monofunctional but their overexpression in Yarrowia lipolytica under a heterologus promoter, such as the Yarrowia glyceraldehyde -3-phosphate dehydrogenase (GPD) promoter, reveals bifunctionalty (see Example 4).
  • a heterologus promoter such as the Yarrowia glyceraldehyde -3-phosphate dehydrogenase (GPD) promoter
  • GPD glyceraldehyde -3-phosphate dehydrogenase
  • over-expression an apparently monofunctional ⁇ 15 desaturase may reveal bifunctional ⁇ 15 desaturase activity.
  • determination of an enzyme's desaturase activity as monofunctional or bifunctional will depend on the methodology used to analyze fatty acid profile and the sensitivity of the equipment to detect extremely low levels of fatty acid conversion.
  • enzyme substrate it is meant that the desaturase polypeptide binds the substrate at an active site and acts upon it in a reactive manner.
  • ⁇ 12/ ⁇ 15 desaturase-like polypeptide in the context of this invention refers to a fungal protein that has homology to known fungal ⁇ 12 and/or ⁇ 15 desaturases. More specifically, “ ⁇ 12/ ⁇ 15 desaturase-like polypeptides” include those “hits” identified when performing a computer-automated sequence comparison using a known fungal ⁇ 12 desaturase or fungal ⁇ 15 desaturase as the query sequence and using an algorithm such as BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993)), along with default search parameters.
  • BLAST Basic Local Alignment Search Tool
  • ⁇ 12/ ⁇ 15 desaturase-like polypeptides also include those proteins, which when used as a query make hits to a known fungal ⁇ 12 desaturase and/or fungal ⁇ 15 desaturase.
  • ⁇ 12/ ⁇ 15 desaturase-like polypeptides include both fungal ⁇ 12 and ⁇ 15 desaturases as exemplified by Fusarium moniliforme, Aspergillus nidulans, Magnaporthe grisea, Neurospora crassa and Fusarium graminearium ⁇ 12 desaturases and ⁇ 15 desaturases (i.e., Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12 and Fg.d15, as described in PCT Publications No.
  • the homology exhibited by the novel “ ⁇ 12/ ⁇ 15 desaturase-like polypeptides” of the invention to Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12, Fg.d15, Sk.d12, Sk.d15, Ma.d12, Ma.d15, Af.d12, Ro.d12, Cc.d12, Mc.d12, Mr.d12 and Cn.d12 ranged from about 24.0%-95% identical (see Table 12 for additional desaturase abbreviations).
  • nucleic acid fragments encoding “ ⁇ 12/ ⁇ 15 desaturase-like polypeptides” will be at least about 24-35% identical, preferably at least about 35-45% identical, and more preferably at least about 45-55% identical to Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12, Fg.d15, Sk.d12, Sk.d15, Ma.d12, Ma.d15, Kl.d12, Kl.d15, Ca.d12, Ca.d15, Cg.d12, Cg.d15, Ct.d12, Ct.d15, Cl.d12, Cl.d15, Dh.d12, Dh.d15, Af.d12, Af.d15, Ao.d12, Ao.d15, Chg.d12, Chg.d15,
  • nucleic acid fragments encode amino acid sequences that are at least about 55-65% identical, more preferred nucleic acid fragments encode amino acid sequences that are at least about 65-85% identical, and most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 85-95% identical to Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12, Fg.d15, Sk.d12, Sk.d15, Ma.d12, Ma.d15, Kl.d12, Kl.d15, Ca.d12, Ca.d15, Cg.d12, Cg.d15, Ct.d12, Ct.d15, Cl.d12, Cl.d15, Dh.d12, Dh.d15, Af.d12, Af.d15, Ao.d12, Ao.d15, Chg.d12, Chg.d15, Ro
  • Suitable nucleic acid fragments not only have the above homologies but typically encode a “ ⁇ 12/ ⁇ 15 desaturase-like polypeptide” having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids.
  • ⁇ 12/ ⁇ 15 desaturase-like polypeptide may be viewed as one that falls into any one or all of the following descriptions:
  • a computer readable format to store electronic information representing the amino acid and encoding polynucleotide sequences of ⁇ 12 desaturase and ⁇ 15 desaturase motifs as well as ⁇ 12/ ⁇ 15 desaturase-like polypeptides.
  • computer readable format will mean any medium for the storage and access of electronic data and information including but not limited to computer disks, compact disks, flash drives, hard drivers, servers or the like.
  • conversion efficiency and “percent substrate conversion” refer to the efficiency by which a particular enzyme (e.g., a desaturase) can convert substrate to product.
  • the conversion efficiency is measured according to the following formula: ([product]/[substrate+product])*100, where ‘product’ includes the immediate product and all products in the pathway derived from it. More specifically, ⁇ 12 percent substrate conversion is calculated according to the following formula: ([18:2+18:3]/[18:1+18:2+18:3])*100; relatedly, ⁇ 15 percent substrate conversion is calculated according to the following formula: ([18:3]/[18:2+18:3])*100.
  • the term “increased ability to act on a ⁇ 12 desaturase substrate” refers to improved ⁇ 12 desaturase substrate conversion; similarly, the term “increased ability to act on a ⁇ 15 desaturase substrate” refers to improved ⁇ 15 desaturase substrate conversion.
  • ⁇ 12/ ⁇ 15 desaturase specificity is calculated as: ( ⁇ 12 percent substrate conversion)/( ⁇ 15 percent substrate conversion).
  • ⁇ 15/ ⁇ 12 desaturase specificity is calculated as: ( ⁇ 15 percent substrate conversion)/( ⁇ 12 percent substrate conversion).
  • elongase refers to a polypeptide that can elongate a fatty acid carbon chain to produce an acid that is 2 carbons longer than the fatty acid substrate that the elongase acts upon. This process of elongation occurs in a multi-step mechanism in association with fatty acid synthase, as described in PCT Publication No. WO 2005/047480. Examples of reactions catalyzed by elongase systems are the conversion of GLA to DGLA, STA to ETA and EPA to DPA. In general, the substrate selectivity of elongases is somewhat broad but segregated by both chain length and the degree and type of unsaturation.
  • a C 14/16 elongase will utilize a C 14 substrate (e.g., myristic acid), a C 16/18 elongase will utilize a C 16 substrate (e.g., palmitate), a C 18/20 elongase (also known as a ⁇ 6 elongase as the terms can be used interchangeably) will utilize a C 18 substrate (e.g., GLA, STA) and a C 20/22 elongase will utilize a C 20 substrate (e.g., EPA).
  • a ⁇ 9 elongase is able to catalyze the conversion of LA and ALA to EDA and ETrA, respectively.
  • elongases have broad specificity and thus a single enzyme may be capable of catalyzing several elongase reactions (e.g., thereby acting as both a C 16/18 elongase and a C 18/20 elongase).
  • oleaginous refers to those organisms that tend to store their energy source in the form of lipid (Weete, In: Fungal Lipid Biochemistry, 2 nd Ed., Plenum, 1980).
  • oleaginous yeast refers to those microorganisms classified as yeasts that can make oil. Generally, the cellular oil or TAG content of oleaginous microorganisms follows a sigmoid curve, wherein the concentration of lipid increases until it reaches a maximum at the late logarithmic or early stationary growth phase and then gradually decreases during the late stationary and death phases (Yongmanitchai and Ward, Appl. Environ. Microbiol., 57:419-25 (1991)).
  • oleaginous microorganisms It is not uncommon for oleaginous microorganisms to accumulate in excess of about 25% of their dry cell weight as oil.
  • oleaginous yeast include, but are no means limited to, the following genera: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces.
  • fungi as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota and Zygomycota, as well as the Oomycota and all mitosporic fungi (Hawksworth et al., In: Ainsworth and Bisby's Dictionary of The Fungi, 8 th ed., 1995, CAB International, University:Cambridge, UK).
  • Ascomycota include, e.g., Neurospora, Eupenicillium (i.e., Penicillium ), Emericella (i.e., Aspergillus ), Eurotiun (i.e., Aspergillus ) and the true yeasts (e.g., Candida, Kluyveromyces, Saccharomyces, Schizosaccharomyces, Pichia and Yarrowia ).
  • Basidiomycota include mushrooms, rusts and smuts.
  • Representative groups of Chytridiomycota include e.g., Allomyces, Blastocladiella, Coelomomyces and aquatic fungi.
  • Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.
  • Representative groups of Oomycota include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya.
  • Non-limiting examples of mitosporic fungi include Aspergillus, Penicilliun, Candida and Alternaria.
  • gene as it applies to a fungal cells encompasses not only chromosomal DNA found within the nucleus, but organelle DNA found within subcellular components (e.g., mitochondrial, Woronin bodies) of the cell.
  • a nucleic acid fragment is “hybridizable” to another nucleic acid fragment, such as a cDNA, genomic DNA, or RNA molecule, when a single-stranded form of the nucleic acid fragment can anneal to the other nucleic acid fragment under the appropriate conditions of temperature and solution ionic strength.
  • Hybridization and washing conditions are well known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1989), particularly Chapter 11 and Table 11.1 therein (entirely incorporated herein by reference).
  • Stringency conditions can be adjusted to screen for moderately similar fragments (such as homologous sequences from distantly related organisms), to highly similar fragments (such as genes that duplicate functional enzymes from closely related organisms).
  • Post-hybridization washes determine stringency conditions.
  • One set of preferred conditions uses a series of washes starting with 6 ⁇ SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2 ⁇ SSC, 0.5% SDS at 45° C. for 30 min, and then repeated twice with 0.2 ⁇ SSC, 0.5% SDS at 50° C. for 30 min.
  • Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible.
  • the appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences.
  • the relative stability (corresponding to higher Tm) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA.
  • the length for a hybridizable nucleic acid is at least about 10 nucleotides.
  • a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides; more preferably at least about 20 nucleotides; and most preferably the length is at least about 30 nucleotides.
  • the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the probe.
  • a “substantial portion” of an amino acid or nucleotide sequence is that portion comprising enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene.
  • gene specific oligonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., in situ hybridization of bacterial colonies or bacteriophage plaques).
  • short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers.
  • a “substantial portion” of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence.
  • homology and “homologous” are used interchangeably herein. They refer to nucleic acid fragments wherein changes in one or more nucleotide bases do not affect the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype. These terms also refer to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially alter the functional properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.
  • homologous nucleic acid sequences encompassed by this invention are also defined by their ability to hybridize, under moderately stringent conditions (e.g., 0.5 ⁇ SSC, 0.1% SDS, 60° C.) with the sequences exemplified herein, or to any portion of the nucleotide sequences disclosed herein and which are functionally equivalent to any of the nucleic acid sequences disclosed herein.
  • moderately stringent conditions e.g., 0.5 ⁇ SSC, 0.1% SDS, 60° C.
  • Gene refers to a nucleic acid fragment that expresses a specific protein, and that may refer to the coding region alone or may include regulatory sequences preceding (5′ non-coding sequences) and following (3′ non-coding sequences) the coding sequence.
  • “Native gene” refers to a gene as found in nature with its own regulatory sequences.
  • “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.
  • Coding sequence refers to a DNA sequence that codes for a specific amino acid sequence.
  • Suitable regulatory sequences refer to nucleotide sequences located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites and stem-loop structures.
  • Promoter refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA.
  • a coding sequence is located 3′ to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.
  • 3′ non-coding sequences and “transcription terminator” refer to DNA sequences located downstream of a coding sequence. This includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression.
  • the polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3′ end of the mRNA precursor.
  • the 3′ region can influence the transcription, RNA processing or stability, or translation of the associated coding sequence.
  • RNA transcript refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA” or “mRNA” refers to the RNA that is without introns and that can be translated into protein by the cell. “cDNA” refers to a double-stranded DNA that is complementary to, and derived from, mRNA. “Sense” RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell.
  • Antisense RNA refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Pat. No. 5,107,065; PCT Publication No. WO 99/28508).
  • the complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5′ non-coding sequence, 3′ non-coding sequence, or the coding sequence.
  • “Functional RNA” refers to antisense RNA, ribozyme RNA, or other RNA that is not translated and yet has an effect on cellular processes.
  • operably linked refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other.
  • a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
  • Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.
  • expression refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragments of the invention. Expression may also refer to translation of mRNA into a polypeptide.
  • “Mature” protein refers to a post-translationally processed polypeptide, i.e., one from which any pre- or propeptides present in the primary translation product have been removed. “Precursor” protein refers to the primary product of translation of mRNA, i.e., with pre- and propeptides still present. Pre- and propeptides may be (but are not limited to) intracellular localization signals.
  • Transformation refers to the transfer of a nucleic acid molecule into a host organism, resulting in genetically stable inheritance.
  • the nucleic acid molecule may be a plasmid that replicates autonomously, for example, or, it may integrate into the genome of the host organism.
  • Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” or “recombinant” or “transformed” organisms.
  • Plasmid refers to an extra chromosomal element often carrying genes that are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments.
  • Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3′ untranslated sequence into a cell.
  • “Expression cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
  • identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
  • Identity and similarity can be readily calculated by known methods, including but not limited to those described in: 1.) Computational Molecular Biology (Lesk, A. M., Ed.) Oxford University: N.Y. (1988); 2.) Biocomputing: Informatics and Genome Projects (Smith, D.
  • Preferred methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using the MegAlignTM program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wis.). Multiple alignment of the sequences is performed using the “Clustal method of alignment” which encompasses several varieties of the algorithm including the “Clustal V method of alignment” corresponding to the alignment method labeled Clustal V (described by Higgins and Sharp, CABIOS. 5:151-153 (1989); Higgins, D. G. et al., Comput. Appl.
  • Clustal W method of alignment is available and corresponds to the alignment method labeled Clustal W (described by Higgins and Sharp, CABIOS. 5:151-153 (1989); Higgins, D. G. et al., Comput. Appl. Biosci. 8:189-191(1992)) and found in the MegAlignTM v6.1 program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.).
  • polypeptides from other species, wherein such polypeptides have the same or similar function or activity.
  • percent identities include, but are not limited to: 24%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or any integer percentage from 24% to 100% may be useful in describing the present invention, such as 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%
  • Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids.
  • motif means a set of amino acids conserved at specific positions along an aligned sequence of evolutionarily related proteins. While amino acids at other positions can vary between homologous proteins, amino acids that are highly conserved at specific positions indicate amino acids that are essential in the structure, the stability, or the activity of a protein. Because they are identified by their high degree of conservation in aligned sequences of a family of protein homologues, they can be used as identifiers, or “signatures”, to determine if a protein with a newly determined sequence belongs to a previously identified protein family. For the purposes herein, the following Table describes motifs of the present invention which are indicative of a fungal protein having ⁇ 12 desaturase activity or ⁇ 15 desaturase activity, respectively.
  • sequence analysis software refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. “Sequence analysis software” may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to: 1.) the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wis.); 2.) BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol., 215:403-410 (1990)); 3.) DNASTAR (DNASTAR, Inc.
  • Palmitate is the precursor of longer-chain saturated and unsaturated fatty acid derivates, which are formed through the action of elongases and desaturases ( FIG. 1 ).
  • TAGs (the primary storage unit for fatty acids) are formed by a series of reactions that involve: 1.) the esterification of one molecule of acyl-CoA to glycerol-3-phosphate via an acyltransferase to produce lysophosphatidic acid; 2.) the esterification of a second molecule of acyl-CoA via an acyltransferase to yield 1,2-diacylglycerol phosphate (commonly identified as phosphatidic acid); 3.) removal of a phosphate by phosphatidic acid phosphatase to yield 1,2-diacylglycerol (DAG); and 4.) the addition of a third fatty acid by the action of an acyltransferase to form TAG.
  • a wide spectrum of fatty acids can be incorporated into TAGs, including saturated and unsaturated fatty acids and short-chain and long-chain fatty acids.
  • ⁇ -6 fatty acids are formed as follows: (1) LA is converted to GLA by a ⁇ 6 desaturase; (2) GLA is converted to DGLA by a C 18/20 elongase; and, (3) DGLA is converted to ARA by a ⁇ 5 desaturase.
  • the “ ⁇ 6 desaturase/ ⁇ 6 elongase pathway” can be utilized for formation of ⁇ -3 fatty acids as follows: (1) LA is converted to ALA, the first of the ⁇ -3 fatty acids, by a ⁇ 15 desaturase; (2) ALA is converted to STA by a ⁇ 6 desaturase; (3) STA is converted to ETA by a C 18/20 elongase; (4) ETA is converted to EPA by a ⁇ 5 desaturase; (5) EPA is converted to DPA by a C 20/22 elongase; and, (6) DPA is converted to DHA by a ⁇ 4 desaturase.
  • other ⁇ -6 fatty acids may be converted to ⁇ -3 fatty acids; for example, ETA and EPA are produced from DGLA and ARA, respectively, by ⁇ 17 desaturase activity.
  • Alternate pathways for the biosynthesis of ⁇ -3/ ⁇ -6 fatty acids utilize a ⁇ 9 elongase and ⁇ 8 desaturase. More specifically, LA and ALA may be converted to EDA and ETrA, respectively, by a ⁇ 9 elongase; then, a ⁇ 8 desaturase converts EDA to DGLA and/or ETrA to ETA.
  • ⁇ -3/ ⁇ -6 fatty acids will depend on the host cell (and its native PUFA profile and/or desaturase/elongase profile), the availability of substrate, and the desired end product(s).
  • One skilled in the art will be able to identify various candidate genes encoding each of the enzymes desired for ⁇ -3/ ⁇ -6 fatty acid biosynthesis.
  • Useful desaturase and elongase sequences may be derived from any source, e.g., isolated from a natural source (from bacteria, algae, fungi, plants, animals, etc.), produced via a semi-synthetic route or synthesized de novo.
  • the particular source of the desaturase and elongase genes introduced into the host is not critical, considerations for choosing a specific polypeptide having desaturase or elongase activity include: 1.) the substrate specificity of the polypeptide; 2.) whether the polypeptide or a component thereof is a rate-limiting enzyme; 3.) whether the desaturase or elongase is essential for synthesis of a desired PUFA; and/or, 4.) co-factors required by the polypeptide.
  • the expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell (see PCT Publication No. WO 2004/101757 for additional details).
  • each enzyme will also be useful to consider the conversion efficiency of each particular desaturase and/or elongase. More specifically, since each enzyme rarely functions with 100% efficiency to convert substrate to product, the final lipid profile of un-purified oils produced in a host cell will typically be a mixture of various PUFAs consisting of the desired ⁇ -3/ ⁇ -6 fatty acid, as well as various upstream intermediary PUFAs. Thus, each enzyme's conversion efficiency is also a variable to consider when optimizing biosynthesis of a desired fatty acid.
  • candidate genes having the appropriate desaturase and elongase activities can be identified according to publicly available literature (e.g., GenBank), the patent literature, and experimental analysis of organisms having the ability to produce PUFAs. These genes will be suitable for introduction into a specific host organism, to enable or enhance the organism's synthesis of PUFAs.
  • WO 2003/099216 includes expression data to support the functional characterization of desaturases having ⁇ 15 activity from Neurospora crassa and Aspergillus nidulans, no corresponding data is presented to support the putative annotation therein of the Botrytis cinerea desaturase as a “ ⁇ 15 desaturase”.
  • a ⁇ 12 desaturase from Yarrowia lipolytica (PCT Publication No. WO 2004/104167; SEQ ID NO:89) was used as a query against a proprietary DuPont expressed sequence tag (EST) library of Fusarium moniliforme strain M-8114 (E.I. du Pont de Nemours and Co., Inc., Wilmington, Del.) as well as against public databases of the filamentous fungi Aspergillus nidulans, Magnaporthe grisea, Neurospora crassa and Fusarium graminearium.
  • EST DuPont expressed sequence tag
  • WO nidulans (SEQ ID NO: 51) 2005/047485; Contig 1.15 (scaffold 1) (SEQ ID NO: 52) 2005/047480 and No. WO in the A. nidulans genome project; 2003/099216; Contig 1.122 (scaffold GenBank Accession No. XP_658641 9) in the A. nidulans genome project; GenBank Accession No. XP_664808 Magnaporthe Mg.d12 PCT Publication No. WO Mg.d15 PCT Publication No.
  • WO grisea (SEQ ID NO: 53) 2005/047485; Locus MG01985.1 in (SEQ ID NO: 54) 2005/047480; Locus MG08474.1 in contig 2.375 in the M. grisea genome contig 2.1597 in the M. grisea genome project; GenBank Accession No. project; GenBank XP_362963 XP_365283 Neurospora Nc.d12 PCT Publication No. WO Nc.d15 PCT Publications No. WO crassa (SEQ ID NO: 55) 2005/047485; GenBank Accession (SEQ ID NO: 56) 2005/047480 and No. WO No. XP_329856 2003/099216; GenBank Accession No.
  • ⁇ 12 desaturases have been isolated from various strains within a particular species (e.g., the M. alpina ⁇ 12 desaturases from ATCC #32221, ATCC #16266 and strain IS-4, corresponding to GenBank Accession Nos. AAF08684, AAL13300 and BAA81754); sequences corresponding to these slight strain variations are not included above.
  • substantially identical is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least about 70%, 80%, 90% or 95% homology to the selected polypeptides, or nucleic acid sequences encoding the amino acid sequence.
  • the length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids or most preferably at least 35 amino acids.
  • the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably at least 110 nucleotides.
  • the Applicants have identified a means to readily distinguish fungal ⁇ 12/ ⁇ 15 desaturase-like polypeptide sequences having ⁇ 15 desaturase activity as opposed to ⁇ 12 desaturase activity. Specifically, when an amino acid sequence alignment was analyzed that comprised Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and Chg.d15 (
  • this motif was defined as: G X W V X A H E C G H X X F S (SEQ ID NO:2; “Fungal ⁇ 12 Desaturase Motif B”), while in a more preferred embodiment, this motif was defined as: G X W V X X H E X G H X X X S (SEQ ID NO:5; “Fungal ⁇ 12 Desaturase Motif E”).
  • ⁇ 15 desaturases i.e., SEQ ID NOs:22, 23, 24, 25, 26, 27, 28, 29 and 30
  • a motif that was representative of all sixteen of the fungal ⁇ 15 desaturases is: G (I/L/V/M/P) W I L (A/G/S) H E (A/C) G H (G/S) A F S (SEQ ID NO:46; “Fungal ⁇ 15 Desaturase Motif A”).
  • this motif was defined as: G X W I L X H E (A/C) G H X A F S (SEQ ID NO:47; “Fungal ⁇ 15 Desaturase Motif B”), while in a more preferred embodiment, this motif was defined as: G X W I X X H E X G H X X X S (SEQ ID NO:48; “Fungal ⁇ 15 Desaturase Motif C”).
  • Amino Acid Alignment Around The His Box I Of Fungal ⁇ 12 And ⁇ 15 Desaturases refers to the location of the first glycine within the conserved region around the His Box I (defined above), with respect to the full-length desaturase protein sequence.
  • the conserved region around the His Box I is located between amino acids 134-148 of the Candida albicans ⁇ 12 desaturase (i.e., Ca.d12; SEQ ID NO: 65); thus, the amino acid residue corresponding to the initial glycine within the conserved region in this particularprotein is residue 134. **Shaded text highlights the His Box I.
  • any fungal ⁇ 12/ ⁇ 15 desaturase-like polypeptide with Ile at the corresponding residue(s) i.e., or the Fungal ⁇ 15 Desaturase Motif A, B or C [SEQ ID NOs:46, 47 and 48, respectively]
  • any fungal ⁇ 12/ ⁇ 15 desaturase-like polypeptide with Val at the corresponding residue(s) i.e., or the Fungal ⁇ 12 Desaturase Motif A, B or E [SEQ ID NOs:1, 2 and 5, respectively]
  • this single isoleucine/valine amino acid is expected to play a pivotal role in the determination of ⁇ 12 or ⁇ 15 desaturase activity.
  • any of the instant desaturase sequences i.e., Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and/or Chg.d15, corresponding to SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79,
  • any of the instant desaturase sequences or portions thereof may also be employed as hybridization reagents for the identification of ⁇ 12 desaturase and ⁇ 15 desaturase homologs.
  • the basic components of a nucleic acid hybridization test include a probe, a sample suspected of containing the gene or gene fragment of interest and a specific hybridization method.
  • Probes of the present invention are typically single-stranded nucleic acid sequences that are complementary to the nucleic acid sequences to be detected. Probes are “hybridizable” to the nucleic acid sequence to be detected. Although the probe length can vary from 5 bases to tens of thousands of bases, typically a probe length of about 15 bases to about 30 bases is suitable.
  • probe molecule Only part of the probe molecule need be complementary to the nucleic acid sequence to be detected. In addition, the complementarity between the probe and the target sequence need not be perfect. Hybridization does occur between imperfectly complementary molecules with the result that a certain fraction of the bases in the hybridized region are not paired with the proper complementary base.
  • Hybridization methods are well defined. Typically the probe and sample must be mixed under conditions that will permit nucleic acid hybridization. This involves contacting the probe and sample in the presence of an inorganic or organic salt under the proper concentration and temperature conditions. The probe and sample nucleic acids must be in contact for a long enough time that any possible hybridization between the probe and sample nucleic acid may occur. The concentration of probe or target in the mixture will determine the time necessary for hybridization to occur. The higher the probe or target concentration, the shorter the hybridization incubation time needed.
  • a chaotropic agent may be added (e.g., guanidinium chloride, guanidinium thiocyanate, sodium thiocyanate, lithium tetrachloroacetate, sodium perchlorate, rubidium tetrachloroacetate, potassium iodide, cesium trifluoroacetate).
  • a chaotropic agent e.g., guanidinium chloride, guanidinium thiocyanate, sodium thiocyanate, lithium tetrachloroacetate, sodium perchlorate, rubidium tetrachloroacetate, potassium iodide, cesium trifluoroacetate.
  • formamide to the hybridization mixture, typically 30-50% (v/v).
  • hybridization solutions can be employed. Typically, these comprise from about 20 to 60% volume, preferably 30%, of a polar organic solvent.
  • a common hybridization solution employs about 30-50% v/v formamide, about 0.15 to 1 M sodium chloride, about 0.05 to 0.1 M buffers (e.g., sodium citrate, Tris-HCl, PIPES or HEPES (pH range about 6-9)), about 0.05 to 0.2% detergent (e.g., sodium dodecylsulfate), or between 0.5-20 mM EDTA, FICOLL (Pharmacia Inc.) (about 300-500 kdal), polyvinylpyrrolidone (about 250-500 kdal) and serum albumin.
  • buffers e.g., sodium citrate, Tris-HCl, PIPES or HEPES (pH range about 6-9)
  • detergent e.g., sodium dodecylsulfate
  • FICOLL Fracia Inc.
  • Nucleic acid hybridization is adaptable to a variety of assay formats. One of the most suitable is the sandwich assay format. The sandwich assay is particularly adaptable to hybridization under non-denaturing conditions.
  • a primary component of a sandwich-type assay is a solid support. The solid support has adsorbed to it or covalently coupled to it immobilized nucleic acid probe that is unlabeled and complementary to one portion of the sequence.
  • any of the ⁇ 12 desaturase and/or ⁇ 15 desaturase nucleic acid fragments of the instant invention may be used to isolate genes encoding homologous proteins from the same or other bacterial, algal, fungal or plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to: 1.) methods of nucleic acid hybridization; 2.) methods of DNA and RNA amplification, as exemplified by various uses of nucleic acid amplification technologies [e.g., polymerase chain reaction (PCR), Mullis et al., U.S. Pat. No.
  • PCR polymerase chain reaction
  • genes encoding similar proteins or polypeptides to the ⁇ 12 and/or ⁇ 15 desaturases described herein could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired yeast or fungus using methodology well known to those skilled in the art (wherein those yeast or fungus producing LA or ALA [or LA and/or ALA-derivatives] would be preferred).
  • Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis, supra).
  • PCR may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3′ end of the mRNA precursor encoding microbial genes.
  • the second primer sequence may be based upon sequences derived from the cloning vector.
  • the skilled artisan can follow the RACE protocol (Frohman et al., Proc. Acad. Sci. U.S.A., 85:8998 (1988)) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3′ or 5′ end.
  • Primers oriented in the 3′ and 5′ directions can be designed from the instant sequences.
  • 3′ RACE or 5′ RACE systems Gibco/BRL, Gaithersburg, Md.
  • specific 3′ or 5′ cDNA fragments can be isolated (Ohara et al., Proc. Acad. Sci. U.S.A., 86:5673 (1989); Loh et al., Science, 243:217 (1989)).
  • probes and/or primers corresponding to the nucleic acids of the invention will be useful for the identification and isolation of ⁇ 12 desaturase and/or ⁇ 15 desaturase enzymes, respectively.
  • AAL13301 Mortierella isabellina; SEQ ID NO:81), Accession No. AAP23194 ( Aspergillus parasiticus; SEQ ID NO:85), Accession No. AAX20125 ( Pichia pastoris; SEQ ID NO:83), Accession No. BAB69056 ( Mucor circinelloides; “Mc.d12”; SEQ ID NO:92), Accession No. AAD55982 ( Mucor rouxii; “Mr.d12”; SEQ ID NO:93), Accession No. AAT58363 ( Rhizopus oryzae; “Ro.d12”; SEQ ID NO:94), Accession No.
  • BAD51484 Lentinula edodes; SEQ ID NO:90), Accession No. AAU12575 ( Cryptococcus curvatus; “Cc.d12”; SEQ ID NO:86), Accession No. AAR20443 ( Saprolegnia diclina; SEQ ID NO:88) and Accession No. AAP33789 ( Aspergillus flavus; SEQ ID NO:95).
  • four additional hypothetical fungal proteins were identified (having the Fungal ⁇ 12 Desaturase Motif B or a variant thereof) that are hypothesized herein to encode ⁇ 12 desaturases: Accession No.
  • AAS53960 Ashbya gossypii ATCC 10895; SEQ ID NO:84), Accession No. XP — 757193 ( Ustilago maydis 521; SEQ ID NO:91), Accession No. EAS31392 ( Coccidioides immitis RS; SEQ ID NO:82) and Accession No. EAL21306 ( Cryptococcus neoformans var. neoformans B-3501A; “Cn.d12”; SEQ ID NO:87).
  • an additional fungal ⁇ 12 desaturase motif was defined as: G (I/L/V) W V (L/I/V) (A/G) H E (A/C) G H (Q/G/L) (A/S) (F/Y) S (SEQ ID NO:3; “Fungal ⁇ 12 Desaturase Motif C”).
  • the motifs of SEQ ID NOs:3, 4 and 5 are thus representative of all of the fungal ⁇ 12 desaturases described in the present application (i.e., Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, as well as the known and putative ⁇ 12 desaturases described above).
  • ⁇ 12 desaturase activity wherein the desaturase is only capable of using oleic acid as enzymatic substrate
  • bifunctional ⁇ 12 desaturase activity wherein the desaturase prefers oleic acid as its enzymatic substrate but additionally has limited ability to use LA such that the enzyme is a “bifunctional” ⁇ 12 desaturase
  • the invention provides a method for identifying a fungal polypeptide having ⁇ 15 desaturase activity from a pool of ⁇ 12/ ⁇ 15 desaturase-like polypeptides comprising:
  • Fm.d12 characterized as a ⁇ 12 desaturase with a trace level of ⁇ 15 desaturase activity
  • Fm.d15 characterized as a primarily a ⁇ 15 desaturase, additionally having some ⁇ 12 desaturase activity
  • the native Val at position 151 of Fm.d12 was changed to Ile by site-specific mutation (i.e., V151I mutation)
  • the native Ile at position 102 of Fm.d15 was similarly changed to Val by site-specific mutation (i.e., I1102V mutation).
  • V118I mutation in the bifunctional Yl.d12 desaturase improves its ⁇ 15/ ⁇ 12 specificity.
  • the present invention encompasses a method for the direct production of PUFAs comprising exposing a fatty acid substrate (i.e., oleic acid or LA) to the desaturase enzymes described herein (e.g., Ca.d12 or Kl.d15), such that the substrate is converted to the desired fatty acid product (i.e., LA or ALA).
  • a fatty acid substrate i.e., oleic acid or LA
  • the desaturase enzymes described herein e.g., Ca.d12 or Kl.d15
  • ⁇ -linolenic acid comprising the steps of:
  • the ⁇ 12 desaturases and/or the ⁇ 15 desaturases described herein may be expressed in conjunction with additional genes encoding enzymes of the PUFA biosynthetic pathway to result in higher levels of production of longer-chain ⁇ -3/ ⁇ -6 fatty acids (e.g., ARA, EPA and DHA).
  • additional genes encoding enzymes of the PUFA biosynthetic pathway to result in higher levels of production of longer-chain ⁇ -3/ ⁇ -6 fatty acids (e.g., ARA, EPA and DHA).
  • the particular genes included within a particular expression cassette will depend on the host cell (and its PUFA profile and/or desaturase/elongase profile), the availability of substrate and the desired end product(s).
  • ⁇ 12 desaturase or ⁇ 15 desaturase it may be useful to disrupt a host organism's native ⁇ 12 desaturase or ⁇ 15 desaturase, based on the complete sequences described herein, the complement of those complete sequences, substantial portions of those sequences, codon-optimized desaturases derived therefrom and those sequences that are substantially homologous thereto.
  • the targeted disruption of the ⁇ 15 desaturase in a host organism produces a mutant strain that is unable to synthesize ALA. This mutant strain could be useful for the production of “pure” ⁇ -6 fatty acids (without co-synthesis of ⁇ -3 fatty acids).
  • ⁇ -linolenic acid nucleic acids encoding the following desaturase polypeptides may be used:
  • Expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of any of the gene products of the instant sequences. These chimeric genes could then be introduced into appropriate host cells via transformation to provide high-level expression of the encoded enzymes.
  • Vectors or DNA cassettes useful for the transformation of suitable host cells are well known in the art. The specific choice of sequences present in the construct is dependent upon the desired expression products (supra), the nature of the host cell and the proposed means of separating transformed cells versus non-transformed cells. Typically, however, the vector or cassette contains sequences directing transcription and translation of the relevant gene(s), a selectable marker and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5′ of the gene that controls transcriptional initiation (e.g., a promoter) and a region 3′ of the DNA fragment that controls transcriptional termination (i.e., a terminator). It is most preferred when both control regions are derived from genes from the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.
  • Initiation control regions or promoters which are useful to drive expression of the instant ORFs in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of directing expression of these genes in the selected host cell is suitable for the present invention. Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest. Stable expression can be achieved by the use of a constituitive promoter operably linked to the gene of interest. As an example, when the host cell is yeast, transcriptional and translational regions functional in yeast cells are provided, particularly from the host species (e.g., see PCT Publication No.
  • WO 2006/052870 for preferred transcriptional initiation regulatory regions for use in Yarrowia lipolytica ). Any one of a number of regulatory sequences can be used, depending upon whether constitutive or induced transcription is desired, the efficiency of the promoter in expressing the ORF of interest, the ease of construction and the like.
  • the termination region can be derived from the 3′ region of the gene from which the initiation region was obtained or from a different gene.
  • a large number of termination regions are known and function satisfactorily in a variety of hosts (when utilized both in the same and different genera and species from where they were derived).
  • the termination region usually is selected more as a matter of convenience rather than because of any particular property.
  • Termination control regions may also be derived from various genes native to the preferred hosts.
  • a termination site may be unnecessary; however, it is most preferred if included.
  • some of the molecular features that have been manipulated to control gene expression include: 1.) the nature of the relevant transcriptional promoter and terminator sequences; 2.) the number of copies of the cloned gene and whether the gene is plasmid-borne or integrated into the genome of the host cell; 3.) the final cellular location of the synthesized foreign protein; 4.) the efficiency of translation and correct folding of the protein in the host organism; 5.) the intrinsic stability of the mRNA and protein of the cloned gene within the host cell; and, 6.) the codon usage within the cloned gene, such that its frequency approaches the frequency of preferred codon usage of the host cell.
  • modifications are encompassed in the present invention, as means to further optimize expression of the ⁇ 12 and ⁇ 15 desaturases described herein.
  • codon-optimized genes encoding desaturases that are substantially identical to Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and/or Chg.d15 (i.e., SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75,
  • the DNA encoding a polypeptide suitable for expression in an appropriate host cell is placed in a plasmid vector capable of autonomous replication in the host cell, or it is directly integrated into the genome of the host cell. Integration of expression cassettes can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.
  • each vector has a different means of selection and should lack homology to the other construct(s) to maintain stable expression and prevent reassortment of elements among constructs. Judicious choice of regulatory regions, selection means and method of propagation of the introduced construct(s) can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.
  • Constructs comprising the gene of interest may be introduced into a host cell by any standard technique. These techniques include transformation (e.g., lithium acetate transformation [ Methods in Enzymology, 194:186-187 (1991)]), protoplast fusion, biolistic impact, electroporation, microinjection, or any other method that introduces the gene of interest into the host cell.
  • transformation e.g., lithium acetate transformation [ Methods in Enzymology, 194:186-187 (1991)]
  • protoplast fusion e.g., biolistic impact, electroporation, microinjection, or any other method that introduces the gene of interest into the host cell.
  • a host cell that has been manipulated by any method to take up a DNA sequence will be referred to as “transformed” or “recombinant” herein.
  • the transformed host will have at least one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers.
  • the transformed host cell can be identified by various selection techniques, as described in PCT Publications No. WO 2004/101757, No. WO 2005/003310 and No. WO 2006/052870.
  • biochemical pathways competing with the ⁇ -3 and/or ⁇ -6 fatty acid biosynthetic pathways for energy or carbon, or native PUFA biosynthetic pathway enzymes that interfere with production of a particular PUFA end-product may be eliminated by gene disruption or down-regulated by other means (e.g., antisense mRNA).
  • Host cells for expression of the instant genes and nucleic acid fragments may include microbial hosts that grow on a variety of feedstocks, including simple or complex carbohydrates, fatty acids, organic acids, oils, alcohols, and/or hydrocarbons over a wide range of temperature and pH values.
  • feedstocks including simple or complex carbohydrates, fatty acids, organic acids, oils, alcohols, and/or hydrocarbons over a wide range of temperature and pH values.
  • the genes described in the instant invention were initially isolated for expression in an oleaginous yeast (and in particular Yarrowia lipolytica ); however, it is contemplated that because transcription, translation and the protein biosynthetic apparatus are highly conserved, any bacteria, yeast, algae and/or fungus will be a suitable host for expression of the present nucleic acid fragments.
  • Preferred hosts are oleaginous organisms, such as oleaginous yeast. These oleaginous organisms are naturally capable of oil synthesis and accumulation, wherein the oil can comprise greater than about 25% of the cellular dry weight, more preferably greater than about 30% of the cellular dry weight, and most preferably greater than about 40% of the cellular dry weight.
  • Genera typically identified as oleaginous yeast include, but are not limited to: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces. More specifically, illustrative oil-synthesizing yeast include: Rhodosporidium toruloides, Lipomyces starkeyii, L.
  • Candida revkaufi C. pulcherrima, C. tropicalis, C. utilis, Trichosporon pullans, T. cutaneum, Rhodotorula glutinus, R. graminis and Yarrowia lipolytica (formerly classified as Candida lipolytica ).
  • oleaginous yeast Yarrowia lipolytica Most preferred is the oleaginous yeast Yarrowia lipolytica; and, in a further embodiment, most preferred are the Y. lipolytica strains designated as ATCC #76982, ATCC #20362, ATCC #8862, ATCC #18944 and/or LGAM S(7)1 (Papanikolaou S., and Aggelis G., Bioresour. Technol., 82(1):43-9 (2002)).
  • WO 2005/047480 and No. WO 2005/047485 The preferred method of expressing genes in this yeast is by integration of linear DNA into the genome of the host; and, integration into multiple locations within the genome can be particularly useful when high level expression of genes are desired [e.g., in the Ura3 locus (GenBank Accession No. AJ306421), the Leu2 gene locus (GenBank Accession No. AF260230), the Lys5 gene locus (GenBank Accession No. M34929), the Aco2 gene locus (GenBank Accession No. AJ001300), the Pox3 gene locus (Pox3: GenBank Accession No. XP — 503244; or, Aco3: GenBank Accession No.
  • Preferred selection methods for use in Yarrowia lipolytica are resistance to kanamycin, hygromycin and the amino glycoside G418, as well as ability to grow on media lacking uracil, leucine, lysine, tryptophan or histidine.
  • 5-fluoroorotic acid (5-fluorouracil-6-carboxylic acid monohydrate; “5-FOA”) is used for selection of yeast Ura ⁇ mutants.
  • the compound is toxic to yeast cells that possess a functioning URA3 gene encoding orotidine 5′-monophosphate decarboxylase (OMP decarboxylase); thus, based on this toxicity, 5-FOA is especially useful for the selection and identification of Ura ⁇ mutant yeast strains (Bartel, P. L. and Fields, S., Yeast 2-Hybrid System, Oxford University: New York, v. 7, pp 109-147, 1997).
  • OMP decarboxylase orotidine 5′-monophosphate decarboxylase
  • microbial hosts include oleaginous bacteria, algae and other fungi; and, within this broad group of microbial hosts, of particular interest are microorganisms that synthesize ⁇ -3/ ⁇ -6 fatty acids.
  • transformation of Mortierella alpina which is commercially used for production of ARA
  • any of the present ⁇ 15 desaturase genes under the control of inducible or regulated promoters could yield a transformant organism capable of synthesizing EPA.
  • the present invention provides a variety of plant hosts for transformation with the ⁇ 12 and ⁇ 15 desaturases described herein.
  • Plants so transformed can be monocotyledonous plants or dicotyledonous plants, and preferably they belong to a class of plants identified as oleaginous (e.g., oilseed plants).
  • oilseed plant hosts include, but are not limited to: soybean ( Glycine and Soja sp.), corn ( Zea mays ), flax ( Linum sp.), rapeseed ( Brassica sp.), primrose, canola, maize, safflower ( Carthamus sp.) and sunflower ( Helianthus sp.).
  • Yarrowia lipolytica are generally grown in complex media (e.g., yeast extract-peptone-dextrose broth (YPD)) or a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes (e.g., Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Mich.)).
  • complex media e.g., yeast extract-peptone-dextrose broth (YPD)
  • a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes (e.g., Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Mich.)).
  • Fermentation media in the present invention must contain a suitable carbon source. Suitable carbon sources are taught in PCT Publication No. WO 2005/047480. Although it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing sources, preferred carbon sources are sugars, glycerol and/or fatty acids. Most preferred is glucose and/or fatty acids containing between 10-22 carbons.
  • Nitrogen may be supplied from an inorganic (e.g., (NH 4 ) 2 SO 4 ) or organic (e.g., urea or glutamate) source.
  • the fermentation media must also contain suitable minerals, salts, cofactors, buffers, vitamins and other components known to those skilled in the art suitable for the growth of the oleaginous host and promotion of the enzymatic pathways necessary for PUFA production.
  • metal ions e.g., Fe +2 , Cu +2 , Mn +2 , Co +2 , Zn +2 , Mg +2
  • metal ions e.g., Fe +2 , Cu +2 , Mn +2 , Co +2 , Zn +2 , Mg +2
  • promote synthesis of lipids and PUFAs Nakahara, T. et al., Ind. Appl. Single Cell Oils, D. J. Kyle and R. Colin, eds. pp 61-97 (1992)).
  • Preferred growth media in the present invention are common commercially prepared media, such as Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Mich.). Other defined or synthetic growth media may also be used and the appropriate medium for growth of the transformant host cells will be known by one skilled in the art of microbiology or fermentation science.
  • a suitable pH range for the fermentation is typically between about pH 4.0 to pH 8.0, wherein pH 5.5 to pH 7.5 is preferred as the range for the initial growth conditions.
  • the fermentation may be conducted under aerobic or anaerobic conditions, wherein microaerobic conditions are preferred.
  • E. coli (XL1-Blue) competent cells were purchased from the Stratagene Company (San Diego, Calif.). E. coli strains were typically grown at 37° C. on Luria Bertani (LB) plates.
  • DNA sequence was generated on an ABI Automatic sequencer using dye terminator technology (U.S. Pat. No. 5,366,860; EP 272,007) using a combination of vector and insert-specific primers. Sequence editing was performed in Sequencher (Gene Codes Corporation, Ann Arbor, Mich.). All sequences represent coverage at least two times in both directions. Comparisons of genetic sequences were accomplished using DNASTAR software (DNASTAR, Inc., Madison, Wis.).
  • Percent identity between desaturase-related proteins were performed by multiple sequence alignment by the slow-accurate method Clustal W method using the MegAlignTM program of LASERGENE (Windows 32 MegAlignTM5.06 1993-2003; DNASTAR Inc.).
  • the synthesis of the Yarrowia expression vector identified herein as pY35 was described in PCT Publication No. WO 2005/047485.
  • the vector comprised the Fusarium monilforme ⁇ 12 desaturase (i.e., Fm.d12 or Fm2) under the control of the Yarrowia lipolytica translation elongation factor-1 ⁇ (TEF) promoter (Muller, S., et al., Yeast 14:1267-1283 (1998); GenBank Accession No. AF054508) and a terminator comprising ⁇ 100 bp of the 3′ region of the Yarrowia Xprgene (GenBank Accession No. M17741) [i.e., a TEF::Fm.d12::XPR chimeric gene].
  • TEF Yarrowia lipolytica translation elongation factor-1 ⁇
  • the synthesis of the Yarrowia expression vector identified herein as pY34 was described in PCT Publication No. WO 2005/047480.
  • the vector comprised the Fusarium moniliforme bifunctional ⁇ 15 desaturase (i.e., Fm.d15 or Fm1) under the control of the Yarrowia glyceraldehyde phosphate dehydrogenase promoter (GPD; PCT Publication No. WO 2005/003310) [i.e., a GPD::Fm.d15::XPR chimeric gene].
  • Both pY34 and pY35 additionally contained: the ARS18 Yarrowia autonomous replication sequence; a ColE1 plasmid origin of replication; an ampicillin resistance gene (Amp R ) for selection in E. coli; the E. coli ‘f1’ replication origin; and the Yarrowia LEU2 gene for selection in Yarrowia.
  • Yarrowia lipolytica strains ATCC #20362, #76982 and #90812 were purchased from the American Type Culture Collection (Rockville, Md.).
  • strain Q-d12D The ⁇ 12 desaturase-disrupted [ ⁇ 12 knockout (KO)] strains of Yarrowia lipolytica ATCC #76982 were utilized herein: strain Q-d12D and strain L38. Both strains will be generically referred to as a “d12KO” strain and are phenotypically identical. Strain “Q-d12D” was previously described in PCT Publication No. WO 2004/104167; briefly, this d12KO strain was derived from Y.
  • lipolytica # 76982 following a ⁇ 12 desaturase knockout created via homologous recombination-mediated replacement of the ⁇ 12 desaturase gene with a targeting cassette comprising a truncated and disrupted version of the wildtype ⁇ 12 desaturase.
  • Strain “L38” is a ⁇ 12 desaturase-disrupted strain of Yarrowia lipolytica similar to strain Q-d12D (supra). It will be described in Example 1, infra.
  • MM minimal medium
  • yeast nitrogen base DIFCO Laboratories, Detroit, Mich.
  • ammonium sulfate or amino acids 2% glucose, 0.1% proline, pH 6.1
  • MM plates additionally contained 20 g/L agar.
  • fatty acid analysis For fatty acid analysis, cells were collected by centrifugation and lipids were extracted as described in Bligh, E. G. & Dyer, W. J. ( Can. J. Biochem. Physiol., 37:911-917 (1959)). Fatty acid methyl esters were prepared by transesterification of the lipid extract with sodium methoxide (Roughan, G. and Nishida I., Arch Biochem Biophys., 276(1):38-46 (1990)) and subsequently analyzed with a Hewlett-Packard 6890 GC fitted with a 30-m X 0.25 mm (i.d.) HP-INNOWAX (Hewlett-Packard) column. The oven temperature was from 170° C. (25 min hold) to 185° C. at 3.5° C./min.
  • Yarrowia culture (3 mL) was harvested, washed once in distilled water, and dried under vacuum in a Speed-Vac for 5-10 min.
  • Sodium methoxide 100 ⁇ l of 1%) was added to the sample, and then the sample was vortexed and rocked for 20 min. After adding 3 drops of 1 M NaCl and 400 ⁇ l hexane, the sample was vortexed and spun. The upper layer was removed and analyzed by GC as described above.
  • Strain L38 is a ⁇ 12 desaturase-disrupted strain of Yarrowia lipolytica similar to the d12KO strain described as Q-d12D (PCT Publication No. WO 2004/10416). It was also derived from Y. lipolytica ATCC #76982 following disruption of its only native ⁇ 12 desaturase gene by replacement with a disrupted version via homologous recombination.
  • the site-specific recombination system consists of two elements: (1) a recombination site having a characteristic DNA sequence [e.g., LoxP]; and, (2) a recombinase enzyme that binds to the DNA sequence specifically and catalyzes recombination (i.e., excision) between DNA sequences when two or more of the recombination sites are oriented in the same direction at a given interval on the same DNA molecule [e.g., Cre].
  • a recombination site having a characteristic DNA sequence e.g., LoxP
  • a recombinase enzyme that binds to the DNA sequence specifically and catalyzes recombination (i.e., excision) between DNA sequences when two or more of the recombination sites are oriented in the same direction at a given interval on the same DNA molecule [e.g., Cre].
  • an integration construct comprising a target gene that was desirable to insert into the host genome (i.e., a first selection marker [i.e., Leu2]) that was flanked by recombination sites.
  • a first selection marker i.e., Leu2
  • the first selection marker was excised from the chromosome by the introduction of a replicating plasmid carrying a second selection marker (i.e., sulfonylurea resistance [AHAS]) and a recombinase suitable to recognize the site-specific recombination sites introduced into the genome (i.e., Cre).
  • the second selection marker gene utilized was a native Yarrowia lipolytica acetohydroxyacid synthase (AHAS or acetolactate synthase; E.C. 4.1.3.18; GenBank Accession No. XM — 501277) containing a single amino acid change (W497L) that confers sulfonyl urea herbicide resistance (SU R ; described in PCT Publication No. WO 2006/052870).
  • AHAS is the first common enzyme in the pathway for the biosynthesis of branched-chain amino acids and it is the target of the sulfonylurea and imidazolinone herbicides.
  • Yarrowia lipolytica ATCC #76982 was transformed with SphI and Asci linearized plasmid pY137.
  • the sequence of plasmid pY137 (labeled as pY137.YID12ko.Leu2 in FIG. 4A ) is disclosed as SEQ ID NO:101 and pY137 Is described in the table below.
  • Bg/II-AscI Contains 3′ portion of Yarrowia lipolytica ⁇ 12 desaturase ORF (2357–2950 bp) that corresponds to 661–1254 bp of GenBank Accession No. XM_500707)
  • AscI-SphI Contains ColE1 plasmid origin of replication (3003–3883), ampicillin resistance gene (Amp R ; 3941–4801) for selection in E. coli , E.
  • SphI-PacI Contains 5′ portion of Yarrowia lipolytica ⁇ 12 desaturase ORF (5662–6262 bp) that corresponds to 1–601 bp of GenBank Accession No. XM_500707)
  • the LEU2 gene in d12KO strain L37 was excised by transient expression of Cre recombinase under the control of Yarrowia glycerol-3-phosphate acyltransferase (GPAT) promoter. Specifically, strain L37 was transformed with plasmid pY117. The mutated Yarrowia AHAS enzyme in plasmid pY117 conferred SU R , which was used as a positive screening marker.
  • GPAT Yarrowia glycerol-3-phosphate acyltransferase
  • Plasmid pY117 was derived from plasmid pY116 (described in U.S. patent application Ser. No. 11/635258) by inserting the mutant AHAS gene flanked by PacI-SwaI sites into PacI-SwaI digested pY116 thereby replacing the LEU selectable marker with the sulfonylurea marker.
  • Plasmid pY117 (SEQ ID NO:102) is represented in FIG. 4B (labeled therein as pY117.Cre.AHASw497L) and is described in Table 7 below.
  • PacI-SwaI Contains Yarrowia lipolytica AHAS gene (corresponding to 27040–30026 bp [complementary] in Genbank Accession No. CR382129) comprising a W497L mutation (3157–4461 bp)
  • Swa I/BsiWI Contains GPAT::Cre::XPR2 comprising: [digestion with GPAT: Yarrowia lipolytica GPAT promoter SwaI-NotI releases (PCT Publication No.
  • GPAT::Cre] (7498–8535 bp)
  • Cre Enterobacteria phage P1 Cre ORF for recombinase protein (GenBank Accession No. X03453) (8537–9570 bp) except for single base change (T4G) resulting in a single amino acid change (S2A) to create a NcoI site for cloning convenience XPR: ⁇ 170 bp of the 3′ region of the Yarrowia Xpr gene (GenBank Accession No. M17741)
  • L37 transformed by pY117 were plated on minimal plates containing Leu and 280 ⁇ g/mL sulfonyurea (chlorimuron ethyl, E. I. duPont de Nemours & Co., Inc., Wilmington, Del.).
  • sulfonyurea chlorimuron ethyl, E. I. duPont de Nemours & Co., Inc., Wilmington, Del.
  • ⁇ 15 desaturases Fm.d15 (SEQ ID NOs:39 and 50), Fg.d15 (SEQ ID NO:58), Mg.d15 (SEQ ID NO:54), Nc.d15 (SEQ ID NO:56), An.d15 (SEQ ID NO:52), Ma.d15 (SEQ ID NO:60) and Sk.d15 (SEQ ID NO:62); and, the following proteins were previously characterized as, or predicted to be, ⁇ 12 desaturases: Fm.d12 (SEQ ID NOs:41 and 49), Fg.d12 (SEQ ID NO:57), Mg.d12 (SEQ ID NO:53), Nc.d12 (SEQ ID NO:55), An.d12 (SEQ ID NO:51), Ma.d12 (SEQ ID NO:59) and Sk.d12 (SEQ ID NO:61) (see Table 4, supra, for additional details).
  • this phylogenetic analysis confirmed that one member of each “pair” of ⁇ 12/ ⁇ 15 desaturase-like polypeptides was more closely related to a known fungal ⁇ 15 desaturase (i.e., Sk.d15, Fm.d15), while the other was more closely related to a known fungal ⁇ 12 desaturase (i.e., Sk.d12, Nc.d12, An.d12).
  • yeast strains Prior to functional characterization of the putative ⁇ 15 desaturases by over-expression in an alternate host, two of the yeast strains were analyzed to confirm the presence of ALA, i.e., the fatty acid product of the putative ⁇ 15 desaturase.
  • ALA i.e., the fatty acid product of the putative ⁇ 15 desaturase.
  • Kluyveromyces lactis NRRL-Y-1140 designated “Kl Y12651” herein
  • Debaromyces hansenii CBS767 designated “Dh Y7426” herein
  • Saccharomyces kluyveri NRRL Y-12651 (designated “Sk Y12651” herein) was also obtained from the ARS Culture Collection as a means to confirm Oura et al.'s identification of a ⁇ 15 desaturase within that strain ( Microbiol., 150:1983-1990 (2004)).
  • Each yeast strain was grown for 2 days on YPD plates and the fatty acid composition was determined by analyzing a loop full of cells, as described in the General Methods. All three strains were confirmed to make a significant amount of the ⁇ 15 desaturation product, ALA. More specifically, the fatty acid profile of each strain is shown below in Table 9. Fatty acids are identified as 16:0 (palmitate), 16:1 (palmitoleic acid), 18:0, 18:1 (oleic acid), 18:2 (LA) and 18:3 (ALA) and the composition of each is presented as a % of the total fatty acids.
  • genomic DNA from all three strains was extracted by the YeaStar Genomic DNA KitTM (Zymo Research Corporation, Orange, Calif.). For this, 1.5 mL of yeast cultures were harvested by spinning. Supernatant was removed and 120 ⁇ l of YD Digestion Buffer and 5 ⁇ l of R-ZymolyaseTM added. Each pellet was resuspended by vortexing and incubated at 37° C. for 60 min. Then, 120 ⁇ l of YD Lysis Buffer was added and mixed by gentle vortexing.
  • Lysates were centrifuged in a table-top centrifuge at >10,000 rpm for 2 min and the supernatant loaded onto the Zymo-spin III column and centrifuged at >10,000 rpm for 1 min.
  • the column was washed by 300 ⁇ l of DNA Wash Buffer and centrifuged for 1 min at 10,000 rpm. Another 300 ⁇ l of DNA Wash Buffer was added to repeat the wash and centrifuged for 1 min.
  • the Zymo-spin III column was transferred to a new 1.5 mL centrifuge tube and the genomic DNAs were eluted with 60 ⁇ l of water.
  • genomic DNAs were used to clone the predicted ⁇ 15 desaturase ORFs. Since each ORF lacked an intron, the genomic DNA was used for cloning the entire ORF by PCR using the following upper primer and lower primer combinations:
  • the primers were designed to allow direct cloning of the ORFs without use of restriction sites using in-fusion cloning (Clontech Laboratories, Inc., Mountain View, Calif.).
  • PCR was performed using standard conditions in a 25 ⁇ l total volume containing: 100 ng genomic DNA, 200 ⁇ M each deoxyribonucleotide triphosphate, 10 pmole of each primer, 2.5 ⁇ l 10 ⁇ PfuUltraTM high-fidelity reaction buffer and 1 ⁇ l PfuUltraTM high-fidelity DNA polymerase (Stratagene, San Diego, Calif.).
  • Amplification was carried out via initial denaturation at 95° C. for 3 min, followed by 30 cycles of the following: 95° C. for 1 min, 55° C. for 30 sec and 72° C. for 1 min. A final extension cycle of 72° C. for 10 min was carried out, followed by reaction termination at 4° C.
  • PCR products were run on an agarose gel and products of the expected length were obtained, gel purified, and cloned by the in-fusion method (Clontech, Catalog No. PT3650-2) into plasmid pY35 linearized with NcoI/NotI digestion (PCT Publication No. WO 2005/047485).
  • the in-fusion reaction was transformed into E. coli XL1-Blue competent cells (Stratagene) and the cells were plated on LB/Amp selection plates. Correct transformants were screened by digesting miniprep DNA with SalI/NcoI and then performing agarose gel electrophoresis for product analysis.
  • Kl.d15, Dh.d15, and Sk.d15 were designated “pY104 Kld15”, “pY106 Dhd15” and “pY107 Skd15”, respectively.
  • Kl.d15 and Dh.d15 in plasmids pY104 Kld15 and pY106 Dhd15, respectively, were sequenced and confirmed to be identical to the public sequences (i.e., GenBank Accession No. XP — 451551 and No. CAG88182, corresponding to SEQ ID NOs:64 and 74, respectively).
  • ORF Sk.d15 in plasmid pY107 Skd15 had 29 bp substitutions (97.7% identity) that resulted in 5 amino acid substitutions (98.8% identity), when compared to the public sequence (i.e., GenBank Accession No. BAD11952; SEQ ID NO:62). The differences presumably arose from strain differences.
  • the nucleotide sequence of ORF Sk.d15 in plasmid pY107 Skd15 is provided herein as SEQ ID NO:103, while the amino acid sequence of ORF Sk.d15 in plasmid pY107 Skd15 is provided herein as SEQ ID NO:37.
  • Plasmids pY104 Kld15, pY106 Dhd15 and pY107 Skd15 were then transformed into wild type (WT) Y. lipolytica ATCC #76982 and the d12KO strain referred to as “Q-d12D”(General Methods; PCT Publication No. WO 2004/104167). Additionally, plasmid pY34 (PCT Publication No. WO 2005/047480) was used as a positive control, comprising the Fusarium moniliforme ⁇ 15 desaturase (i.e., Fm.d15 [SEQ ID NOs:39 and 50], which additionally possessed some ⁇ 12 desaturase activity). Plasmids pY34 and pY35 shared the same vector background to allow direct comparison of expression results.
  • Fm.d15 is a bifunctional ⁇ 15 desaturase having primarily ⁇ 15 desaturase activity and some ⁇ 12 desaturase activity.
  • Kl.d15, Dh.d15 or Sk.d15 possessed ⁇ 12 desaturase activity in addition to ⁇ 15 desaturase activity; thus, these desaturases can not be characterized as bifunctional ⁇ 15 desaturases but should instead be classified as monofunctional ⁇ 15 desaturases.
  • the Fungal ⁇ 12 Desaturase Motif of SEQ ID NO:2 was used as a means to identity other fungal ⁇ 12 desaturases using the BLASTP program of analysis (Basic Local Alignment Search Tool; Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993) and Nucleic Acids Res., 25:3389-3402 (1997)), with hits limited to fungal organisms.
  • Motif “C” is representative of all of the fungal ⁇ 12 desaturases described in Table 14, in addition to Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12 and Chg.d12 (i.e., SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 and 79, respectively), this motif is preferred (relative to either SEQ ID NO:1 or SEQ ID NO:2) for the identification of fungal polypeptides having ⁇ 12 desaturase activity, wherein the presence of Fungal ⁇ 12 Desaturase Motif “C” motif is indicative of ⁇ 12 desaturase activity.
  • a motif indicative of ⁇ 12 desaturase activity was defined as: G X W V X (A/G) H E (A/C) G H X X (F/Y) S (SEQ ID NO:4; “Fungal ⁇ 12 Desaturase Motif D”), while even more broadly, this motif was defined as: G X W V X X H E X G H X X X S (SEQ ID NO:5; “Fungal ⁇ 12 Desaturase Motif E”).
  • the percent identities revealed by this method allowed determination of: 1.) the percent identity between each of the fungal ⁇ 12 and ⁇ 15 desaturases (of putative and known function); 2.) the percent identity among the putative and known fungal ⁇ 12 desaturase proteins; and 3.) the percent identity among the putative and known fungal ⁇ 15 desaturase proteins.
  • comparison of the fungal ⁇ 12 desaturases (putative and confirmed) to the fungal ⁇ 15 desaturases (putative and confirmed) determined that the sequences collectively shared between 27.3%-61.2% identity; minimum identity was between Chg.d12 and Nc.d15, while the maximum identity was between Cl.d12 and Cg.d15 (61.2% identity), Kl.d12 and Cg.d15 (61.2% identity), and Sk.d12 and Cg.d15 (61.2% identity).
  • the percent identity ranged from 24.0% to 95%; minimum identity was between Chg.d12 and Mr.d12, while maximum identity was between Fm.d12 and Fg.d12.
  • percent identity ranged from 31.8% to 88.8%; minimum identity was between Fg.d15 and Ma.d15, while maximum identity was between Fg.d15 and Fm.d15. Boxes in FIG. 3 corresponding to the specific maximum and minimum interspecies percent identities described above are outlined in bold.
  • the percent identity between the ⁇ 12 desaturase and the ⁇ 15 desaturase within the same organism ranged between 29.5%-61.0% identity (shown as individual gray highlighted boxes in FIG. 3 ).
  • the present Example demonstrates that a Val-to-Ile mutation within the Fungal ⁇ 12 Desaturase Motif (SEQ ID NO:3, 4 or 5) of a bifunctional ⁇ 12 desaturase or a Ile-to-Val mutation within the Fungal ⁇ 15 Desaturase Motif (SEQ ID NO:46, 47 or 48) of a bifunctional ⁇ 15 desaturase is an effective means to alter the ⁇ 12/ ⁇ 15 specificity of fungal ⁇ 12 and ⁇ 15 desaturases, respectively.
  • wild type Fm.d12 is a bifunctional ⁇ 12 desaturase having only a trace level of ⁇ 15 desaturase activity
  • wild type Fm.d15 is a bifunctional ⁇ 15 desaturase, wherein the polypeptide prefers LA as its enzymatic substrate but additionally has some ability to utilize oleic acid as substrate.
  • mutant enzymes The activity of these wildtype enzymes were compared to mutant enzymes, created via site-directed mutagenesis. Specifically, single nucleotide base pair changes resulting in single amino acid substitutions of V-to-I in Fm.d12 and I-to-V in Fm.d15 were engineered. Then, both mutant enzymes were evaluated according to: 1.) their ⁇ 12 activity; 2.) their ⁇ 15 activity; and 3.) the ratio of ⁇ 15 to ⁇ 12 substrate conversion.
  • Site directed mutagenesis was carried out using Stratagene's QuikChange® XL Site-Directed Mutagenesis kit, per the manufacturer's instructions. Nucleotide ‘G’ at position 451 of Fm.d12 was changed to ‘A’, resulting in a V-to-I substitution at amino acid residue 151 (i.e., a V151I mutation). Plasmid pY35 (comprising a TEF::Fm.d12 chimeric gene) was used as the template with sense and antisense mutant primers 515 and 516 (SEQ ID NOs:42 and 43), respectively.
  • Plasmid pY34 (comprising a GPD::Fm.d15 chimeric gene) was used as the template with sense and antisense mutant primers 517 and 518 (SEQ ID NOs:44 and 45), respectively.
  • Plasmids pY34M #1 and pY35M #20 were transformed into wild type (WT) transformed into wild type (WT) Y. lipolytica ATCC #76982 and the d12KO strain referred to as “Q-d12D”(General Methods; PCT Publication No. WO 2004/104167) using standard lithium acetate methods and plated onto MM selection plates. After 3-4 days selection on MM plates, four colonies from each transformation were streaked onto fresh MM plates. After incubation at 30° C. overnight, cells from each plate were used to inoculate 3 mL MM liquid medium and grown on a shaker at 30° C. for 2 days.
  • Wild type (WT) and d12KO Yarrowia lipolytica ATCC #76982 strains transformed with parental plasmids pY34 and pY35 were also similarly grown.
  • the cells were collected by centrifugation, total lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC as described in the General Methods.
  • ⁇ 15% SC was calculated according to the following formula: ([18:3]/[18:2+18:3])*100 and represents percent substrate conversion to ALA.
  • ⁇ 15/ ⁇ 12 SC is calculated as ⁇ 15% SC/ ⁇ 12% SC;
  • ⁇ 12/ ⁇ 15 SC is calculated as ⁇ 12% SC/ ⁇ 15% SC;
  • A15/ ⁇ 12SC % WT is calculated as ([ ⁇ 15/ ⁇ 12 SC of the mutant enzyme]/[ ⁇ 15/ ⁇ 12 SC of the wild type enzyme])*100;
  • ⁇ 12/ ⁇ 15 SC % WT is calculated as ([ ⁇ 12/ ⁇ 15 SC of the mutant enzyme]/[ ⁇ 12/ ⁇ 15 SC of the wild type enzyme])*100.
  • results showed that I102V mutation in Fm.d15 resulted in a mutant enzyme with improved ⁇ 12 desaturation and poorer ⁇ 15 desaturation. Specifically, in the ⁇ 12 desaturase-disrupted strain, the I102V mutant had a ratio of ⁇ 15/ ⁇ 12 SC of 46% (Experiment 2) to 55% (Experiment 1), as compared to the wild type enzyme. Conversely, the V151I mutation in Fm.d12 resulted in poorer ⁇ 12 desaturation and improved ⁇ 15 desaturation.
  • the V151I mutant had a 381% (Experiment 2) to 401% (Experiment 1) improvement in ⁇ 15/ ⁇ 12 SC, as compared to the wild type enzyme. This showed that the catalytic activity and specificity of the Fusarium monoliforme desaturases can be improved by the mutations.
  • a Val-to-Ile mutation within the Fungal ⁇ 12 Desaturase Motif (SEQ ID NO:3, 4 or 5) in the ⁇ 12 desaturase of Fusarium moniliforme i.e., a V151I mutation in the ⁇ 12 desaturase having bifunctional ⁇ 12 desaturase activity
  • the Applicant made the corresponding mutations in the monofunctional ⁇ 15 desaturase (Sk.d15) from Saccharomyces kluyveri and the apparently monofunctional ⁇ 12 desaturase (Yl.d12) from Yarrowia lipolytica. Both mutant enzymes were compared to their parent controls with respect to: 1.) their ⁇ 12 activity; 2.) their ⁇ 15 activity; and 3.) the ratio of ⁇ 15 to ⁇ 12 substrate conversion.
  • Plasmid pY107 Skd15 comprising a TEF::Sk.d12 chimeric gene, described in Example 2, was used as the template with sense and antisense mutant primers 631 and 632 (SEQ ID NOs:96 and 97), respectively, for site-directed mutagenesis using Stratagene's QuikChange® XL Site-Directed Mutagenesis kit, per the manufacturer's instructions. These primers were designed to change nucleotide ‘A’ at position 355 of Sk.d15 ORF to ‘G’ (i.e., a A355G mutation) resulting in an I-to-V substitution at amino acid residue 119 (i.e., a I119V mutation).
  • the QuickChange reaction was transformed into E. coli GOLD XL competent cells (BRL, Bethesda, Md.). Several transformants were sequenced. Plasmid pY123 #5 was identified as a Sk.d15 mutant containing only the desired A355G mutation resulting in a I119V mutation. To ensure that there were no mutations in the unsequenced portion of pY123 #5, the sequenced region of pY123 #5 between SphI and NcoI was isolated and used to replace the corresponding sequence of the parent pY107. This resulted in plasmid pY125 that contained Sk.d15 with I119V as the sole mutation.
  • Plasmid pY28 (SEQ ID NO: 98) RE Sites And Nucleotides Within SEQ ID NO: 98 Description Of Fragment And Chimeric Gene Components SalI/NcoI Yarrowia lipolytica GPD promoter (WO 2005/003310; (1–971) GenBank Accession No. XM_501515) (corresponding to 825835–826763 bp in GenBank Accession No.
  • CR382129 except for a single bp change (C826238T) made to destroy the NcoI for cloning convenience, a single A insertion at position 826161 and a 37 bp direct repeat of nucleotides 825884–825922) NcoI/NotI Yarrowia lipolytica ⁇ 12 desaturase (WO 2004/104167; (971–2234) GenBank Accession No. CR382128) (SEQ ID NO: X) NotI (2234)- Lip1: Lip1 terminator sequence from Yarrowia Lip1 gene 2561 (GenBank Accession No.
  • Plasmid pY6 was derived from plasmid pY28 by removal of the Yl.d12 ORF. It served as an empty vector control.
  • Plasmid pY28 was used as the template with sense and antisense mutant primers 633 and 634 (SEQ ID NOs:99 and 100), respectively, for site-directed mutagenesis using Stratagene's QuikChange® XL Site-Directed Mutagenesis kit, per the manufacturer's instructions. These primers were designed to change nucleotide ‘G’ at position 352 of the Yl.d12 ORF to ‘A’ (i.e., a G352A mutation) resulting in a V-to-I substitution at amino acid residue 118 (i.e., a V118I mutation).
  • the QuickChange reaction was transformed into E. coli GOLD XL competent cells (BRL, Bethesda, Md.). Several transformants were sequenced to identify mutant enzymes. Plasmid pY124 #7 was identified as a Yl.d12 desaturase mutant containing only the desired G352A mutation resulting in a V118I mutation. In addition, plasmid pY124 #9 was also identified with an inadvertent Yl.d12 desaturase mutant containing a G352T mutation resulting in a V118F mutation.
  • mutant Yl.d12 ORFs were isolated from pY124 #7 and pY124 #9, and used to replace the Yl.d12 WT ORF in the parental plasmid pY28 resulting in plasmids pY128 (Yl.d12 V118I mutant) and pY127 (Yl.d12 V118F mutant), respectively.
  • WO 2004/104167 using standard lithium acetate methods and plated onto MM selection plates. After 3-4 days selection on MM plates, three colonies from each transformation were streaked onto fresh MM plates. After incubation at 30° C. overnight, cells from each plate were used to inoculate 3 mL MM liquid medium and grown on a shaker at 30° C. for 2 days. The cells were collected by centrifugation, total lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC as described in the General Methods.
  • Plasmid pY129 comprising a Y. lipolytica GPD promoter and the Mortierella alpina ⁇ 12 desaturase (Ma.d12; GenBank Accession No. AF417244) was created as follows. First, the Ma.d12 ORF was cloned by PCR from a M. alpina cDNA library with 5′ NcoI and 3′ NotI. The encoded ⁇ 12 desaturase protein was identical to the sequence in GenBank Accession No. AF417244, except for a H392Q mutation.
  • the NcoI/NotI fragment carrying the Ma.d12 ORF was used to replace the NcoI/NotI fragment carrying the Yl.d12 ORF in plasmid pY28, resulting in plasmid pY129 comprising a chimeric GPD::Ma.d12 ORF gene.
  • Plasmids pY6 empty vector control
  • pY28 Yl.d12 WT
  • pY128 Yl.d12 V118I mutant
  • pY127 Yl.d12 V118F mutant
  • pY129 pY129
  • Tables 17 and 18 show fatty acid composition (% of the total fatty acids) with standard deviation (“SD”) in experiments 1 and 2, respectively.
  • Fatty acids are identified as 16:0 (palmitate), 16:1 (palmitoleic acid), 18:0, 18:1 (oleic acid), 18:2 (c9, 12) (LA) and 18:3 (c9, 12, 15) (ALA).
  • LA lamitate
  • oleic acid oleic acid
  • 18:2 c9, 12
  • 18:3 c9, 12, 15
  • ALA 18:3 (c9, 12, 15)
  • ⁇ 15% SC was calculated according to the following formula: ([18:3]/[18:2+18:3])*100 and represents percent substrate conversion to ALA. ⁇ 15/ ⁇ 12 SC is calculated as ⁇ 15% SC/ ⁇ 12% SC.
  • Fatty acid composition in Table 17 is the average of triplicate cultures of all samples, except WT host transformed with pY124, which was the average of duplicate cultures.
  • Fatty acid composition in Table 18 is the average of quadruplicate cultures of all samples, except the d12KO host transformed with pY28, which was the average of triplicate cultures.
  • Results showed no ⁇ 12 desaturase activity in the d12KO strain transformed with plasmid pY127 carrying the Yl.d12 V118F mutant; thus, residue 118 of Yl.d12 desaturase is important for enzyme activity.
  • Modification of ⁇ 12/ ⁇ 15 desaturase-like polypeptides having ⁇ 12 and/or ⁇ 15 desaturase activity could be achieved using the methodology described in the present Example in e.g., An.d12 (SEQ ID NO:51), Mg.d12 (SEQ ID NO:53), Nc.d12 (SEQ ID NO:55), Fg.d12 (SEQ ID NO:57), Ma.d12 (SEQ ID NO:59), Sk.d12 (SEQ ID NO:61), Kl.d12 (SEQ ID NO:63), Ca.d12 (SEQ ID NO:65), Cg.d12 (SEQ ID NO:67), Ct.d12 (SEQ ID NO:69), Cl.d12 (SEQ ID NO:71), Dh.d12 (SEQ ID NO:73), Af.d12 (SEQ ID NO:75), Ao.d12 (SEQ ID NO:77), Chg.d12 (SEQ ID NO:79), An.d15 (SEQ ID NO:52),

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to fungal Δ12 desaturases (responsible for conversion of oleic acid to linoleic acid (18:2, LA)) and Δ15 fatty acid desaturases (responsible for conversion of LA to α-linolenic acid (18:3, ALA)). Amino acid motifs diagnostic of Δ12 desaturases and Δ15 desaturases are also provided. Methods of altering enzyme specificity towards Δ12 desaturation or towards Δ15 desaturation and/or increasing production of specific ω-3 and ω-6 fatty acids by over-expression of the fungal desaturases are also described.

Description

  • This application claims the benefit of U.S. Provisional Application No. 60/796637, filed May 1, 2006.
    • FIELD OF THE INVENTION
  • This invention is in the field of biotechnology. More specifically, this invention pertains to the identification of nucleic acid fragments encoding fungal motifs indicative of Δ15 fatty acid desaturase enzymes and Δ12 fatty acid desaturase enzymes.
    • BACKGROUND OF THE INVENTION
  • The importance of long chain polyunsaturated fatty acids (PUFAs) is undisputed. For example, certain PUFAs are important biological components of healthy cells and are recognized as: “essential” fatty acids that cannot be synthesized de novo in mammals and instead must be obtained either in the diet or derived by further desaturation and elongation of linoleic acid (LA;18:2 ω-6) or α-linolenic acid (ALA; 18:3 ω-3); constituents of plasma membranes of cells, where they may be found in such forms as phospholipids or triacylglycerols; necessary for proper development (particularly in the developing infant brain) and for tissue formation and repair; and, precursors to several biologically active eicosanoids of importance in mammals (e.g., prostacyclins, eicosanoids, leukotrienes, prostaglandins). Additionally, a high intake of long-chain ω-3 PUFAs produces cardiovascular protective effects (Dyerberg, J. et al., Amer. J. Clin Nutr., 28:958-966 (1975); Dyerberg, J. et al., Lancet, 2(8081):117-119 (Jul. 15, 1978); Shimokawa, H., World Rev. Nutr. Diet, 88:100-108 (2001); von Schacky, C. and Dyerberg, J., World Rev. Nutr. Diet, 88:90-99 (2001)). And, numerous other studies document wide-ranging health benefits conferred by administration of ω-3 and/or ω-6 PUFAs against a variety of symptoms and diseases (e.g., asthma, psoriasis, eczema, diabetes, cancer).
  • A variety of different hosts including plants, algae, fungi and yeast are being investigated as means for commercial PUFA production. Genetic engineering has demonstrated that the natural abilities of some hosts (even those natively limited to LA and ALA fatty acid production) can be substantially altered to result in high level production of e.g., arachidonic acid (ARA; 20:4 ω-6), eicosapentaenoic acid (EPA; 20:5 ω-3) and docosahexaenoic acid (DHA; 22:6 ω-3) PUFAs. Whether ω-3/ω-6 PUFA production is the result of natural abilities or recombinant technology, both strategies may require conversion of oleic acid (18:1) to LA by the action of a Δ12 desaturase; ω-3 PUFA production is typically enhanced by the conversion of LA to ALA by the action of a Δ15 desaturase. Subsequent longer-chain PUFAs are generally synthesized via either the Δ6 desaturase/Δ6 elongase pathway (which is predominantly found in algae, mosses, fungi, nematodes and humans and which is characterized by production of γ-linoleic acid (GLA; 18:3 ω-6) and/or stearidonic acid (STA; 18:4 ω-3)) or the Δ9 elongase/Δ8 desaturase pathway (which operates in some organisms, such as euglenoid species and which is characterized by production of eicosadienoic acid (EDA; 20:2 ω-6) and/or eicosatrienoic acid (ETrA; 20:3 ω-3)) (FIG. 1).
  • Based on the role that Δ12 desaturase and Δ15 desaturase enzymes play to thereby effectively “push” carbon into the ω-3/ω-6 PUFA biosynthetic pathway, there has been considerable effort to identify and characterize these enzymes from various sources. Although a variety of fungal Δ12 desaturases have been publically disclosed, a limited number of fungal Δ15 desaturases with an unexpectedly high degree of sequence homology to fungal Δ12 desaturases have been described only recently. More specifically, many fungal Δ15 desaturases were initially described as a “Δ12 desaturase-like” protein or polypeptide, based on their significant similarity with known fungal Δ12 desaturases (PCT Publications No. WO 2005/047485 and No. WO 2005/047480).
  • PCT Publication No. WO 2003/099216 (Monsanto Technology, LLC) teaches fungal sequences and their expression, and specifically includes data supporting the functional characterization of desaturases having Δ15 activity from Neurospora crassa and Aspergillus nidulans, as well as some amino acid motifs derived thereof; a putative “Δ15 desaturase” sequence from Botrytis cinerea is also disclosed. PCT Publication No. WO 2006/019192 describes the Δ15 desaturase of Mortierella alpina. Additionally, Kainou et al. (Yeast, 23(8):605-612 (2006)) and Murayama et al. (Microbiol., 152(5):1551-1558 (2006)) independently characterized Δ12 and Δ15 desaturases from Kluyveromyces lactis and Candida albicans, respectively. Kainou et al. suggests amino acid alterations responsible for the substrate preferences between the Kluyveromyces lactis Δ12 and Δ15 desaturase.
  • Relatively few fungal Δ15 desaturases are known. Additionally, no facile sequence-based method is available to facilitate the distinction between Δ15 and Δ12 desaturase sequences. The problem to be solved, therefore, is to provide a sequence-based method that easily distinguishes polypeptides having Δ15 desaturase activity as opposed to Δ12 desaturase activity. Applicants have solved the stated problem via a sequence of empirical steps comprising: (1) isolating a pool of Δ12/Δ15 desaturase-like polypeptides of fungal origin; (2) developing a sequence-based means to distinguish fungal Δ12 desaturases from fungal Δ15 desaturases; and, (3) identifying a specific amino acid residue(s) that enables one to alter fungal desaturase enzyme activity, substrate specificity and Δ12/Δ15 regiospecificity.
    • SUMMARY OF THE INVENTION
  • The invention relates to the discovery of motifs present in desaturases enzymes having either Δ12 or Δ15 desaturase activity. The Δ12 desaturase motifs are diagnostic for Δ12 desaturase activity; and conversely, the Δ15 desaturase motifs are diagnostic for Δ15 desaturase activity. Additionally the invention describes specific amino acid residues that, when altered, have the effect of altering the Δ12 or Δ15 desaturase specificity.
  • Accordingly the invention provides a fungal Δ12 desaturase motif having an amino acid sequence as set forth in SEQ ID NO:5. Other preferred Δ12 desaturase motifs are encompassed by the amino acid sequences of SEQ ID NOs:3 and 4. Similarly the invention provides a fungal Δ15 desaturase motif having an amino acid sequence as set forth in SEQ ID NO:48, where other preferred motifs have the amino acid motifs set forth in SEQ ID NOs:46 and 47.
  • In another embodiment the invention provides a method for identifying a fungal polypeptide having Δ12 desaturase activity from a pool of Δ12/Δ15 desaturase-like polypeptides comprising:
      • a) identifying a fungal Δ12/Δ15 desaturase-like polypeptide of; and,
      • b) confirming the presence of a Δ12 desaturase motif in the Δ12/Δ15 desaturase-like polypeptide, wherein the Δ12 desaturase motif is selected from the group consisting of SEQ ID NOs:3, 4 and 5 and wherein the presence of the Δ12 desaturase motif is indicative of Δ12 desaturase activity.
  • In another embodiment the invention provides a method for identifying a fungal polypeptide having Δ15 desaturase activity from a pool of Δ12/Δ15 desaturase-like polypeptides comprising:
      • a) identifying a fungal Δ12/Δ15 desaturase-like polypeptide; and,
      • b) confirming the presence of a Δ15 desaturase motif in the Δ12/Δ15 desaturase-like polypeptide, wherein the Δ15 desaturase motif is selected from the group consisting of SEQ ID NOs:46, 47 and 48 and wherein the presence of the Δ15 desaturase motif is indicative of Δ15 desaturase activity.
  • In a related embodiment the invention provides a fungal polypeptide having Δ12 desaturase activity isolated by the methods of the invention, excluding Δ12 desaturase polypeptides isolated from the following species: Saccharomyces kluyveri, Mortierella alpina, Fusarium graminearum, Fusarium moniliforme, Magnaporthe grisea, Neurospora crassa, Aspergillus nidulans, Mortierella isabellina, Pichia pastoris, Aspergillus parasiticus, Cryptococcus curvatus, Saprolegnia diclina, Yarrowia lipolytica, Lentinula edodes, Mucor circinelloides, Mucor rouxii, Rhizopus oryzae, Botrytis cinerea and Aspergillus flavus.
  • In a similar embodiment the invention provides an isolated fungal polypeptide having Δ15 desaturase activity isolated by the methods of the invention, excluding Δ15 desaturase polypeptides isolated from the following species: Saccharomyces kluyveri, Mortierella alpina, Aspergillus nidulans, Neurospora crassa, Fusarium graminearum, Fusarium moniliforme and Magnaporthe grisea.
  • In a related embodiment the invention provides methods for obtaining nucleic acid molecules encoding the Δ12 and Δ15 desaturase polypeptides of the invention using primer directed amplification protocols or nucleic acid hybridization methods in combination with primers or probes having sequence homology based on the motifs disclosed herein against fungal libraries or genomic DNA.
  • In another embodiment the invention provides a method for increasing the ability of a bifunctional fungal Δ15 desaturase enzyme to act on a Δ12 desaturase substrate comprising:
      • a) providing a nucleic acid molecule encoding a polypeptide having bifunctional Δ15 desaturase activity and comprising a Δ15 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:46, 47 and 48, wherein each of the motif sequences comprises an isoleucine at amino acid residue 4; and,
      • b) altering the nucleic acid molecule of (a) such that it encodes a mutant polypeptide comprising a mutant Δ15 desaturase motif of (a) wherein the isoleucine at amino acid residue 4 is replaced with valine, wherein the mutant polypeptide having Δ15 desaturase activity has an increased ability to act on a Δ12 desaturase substrate.
  • Similarly the invention provides a method for increasing the ability of a bifunctional fungal Δ12 desaturase enzyme to act on a Δ15 desaturase substrate comprising:
      • a) providing a nucleic acid molecule encoding a polypeptide having bifunctional Δ12 desaturase activity and comprising a Δ12 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4 and 5, wherein each of the motif sequences comprises a valine at amino acid residue 4; and,
      • b) altering the nucleic acid molecule of (a) such that it encodes a mutant polypeptide comprising a mutant Δ12 desaturase motif of (a) wherein the valine at amino acid residue 4 is replaced with isoleucine, wherein the mutant polypeptide having Δ12 desaturase activity has an increased ability to act on a Δ15 desaturase substrate.
  • In another embodiment the invention provides a method for the production of linoleic acid comprising:
      • a.) providing a host cell comprising:
        • i.) an isolated nucleic acid fragment encoding a desaturase polypeptide comprising a fungal Δ12 desaturase motif selected from the group consisting of SEQ ID NOs:3, 4 and 5; and,
        • ii.) a source of oleic acid;
      • b.) growing the host cell of step (a) under conditions wherein the nucleic acid fragment encoding the desaturase polypeptide is expressed and the oleic acid is converted to linoleic acid; and,
      • c.) optionally recovering the linoleic acid of step (b).
  • In a similar embodiment the invention provides a method for the production of α-linolenic acid comprising:
      • a.) providing a host cell comprising:
        • i.) an isolated nucleic acid fragment encoding a desaturase polypeptide comprising a fungal Δ15 desaturase motif selected from the group consisting of SEQ ID NOs:46, 47 and 48; and,
        • ii.) a source of linoleic acid;
      • b.) growing the host cell of step (a) under conditions wherein the nucleic acid fragment encoding the desaturase protein is expressed and the linoleic acid is converted to α-linolenic acid; and,
      • c.) optionally recovering the α-linolenic acid of step (b).
  • In another embodiment the invention provides a method for identifying a polynucleotide sequence encoding a fungal polypeptide having Δ15 desaturase activity comprising:
      • a) providing at least one polynucleotide sequence encoding a Δ15 desaturase motif selected from the group consisting of SEQ ID NOs:46, 47 and 48, on a computer-readable format;
      • b) comparing on the computer-readable format the at least one polynucleotide sequence of (a) with at least on e polynucleotide sequence of at least one fungal genome; and
      • c) identifying a fungal sequence comprising the at least one polynucleotide sequence encoding a Δ15 desaturase motif;
        wherein the fungal sequences of (c) comprising the at least one polynucleotide sequences encoding a Δ15 desaturase motif encode a Δ15 desaturase polypeptide having Δ15 desaturase activity.
  • Similarly the invention provides a method for identifying an amino acid sequence of fungal polypeptide having Δ15 desaturase activity comprising:
      • a) providing at least one amino acid sequence of a Δ15 desaturase motif selected from the group consisting of SEQ ID NOs:46, 47 and 48, on a computer-readable format;
      • b) comparing, on the computer-readable format, the at least one amino acid sequence of (a) with at least one amino acid sequence of at least one fungal genome;
      • c) identifying a fungal sequence comprising the at least one amino acid sequence of a Δ15 desaturase motif;
        wherein the fungal sequence of (c) comprising the at least one amino acid sequence of a Δ15 desaturase motif define a Δ15 desaturase polypeptide having Δ15 desaturase activity.
  • In a related embodiment the invention provides a method for identifying a polynucleotide sequence encoding a fungal polypeptide having Δ12 desaturase activity comprising:
      • a) providing at least one polynucleotide sequence encoding a Δ12 desaturase motif selected from the group consisting of SEQ ID NOs:3, 4 and 5, on a computer-readable format;
      • b) comparing, on the computer-readable format the at least one polynucleotide sequence of (a) with at least one polynucleotide sequence of at least one fungal genome; and
      • c) identifying a fungal sequence comprising the at least one polynucleotide sequence encoding a Δ12 desaturase motif;
        wherein the fungal sequences of (c) comprising the at least one polynucleotide sequences encoding a Δ12 desaturase motif encode a Δ12 desaturase polypeptide having Δ12 desaturase activity.
  • Similarly the invention provides a method for identifying an amino acid sequence of fungal polypeptide having Δ12 desaturase activity comprising:
      • a) providing at least one amino acid sequence of a Δ12 desaturase motif selected from the group consisting of SEQ ID NOs:3, 4 and 5, on a computer-readable format;
      • b) comparing, on the computer-readable format, the at least one amino acid sequence of (a) with at least one amino acid sequence of at least one fungal genome;
      • c) identifying a fungal sequence comprising the at least one amino acid sequence of a Δ12 desaturase motif;
        wherein the fungal sequences of (c) comprising the at least one amino acid sequence of a Δ12 desaturase motif define a Δ12 desaturase polypeptide having Δ12 desaturase activity.
    BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE DESCRIPTIONS
  • FIG. 1 illustrates the ω-3/ω-6 fatty acid biosynthetic pathway.
  • FIG. 2 shows a phylogenetic tree of fungal Δ12 desaturase and fungal Δ15 desaturase proteins, created using the MegAlign™ program of DNASTAR software.
  • FIG. 3 shows a pairwise comparison (% Identity) between and among proteins from different fungi using a Clustal W analysis (MegAlign™ program of DNASTAR software).
  • FIG. 4 provides plasmid maps for the following: (A) pY137; and, (B) pY117.
  • The invention can be more fully understood from the following detailed description and the accompanying sequence descriptions, which form a part of this application.
  • The following sequences comply with 37 C.F.R. §1.821-1.825 (“Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures—the Sequence Rules”) and are consistent with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.
  • A Sequence Listing is provided herewith on Compact Disk. The contents of the Compact Disk containing the Sequence Listing are hereby incorporated by reference in compliance with 37 C.F.R. §1.52(e). The Compact Disks are submitted in triplicate and are identical to one another.
  • SEQ ID NOs:1-30 and 46-95 are motifs, regions of conserved amino acids or proteins encoding desaturases, as identified in Table 1.
  • TABLE 1
    Summary Of Protein SEQ ID Numbers
    Protein
    Description and Abbreviation SEQ ID NO.
    Fungal Δ12 Desaturase Motif “A”  1
    Fungal Δ12 Desaturase Motif “B”  2
    Fungal Δ12 Desaturase Motif “C”  3
    Fungal Δ12 Desaturase Motif “D”  4
    Fungal Δ12 Desaturase Motif “E”  5
    Fungal Δ15 Desaturase Motif “A” 46
    Fungal Δ15 Desaturase Motif “B” 47
    Fungal Δ15 Desaturase Motif “C” 48
    HIS Box I motif 6
    Fungal Δ12 Desaturase Conserved Region #1  7
    Fungal Δ12 Desaturase Conserved Region #2  8
    Fungal Δ12 Desaturase Conserved Region #3  9
    Fungal Δ12 Desaturase Conserved Region #4 10
    Fungal Δ12 Desaturase Conserved Region #5 11
    Fungal Δ12 Desaturase Conserved Region #6 12
    Fungal Δ12 Desaturase Conserved Region #7 13
    Fungal Δ12 Desaturase Conserved Region #8 14
    Fungal Δ12 Desaturase Conserved Region #9 15
    Fungal Δ12 Desaturase Conserved Region #10 16
    Fungal Δ12 Desaturase Conserved Region #11 17
    Fungal Δ12 Desaturase Conserved Region #12 18
    Fungal Δ12 Desaturase Conserved Region #13 19
    Fungal Δ12 Desaturase Conserved Region #14 20
    Fungal Δ12 Desaturase Conserved Region #15 21
    Fungal Δ15 Desaturase Conserved Region #1 22
    Fungal Δ15 Desaturase Conserved Region #2 23
    Fungal Δ15 Desaturase Conserved Region #3 24
    Fungal Δ15 Desaturase Conserved Region #4 25
    Fungal Δ15 Desaturase Conserved Region #5 26
    Fungal Δ15 Desaturase Conserved Region #6 27
    Fungal Δ15 Desaturase Conserved Region #7 28
    Fungal Δ15 Desaturase Conserved Region #8 29
    Fungal Δ15 Desaturase Conserved Region #9 30
    Gibberella fujikuroi Δ12 desaturase (GenBank 49 (477 AA)
    Accession No. DQ272515)
    Gibberella fujikuroi Δ15 desaturase (GenBank 50 (402 AA)
    Accession No. DQ272516)
    Aspergillus nidulans FGSC A4 Δ12 desaturase 51 (426 AA)
    (GenBank Accession No. XP_658641)
    Aspergillus nidulans FGSC A4 Δ15 desaturase 52 (394 AA)
    (GenBank Accession No. XP_664808)
    Magnaporthe grisea 70-15 Δ12 desaturase 53 (551 AA)
    (GenBank Accession No. XP_365283)
    Magnaporthe grisea 70-15 Δ15 desaturase 54 (394 AA)
    (GenBank Accession No. XP_362963)
    Neurospora crassa Δ12 desaturase (GenBank 55 (429 AA)
    Accession No. XP_329856)
    Neurospora crassa Δ15 desaturase (GenBank 56 (481 AA)
    Accession No. XP_330985)
    Gibberella zeae PH-1 Δ12 desaturase (GenBank 57 (475 AA)
    Accession No. EAA75859)
    Gibberella zeae Δ15 desaturase (GenBank 58 (193 AA)
    Accession No. BAA33772)
    Mortierella alpina Δ12 desaturase (GenBank 59 (400 AA)
    Accession No. BAA81754)
    Mortierella alpina Δ15 desaturase (GenBank 60 (403 AA)
    Accession No. AB182163)
    Saccharomyces kluyveri Δ12 desaturase (GenBank 61 (416 AA)
    Accession No. BAD08375)
    Saccharomyces kluyveri Δ15 desaturase (GenBank 62 (419 AA)
    Accession No. BAD11952)
    Kluyveromyces lactis Δ12 desaturase (GenBank 63 (410 AA)
    Accession No. XP_455402)
    Kluyveromyces lactis Δ15 desaturase (GenBank 64 (415 AA)
    Accession No. XP_451551)
    Candida albicans SC5314 Δ12 desaturase 65 (436 AA)
    (GenBank Accession No. EAK94955)
    Candida albicans SC5314 Δ15 desaturase 66 (433 AA)
    (GenBank Accession No. EAL03493)
    Candida guilliermondii Δ12 desaturase 67 (417 AA)
    Candida guilliermondii Δ15 desaturase 68 (370 AA)
    Candida tropicalis Δ12 desaturase 69 (340 AA)
    Candida tropicalis Δ15 desaturase 70 (349 AA)
    Candida lusitaniae Δ12 desaturase 71 (418 AA)
    Candida lusitaniae Δ15 desaturase 72 (346 AA)
    Debaryomyces hansenii CBS767 Δ12 desaturase 73 (416 AA)
    (GenBank Accession No. CAG90237)
    Debaryomyces hansenii CBS767 Δ15 desaturase 74 (435 AA)
    (GenBank Accession No. CAG88182)
    Aspergillus fumigatus Af293 Δ12 desaturase 75 (469 AA)
    (GenBank Accession No. EAL90585)
    Aspergillus fumigatus Af293 Δ15 desaturase 76 (396 AA)
    (GenBank Accession No. EAL85733)
    Aspergillus oryzae Δ12 desaturase (GenBank 77 (466 AA)
    Accession No. BAD04850)
    Aspergillus oryzae Δ15 desaturase (GenBank 78 (392 AA)
    Accession No. BAE66531)
    Chaetomium globosum CBS 148.51 Δ12 79 (348 AA)
    desaturase (GenBank Accession No. EAQ83131)
    Chaetomium globosum CBS 148.51 Δ15 80 (400 AA)
    desaturase (GenBank Accession No. EAQ88866)
    Mortierella isabellina Δ12 desaturase (GenBank 81 (400 AA)
    Accession No. AAL13301)
    Coccidioides immitis RS Δ12 desaturase (GenBank 82 (445 AA)
    Accession No. EAS31392)
    Pichia pastoris Δ12 desaturase (GenBank 83 (420 AA)
    Accession No. AAX20125)
    Ashbya gossypii [ATCC #10895] Δ12 desaturase 84 (413 AA)
    (GenBank Accession No. AAS53960)
    Aspergillus parasiticus Δ12 desaturase (GenBank 85 (466 AA)
    Accession No. AAP23194)
    Cryptococcus curvatus Δ12 desaturase (GenBank 86 (446 AA)
    Accession No. AAU12575)
    Cryptococcus neoformans var. neoformans B3501A 87 (448 AA)
    Δ12 desaturase (GenBank Accession No.
    EAL21306)
    Saprolegnia diclina Δ12 desaturase (GenBank 88 (393 AA)
    Accession No. AAR20443)
    Yarrowia lipolytica CLIB122 Δ12 desaturase 89 (419 AA)
    (GenBank Accession No. CAG82952)
    Lentinula edodes Δ12 desaturase (GenBank 90 (435 AA)
    Accession No. BAD51484)
    Ustilago maydis 521 Δ12 desaturase (GenBank 91 (553 AA)
    Accession No. XP_757193)
    Mucor circinelloides Δ12 desaturase (GenBank 92 (396 AA)
    Accession No. BAB69056)
    Mucor rouxii Δ12 desaturase (GenBank Accession 93 (396 AA)
    No. AAD55982)
    Rhizopus oryzae Δ12 desaturase (GenBank 94 (389 AA)
    Accession No. AAT58363)
    Aspergillus flavus Δ12 desaturase (GenBank 95 (466 AA)
    Accession No. AAP33789)
  • SEQ ID NOs:31-32 correspond to primers 513 and 514, respectively, used to PCR amplify Kl.d15 from Kluyveromyces lactis NRRL Y-1140.
  • SEQ ID NOs:33-34 correspond to primers 519 and 520, respectively, used to PCR amplify Sk.d15 from Saccharomyces kluyveri.
  • SEQ ID NOs:35-36 correspond to primers 521 and 522, respectively, used to PCR amplify Dh.d15 from Debaryomyces hansenii CBS767.
  • SEQ ID NO:37 provides the amino acid sequence of the Saccharomyces kluyveri Δ15 desaturase (i.e., Sk.d15) in plasmid pY107 Skd15.
  • SEQ ID NO:38 shows the DNA sequence of the Fusarium moniliforme Δ15 desaturase gene, while SEQ ID NO:39 shows the corresponding amino acid sequence of the F. moniliforme Δ15 desaturase (i.e., Fm.d15).
  • SEQ ID NO:40 shows the DNA sequence of the Fusarium moniliforme Δ12 desaturase gene, while SEQ ID NO:41 shows the corresponding amino acid sequence of the F. moniliforme Δ12 desaturase (i.e., Fm.d12).
  • SEQ ID NOs:42-45 correspond to primers 515, 516, 517 and 518, respectively, used during site-directed mutagenesis of Fm.d12 and Fm.d15, respectively.
  • SEQ ID NOs:96 and 97 correspond to primers 631 and 632, respectively, used during site-directed mutagenesis of Sk.d15.
  • SEQ ID NO:98 provides the 9,099 bp nucleotide sequence of plasmid pY28.
  • SEQ ID NOs:99 and 100 correspond to primers 633 and 634, respectively, used during site-directed mutagenesis of Yl.d12.
  • SEQ ID NO:101 provides the 6,267 bp nucleotide sequence of plasmid pY137.
  • SEQ ID NO:102 provides the 9,570 bp nucleotide sequence of plasmid pY117.
  • SEQ ID NO:103 provides the nucleic acid sequence of the Saccharomyces kluyveri Δ15 desaturase (i.e., Sk.d15) in plasmid pY107 Skd15.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • All patents, patent applications, and publications cited herein are incorporated by reference in their entirety. This specifically includes the following Applicants' Assignee's co-pending applications: U.S. Pat. No. 7,125,672, U.S. Pat. No. 7,189,559, U.S. Pat. No. 7,192,762, U.S. Pat. No. 7,198,937, U.S. Pat. No. 7,202,356, U.S. patent application Ser. No. 10/840,579 and Ser. No. 10/840,325 (filed May 6, 2004), U.S. patent application Ser. No. 10/869,630 (filed Jun. 16, 2004), U.S. patent application Ser. No. 10/882,760 (filed Jul. 1, 2004), U.S. patent application Ser. No. 10/985,254 and Ser. No. 10/985,691 (filed Nov. 10, 2004), U.S. patent application Ser. No. 11/024,544 (filed Dec. 29, 2004), U.S. patent application Ser. No. 11/166,993 (filed Jun. 24, 2005), U.S. patent application Ser. No. 11/183,664 (filed Jul. 18, 2005), U.S. patent application Ser. No. 11/185,301 (filed Jul. 20, 2005), U.S. patent application Ser. No. 11/190,750 (filed Jul. 27, 2005), U.S. patent application Ser. No. 11/198,975 (filed Aug. 8, 2005), U.S. patent application Ser. No. 11/225,354 (filed Sep. 13, 2005), U.S. patent application Ser. No. 11/253,882 (filed Oct. 19, 2005), U.S. patent application No. 11/264784 and Ser. No. 11/264,737 (filed Nov. 1, 2005), U.S. patent application Ser. No. 11/265,761 (filed Nov. 2, 2005), U.S. Patent Application No. 60/795,810 (filed Apr. 28, 2006), U.S. Patent Application No. 60/793,575 (filed Apr. 20, 2006), U.S. Patent Application No. 60/796,637 (filed May 2, 2006), U.S. Patent Application No. 60/801,172 and No. 60/801,119 (filed May 17, 2006), U.S. Patent Application No. 60/853,563 (filed Oct. 23, 2006), U.S. Patent Application No. 60/855,177 (filed Oct. 30, 2006), U.S. patent application Ser. No. 11/601,563 and Ser. No. 11/601,564 (filed Nov. 16, 2006), U.S. patent application Ser. No. 11/635,258 (filed Dec. 7, 2006) and U.S. patent application Ser. No. 11/613,420 (filed Dec. 20, 2006).
  • Applicants have identified Δ15 desaturases from Kluyveromyces lactis, Candida albicans, C. guilliermondii, C. tropicalis, C. lusitaniae, Debaryomyces hansenii CBS767, Aspergillus fumigatus, A. oryzae and Chaetomium globosum. Methods are also provided to readily distinguish fungal protein sequences having Δ15 desaturase activity as opposed to Δ12 desaturase activity, based on a single isoleucine/valine amino acid. Mutation of this specific residue has proven an effective means to alter enzyme substrate specificity or regioselectivity, such as towards Δ12 desaturation or towards Δ15 desaturation.
  • The invention relates to novel fungal Δ12 and Δ15 desaturase enzymes and genes encoding the same that may be used for the manipulation of biochemical pathways for the production of healthful PUFAs. Thus, the subject invention finds many applications. PUFAs, or derivatives thereof, made by the methodology disclosed herein can be used as dietary substitutes, or supplements, particularly infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition. Alternatively, the purified PUFAs (or derivatives thereof) may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount for dietary supplementation. The PUFAs may also be incorporated into infant formulas, nutritional supplements or other food products and may find use as anti-inflammatory or cholesterol lowering agents. Optionally, the compositions may be used for pharmaceutical use (human or veterinary).
  • Supplementation of humans or animals with PUFAs produced by recombinant means can result in increased levels of the added PUFAs, as well as their metabolic progeny. For example, treatment with EPA can result not only in increased levels of EPA, but also downstream products of EPA such as eicosanoids (i.e., prostaglandins, leukotrienes, thromboxanes). Complex regulatory mechanisms can make it desirable to combine various PUFAs, or add different conjugates of PUFAs, in order to prevent, control or overcome such mechanisms to achieve the desired levels of specific PUFAs in an individual.
    • Definitions
  • In this disclosure, a number of terms and abbreviations are used. The following definitions are provided.
      • “Open reading frame” is abbreviated ORF.
      • “Polymerase chain reaction” is abbreviated PCR.
      • “American Type Culture Collection” is abbreviated ATCC.
      • “Polyunsaturated fatty acid(s)” is abbreviated PUFA(s).
      • “Triacylglycerols” are abbreviated TAGs.
  • The term “Fusarium moniliforme” is synonymous with “Fusarium verticillioides” and is also synonymous with “Gibberella fujikuroi”. More specifically, the Fusarium moniliforme Δ12 desaturase described herein as SEQ ID NO:41 (Fm.d12) is identical to the Gibberella fujikuroiΔ12 desaturase described as GenBank Accession No. DQ272515 (SEQ ID NO:49 herein). Similarly, the Fusarium moniliforme Δ15 desaturase described herein as SEQ ID NO:39 (Fm.d15) is identical to the Gibberella fujikuroi Δ15 desaturase described as GenBank Accession No. DQ272516 (SEQ ID NO:50 herein).
  • The term “Fusarium graminearium” is synonymous with “Gibberella zeae”. More specifically, the Fusarium graminearium Δ12 desaturase described herein as Fg.d12 is identical to the Gibberella zeae Δ12 desaturase described as GenBank Accession No. EAA75859 (SEQ ID NO:57 herein). Similarly, the Fusarium graminearium Δ15 desaturase described herein as Fg.d15 is identical to the partial Gibberella zeae Δ15 desaturase fragment described as GenBank Accession No. BAA33772 (SEQ ID NO:58 herein).
  • The term “invention” or “present invention” as used herein is not meant to be limiting to any one specific embodiment of the invention but applies generally to any and all embodiments of the invention as described in the claims and specification.
  • The term “fatty acids” refers to long chain aliphatic acids (alkanoic acids) of varying chain lengths, from about C12 to C22 (although both longer and shorter chain-length acids are known). The predominant chain lengths are between C16 and C22. The structure of a fatty acid is represented by a simple notation system of “X:Y”, where X is the total number of carbon (C) atoms in the particular fatty acid and Y is the number of double bonds. Additional details concerning the differentiation between “saturated fatty acids” versus “unsaturated fatty acids”, “monounsaturated fatty acids” versus “polyunsaturated fatty acids” (or “PUFAs”), and “omega-6 fatty acids” (ω-6 or n-6) versus “omega-3 fatty acids” (ω-3 or n-3) are provided in PCT Publication No. WO 2004/101757.
  • Nomenclature used to describe PUFAs in the present disclosure is shown below in Table 2. In the column titled “Shorthand Notation”, the omega-reference system is used to indicate the number of carbons, the number of double bonds and the position of the double bond closest to the omega carbon, counting from the omega carbon (which is numbered 1 for this purpose). The remainder of the Table summarizes the common names of ω-3 and ω-6 fatty acids and their precursors, the abbreviations that will be used throughout the specification and each compounds' chemical name.
  • TABLE 2
    Nomenclature of Polyunsaturated Fatty Acids And Precursors
    Shorthand
    Common Name Abbreviation Chemical Name Notation
    Myristic — tetradecanoic 14:0
    Palmitic Palmitate hexadecanoic 16:0
    Palmitoleic — 9-hexadecenoic 16:1
    Stearic — octadecanoic 18:0
    Oleic — cis-9-octadecenoic 18:1
    Linoleic LA cis-9,12-octadecadienoic 18:2 ω-6
    γ-Linoleic GLA cis-6,9,12- 18:3 ω-6
    octadecatrienoic
    Eicosadienoic EDA cis-11,14-eicosadienoic 20:2 ω-6
    Dihomo-γ- DGLA cis-8,11,14- 20:3 ω-6
    Linoleic eicosatrienoic
    Arachidonic ARA cis-5,8,11,14- 20:4 ω-6
    eicosatetraenoic
    α-Linolenic ALA cis-9,12,15- 18:3 ω-3
    octadecatrienoic
    Stearidonic STA cis-6,9,12,15- 18:4 ω-3
    octadecatetraenoic
    Eicosatrienoic ETrA cis-11,14,17- 20:3 ω-3
    eicosatrienoic
    Eicosatetraenoic ETA cis-8,11,14,17- 20:4 ω-3
    eicosatetraenoic
    Eicosapentaenoic EPA cis-5,8,11,14,17- 20:5 ω-3
    eicosapentaenoic
    Docosapentaenoic DPA cis-7,10,13,16,19- 22:5 ω-3
    docosapentaenoic
    Docosahexaenoic DHA cis-4,7,10,13,16,19- 22:6 ω-3
    docosahexaenoic
  • The terms “triacylglycerol”, “oil” and “TAGs” refer to neutral lipids composed of three fatty acyl residues esterified to a glycerol molecule (and such terms will be used interchangeably throughout the present disclosure herein). Such oils can contain long chain PUFAs, as well as shorter saturated and unsaturated fatty acids and longer chain saturated fatty acids. Thus, “oil biosynthesis” generically refers to the synthesis of TAGs in the cell.
  • “Percent (%) PUFAs in the total lipid and oil fractions” refers to the percent of PUFAs relative to the total fatty acids in those fractions. The term “total lipid fraction” or “lipid fraction” both refer to the sum of all lipids (i.e., neutral and polar) within an oleaginous organism, thus including those lipids that are located in the phosphatidylcholine (PC) fraction, phosphatidyletanolamine (PE) fraction and triacylglycerol (TAG or oil) fraction. However, the terms “lipid” and “oil” will be used interchangeably throughout the specification.
  • A metabolic pathway, or biosynthetic pathway, in a biochemical sense, can be regarded as a series of chemical reactions occurring within a cell, catalyzed by enzymes, to achieve either the formation of a metabolic product to be used or stored by the cell, or the initiation of another metabolic pathway (then called a flux generating step). Many of these pathways are elaborate, and involve a step by step modification of the initial substance to shape it into a product having the exact chemical structure desired.
  • The term “PUFA biosynthetic pathway” refers to a metabolic process that converts oleic acid to LA, EDA, GLA, DGLA, ARA, ALA, STA, ETrA, ETA, EPA, DPA and DHA. This process is well described in the literature (e.g., see PCT Publication No. WO2006/052870). Briefly, this process involves elongation of the carbon chain through the addition of carbon atoms and desaturation of the molecule through the addition of double bonds, via a series of special desaturation and elongation enzymes (i.e., “PUFA biosynthetic pathway enzymes”) present in the endoplasmic reticulim membrane. More specifically, “PUFA biosynthetic pathway enzymes” refer to any of the following enzymes (and genes which encode said enzymes) associated with the biosynthesis of a PUFA, including: a Δ4 desaturase, a Δ5 desaturase, a Δ6 desaturase, a Δ12 desaturase, a Δ15 desaturase, a Δ17 desaturase, a Δ9 desaturase, a Δ8 desaturase, a Δ9 elongase, a C14/16 elongase, a C16/18 elongase, a C18/20 elongase and/or a C20/22 elongase.
  • The term “ω-3/ω-6 fatty acid biosynthetic pathway” refers to a set of genes which, when expressed under the appropriate conditions encode enzymes that catalyze the production of either or both ω-3 and ω-6 fatty acids. Typically the genes involved in the ω-3/ω-6 fatty acid biosynthetic pathway encode PUFA biosynthetic pathway enzymes. A representative pathway is illustrated in FIG. 1, providing for the conversion of myristic acid through various intermediates to DHA, which demonstrates how both ω-3 and ω-6 fatty acids may be produced from a common source. The pathway is naturally divided into two portions where one portion will generate ω-3 fatty acids and the other portion, only ω-6 fatty acids. That portion that only generates ω-3 fatty acids will be referred to herein as the ω-3 fatty acid biosynthetic pathway, whereas that portion that generates only ω-6 fatty acids will be referred to herein as the ω-6 fatty acid biosynthetic pathway.
  • The term “amplification” refers to the process in which “replication” is repeated in cyclic process such that the number of copies of the nucleic acid sequence is increased in either a linear or logarithmic fashion. Such replication processes may include but are not limited to, for example, Polymerase Chain Reaction (PCR) [(see, Thein and Wallace, “The use of oligonucleotide as specific hybridization probes in the Diagnosis of Genetic Disorders”, in Human Genetic Diseases: A Practical Approach, K. E. Davis Ed., (1986) pp 33-50, IRL: Herndon, Va.); and Rychlik, W. In, Methods in Molecular Biology, PCR Protocols: Current Methods and Applications. White, B. A., Ed. (1993), Vol. 15, pp 31-39, Humania: Totowa, N.J.).], Ligase Chain Reaction (LCR) Strand Displacement Amplification (SDA) [Walker et al. (Proc. Natl. Acad. Sci. U.S.A., 89:392 (1992))], or other such enzymatic reactions.
  • The term “primer directed nucleic acid amplification” or “primer-directed amplification” refers to any method known in the art wherein primers are used to sponsor replication of nucleic acid sequences in the linear or logarithmic amplification of nucleic acid molecules. Applicants contemplate that primer-directed amplification may be accomplished by any of several schemes known in this art, including but not limited to the polymerase chain reaction (PCR), ligase chain reaction (LCR) or strand-displacement amplification (SDA).
  • The term “amplification product” refers to portions of nucleic acid fragments that are produced during a primer directed amplification reaction. Typical methods of primer directed amplification include polymerase chain reaction (PCR), ligase chain reaction (LCR) or Strand displacement Amplification (SDA). If PCR methodology is selected, the replication composition would include for example, nucleotide triphosphates, two primers with appropriate sequences, DNA or RNA polymerase and proteins. These reagents and details describing procedures for their use in amplifying nucleic acids are provided in U.S. Pat. No. 4,683,202 (1987, Mullis, et al.) and U.S. Pat. No. 4,683,195 (1986, Mullis, et al.). If LCR methodology is selected, then the nucleic acid replication compositions would comprise, for example, a thermostable ligase, e.g., T. aquaticus ligase, two sets of adjacent oligonucleotides wherein one member of each set is complementary to each of the target strands, Tris HCl buffer, KCl, EDTA, NAD, dithiothreitol and salmon sperm DNA. See, for example, Tabor et al., Proc. Acad. Sci. U.S.A., 82, 1074-1078 (1985)).
  • The term “functional” as used herein in context with the ω-3/ω-6 fatty acid biosynthetic pathway means that some (or all of) the genes in the pathway express active enzymes, resulting in in vivo catalysis or substrate conversion. It should be understood that “ω-3/ω-6 fatty acid biosynthetic pathway” or “functional ω-3/ω-6 fatty acid biosynthetic pathway” does not imply that all the genes listed in the above paragraph are required, as a number of fatty acid products will only require the expression of a subset of the genes of this pathway.
  • The term “desaturase” refers to a polypeptide that can desaturate, i.e., introduce a double bond, in one or more fatty acids to produce a fatty acid or precursor of interest. Despite use of the omega-reference system throughout the specification to refer to specific fatty acids, it is more convenient to indicate the activity of a desaturase by counting from the carboxyl end of the substrate using the delta-system. Of interest herein are: 1.) Δ17 desaturases that desaturate a fatty acid between the 17th and 18th carbon atom numbered from the carboxyl-terminal end of the molecule and which, for example, catalyze the conversion of ARA to EPA and/or DGLA to ETA; 2.) Δ6 desaturases that catalyze the conversion of LA to GLA and/or ALA to STA; 3.) Δ5 desaturases that catalyze the conversion of DGLA to ARA and/or ETA to EPA; 4.) Δ4 desaturases that catalyze the conversion of DPA to DHA; 5.) Δ8 desaturases that catalyze the conversion of EDA to DGLA and/or ETrA to ETA; 6.) Δ9 desaturases that catalyze the conversion of palmitate to palmitoleic acid (16:1) and/or stearate to oleic acid; 7.) Δ12 desaturases that catalyze the conversion of oleic acid to LA; and 8.) Δ15 desaturases that catalyze the conversion of LA to ALA and/or GLA to STA. In the art, Δ15 and Δ17 desaturases are also occasionally referred to as “omega-3 desaturases”, “w-3 desaturases” and/or “ω-3 desaturases”, based on their ability to convert ω-6 fatty acids into their ω-3 counterparts (e.g., conversion of LA into ALA and ARA into EPA, respectively).
  • Of particular interest herein, however, are Δ12 desaturases and Δ15 desaturases. These enzymes are further classified with respect to only Δ12 and Δ15 desaturase activities as being either “monofunctional” or “bifunctional” Δ12 or Δ15 desaturases.
  • More specifically, Δ12 desaturases are defined as those fatty acid desaturases having monofunctional or bifunctional Δ12 desaturase activity, wherein Δ12 desaturase activity is the conversion of oleic acid to LA. The term “monofunctional Δ12 desaturase”, “monofunctional Δ12 desaturase activity” or “exclusive Δ12 desaturase activity” refers to a Δ12 desaturase that is capable of converting oleic acid to LA but that is not capable of converting LA to ALA. In contrast, “bifunctional Δ12 desaturase”, “bifunctional Δ12 desaturase activity” or “primary Δ12 desaturase activity” refers to a Δ12 desaturase that preferentially converts oleic acid to LA but additionally has limited ability to convert LA into ALA. One example of a bifunctional Δ12 desaturase is the Fusarium moniliforme Δ12 desaturase, Fm.d12 (SEQ ID NOs:41 and 49; PCT Publications No. WO 2005/047485 and No. WO 2005/047480).
  • Similarly, Δ15 desaturases are defined as those fatty acid desaturases having monofunctional or bifunctional Δ15 desaturase activity, wherein Δ15 desaturase activity is the conversion of LA to ALA. The term “monofunctional Δ15 desaturase”, “monofunctional Δ15 desaturase activity” or “exclusive Δ15 desaturase activity” refers to a Δ15 desaturase that is capable of converting LA to ALA but that is not capable of converting oleic acid to LA. In contrast, “bifunctional Δ15 desaturase”, “bifunctional Δ15 desaturase activity” or “primary Δ15 desaturase activity” refers to a Δ15 desaturase that preferentially converts LA into ALA but additionally has limited ability to convert oleic acid to LA; one example of a bifunctional Δ15 desaturase is the Fusarium moniliforme Δ15 desaturase, Fm.d15 (SEQ ID NOs:39 and 50; PCT Publications No. WO 2005/047485 and No. WO 2005/047480).
  • It should be noted that Δ12 and Δ15 desaturases can have specificities other than Δ12 and Δ15 desaturation that are not relevant in the present classification. It should also be noted that the distinction between monofunctional and bifunctional Δ12 or Δ15 desaturases is a practical one and not absolute in fungi; the same enzyme can function with e.g., either monofunctional or bifunctional Δ12 desaturase activity, depending on the level of its expression, growth condition, etc.. For example, in some fungi, such as Yarrowia lipolytica and Mortierella alpina, the native Δ12 desaturases appear monofunctional but their overexpression in Yarrowia lipolytica under a heterologus promoter, such as the Yarrowia glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter, reveals bifunctionalty (see Example 4). Similarly, over-expression an apparently monofunctional Δ15 desaturase may reveal bifunctional Δ15 desaturase activity. Furthermore, in some cases, determination of an enzyme's desaturase activity as monofunctional or bifunctional will depend on the methodology used to analyze fatty acid profile and the sensitivity of the equipment to detect extremely low levels of fatty acid conversion.
  • By “enzymatic substrate” it is meant that the desaturase polypeptide binds the substrate at an active site and acts upon it in a reactive manner. In some embodiments, it is most desirable to empirically determine the specificity of a fatty acid desaturase by transforming a suitable host with the gene for the fatty acid desaturase and determining its effect on the fatty acid profile of the host.
  • The term “Δ12/Δ15 desaturase-like polypeptide” in the context of this invention refers to a fungal protein that has homology to known fungal Δ12 and/or Δ15 desaturases. More specifically, “Δ12/Δ15 desaturase-like polypeptides” include those “hits” identified when performing a computer-automated sequence comparison using a known fungal Δ12 desaturase or fungal Δ15 desaturase as the query sequence and using an algorithm such as BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993)), along with default search parameters. Conversely, “Δ12/Δ15 desaturase-like polypeptides” also include those proteins, which when used as a query make hits to a known fungal Δ12 desaturase and/or fungal Δ15 desaturase. Thus, “Δ12/Δ15 desaturase-like polypeptides” include both fungal Δ12 and Δ15 desaturases as exemplified by Fusarium moniliforme, Aspergillus nidulans, Magnaporthe grisea, Neurospora crassa and Fusarium graminearium Δ12 desaturases and Δ15 desaturases (i.e., Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12 and Fg.d15, as described in PCT Publications No. WO 2005/047485 and No. WO 2005/047480 and corresponding herein to SEQ ID NOs:41 [or 49], 39 [or 50], 51, 52, 53, 54, 55, 56, 57 and 58, respectively). As demonstrated in the invention herein, once a pair of “Δ12/Δ15 desaturase-like polypeptides” are identified in a fungus, phylogenetic analysis frequently suggests that one protein encodes a Δ15 desaturase while the other protein encodes a Δ12 desaturase (especially when the organism from which the pair of proteins are identified belongs to a fungal group that comprises a second fungal organism with a known Δ15 desaturase). Although not to be construed as limiting to the invention herein, the homology exhibited by the novel “Δ12/Δ15 desaturase-like polypeptides” of the invention to Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12, Fg.d15, Sk.d12, Sk.d15, Ma.d12, Ma.d15, Af.d12, Ro.d12, Cc.d12, Mc.d12, Mr.d12 and Cn.d12 ranged from about 24.0%-95% identical (see Table 12 for additional desaturase abbreviations). Thus, other suitable nucleic acid fragments (isolated polynucleotides) encoding “Δ12/Δ15 desaturase-like polypeptides” will be at least about 24-35% identical, preferably at least about 35-45% identical, and more preferably at least about 45-55% identical to Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12, Fg.d15, Sk.d12, Sk.d15, Ma.d12, Ma.d15, Kl.d12, Kl.d15, Ca.d12, Ca.d15, Cg.d12, Cg.d15, Ct.d12, Ct.d15, Cl.d12, Cl.d15, Dh.d12, Dh.d15, Af.d12, Af.d15, Ao.d12, Ao.d15, Chg.d12, Chg.d15, Ro.d12, Cc.d12, Mc.d12, Mr.d12 and Cn.d12 (i.e., SEQ ID NOs:41 [or 49], 39 [or 50], 51, 52, 53, 54, 55, 56, 57, 58, 61, 62, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,78, 79, 80, 94, 86, 92, 93 and 87, respectively). Preferred nucleic acid fragments encode amino acid sequences that are at least about 55-65% identical, more preferred nucleic acid fragments encode amino acid sequences that are at least about 65-85% identical, and most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 85-95% identical to Fm.d12, Fm.d15, An.d12, An.d15, Mg.d12, Mg.d15, Nc.d12, Nc.d15, Fg.d12, Fg.d15, Sk.d12, Sk.d15, Ma.d12, Ma.d15, Kl.d12, Kl.d15, Ca.d12, Ca.d15, Cg.d12, Cg.d15, Ct.d12, Ct.d15, Cl.d12, Cl.d15, Dh.d12, Dh.d15, Af.d12, Af.d15, Ao.d12, Ao.d15, Chg.d12, Chg.d15, Ro.d12, Cc.d12, Mc.d12, Mr.d12 and Cn.d12 (i.e., SEQ ID NOs:41 [or 49], 39 [or 50], 51, 52, 53, 54, 55, 56, 57, 58, 61, 62, 59, 60, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 94, 86, 92, 93 and 87, respectively). Suitable nucleic acid fragments not only have the above homologies but typically encode a “Δ12/Δ15 desaturase-like polypeptide” having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids.
  • Concisely stated then, a “Δ12/Δ15 desaturase-like polypeptide” may be viewed as one that falls into any one or all of the following descriptions:
      • i. a fungal polypeptide that is identified as a “hit” when performing BLAST analysis using a known fungal desaturase as the query sequence and default search parameters, wherein the known fungal desaturase is selected from the group consisting of Δ12 desaturases and Δ15 desaturases;
      • ii. a fungal polypeptide that has primary “hits” to known fungal desaturases when used as a query sequence in a BLAST analysis using default search parameters, wherein the known fungal desaturase is selected from the group consisting of Δ12 desaturases and Δ15 desaturases;
      • iii. a fungal polypeptide that has at least 27.3% identity with a known fungal Δ12 desaturase or Δ15 desaturase based on the Clustal W method of alignment;
      • iv. a fungal polypeptide having a motif selected from the group consisting of SEQ ID NOs:3, 4 and 5 that has at least 24.0% identity with a known fungal Δ12 desaturase based on the Clustal W method of alignment; and/or,
      • vii. a fungal polypeptide having a motif selected from the group consisting of SEQ ID NOs:46, 47 and 48 that has at least 31.8% identity with a known fungal Δ15 desaturase based on the Clustal W method of alignment.
  • It will be apparent to the skilled person that the methods of the invention may make use of a computer readable format to store electronic information representing the amino acid and encoding polynucleotide sequences of Δ12 desaturase and Δ15 desaturase motifs as well as Δ12/Δ15 desaturase-like polypeptides. As used herein “computer readable format” will mean any medium for the storage and access of electronic data and information including but not limited to computer disks, compact disks, flash drives, hard drivers, servers or the like.
  • The terms “conversion efficiency” and “percent substrate conversion” refer to the efficiency by which a particular enzyme (e.g., a desaturase) can convert substrate to product. The conversion efficiency is measured according to the following formula: ([product]/[substrate+product])*100, where ‘product’ includes the immediate product and all products in the pathway derived from it. More specifically, Δ12 percent substrate conversion is calculated according to the following formula: ([18:2+18:3]/[18:1+18:2+18:3])*100; relatedly, Δ15 percent substrate conversion is calculated calculated according to the following formula: ([18:3]/[18:2+18:3])*100.
  • The term “increased ability to act on a Δ12 desaturase substrate” refers to improved Δ12 desaturase substrate conversion; similarly, the term “increased ability to act on a Δ15 desaturase substrate” refers to improved Δ15 desaturase substrate conversion.
  • The term “Δ12/Δ15 desaturase specificity” is calculated as: (Δ12 percent substrate conversion)/(Δ15 percent substrate conversion). The term “Δ15/Δ12 desaturase specificity” is calculated as: (Δ15 percent substrate conversion)/(Δ12 percent substrate conversion).
  • The term “elongase” refers to a polypeptide that can elongate a fatty acid carbon chain to produce an acid that is 2 carbons longer than the fatty acid substrate that the elongase acts upon. This process of elongation occurs in a multi-step mechanism in association with fatty acid synthase, as described in PCT Publication No. WO 2005/047480. Examples of reactions catalyzed by elongase systems are the conversion of GLA to DGLA, STA to ETA and EPA to DPA. In general, the substrate selectivity of elongases is somewhat broad but segregated by both chain length and the degree and type of unsaturation. For example, a C14/16 elongase will utilize a C14 substrate (e.g., myristic acid), a C16/18 elongase will utilize a C16 substrate (e.g., palmitate), a C18/20 elongase (also known as a Δ6 elongase as the terms can be used interchangeably) will utilize a C18 substrate (e.g., GLA, STA) and a C20/22 elongase will utilize a C20 substrate (e.g., EPA). In like manner, a Δ9 elongase is able to catalyze the conversion of LA and ALA to EDA and ETrA, respectively. It is important to note that some elongases have broad specificity and thus a single enzyme may be capable of catalyzing several elongase reactions (e.g., thereby acting as both a C16/18 elongase and a C18/20 elongase).
  • The term “oleaginous” refers to those organisms that tend to store their energy source in the form of lipid (Weete, In: Fungal Lipid Biochemistry, 2nd Ed., Plenum, 1980). The term “oleaginous yeast” refers to those microorganisms classified as yeasts that can make oil. Generally, the cellular oil or TAG content of oleaginous microorganisms follows a sigmoid curve, wherein the concentration of lipid increases until it reaches a maximum at the late logarithmic or early stationary growth phase and then gradually decreases during the late stationary and death phases (Yongmanitchai and Ward, Appl. Environ. Microbiol., 57:419-25 (1991)). It is not uncommon for oleaginous microorganisms to accumulate in excess of about 25% of their dry cell weight as oil. Examples of oleaginous yeast include, but are no means limited to, the following genera: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces.
  • The term “fungi” as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota and Zygomycota, as well as the Oomycota and all mitosporic fungi (Hawksworth et al., In: Ainsworth and Bisby's Dictionary of The Fungi, 8th ed., 1995, CAB International, University:Cambridge, UK). Representative groups of Ascomycota include, e.g., Neurospora, Eupenicillium (i.e., Penicillium), Emericella (i.e., Aspergillus), Eurotiun (i.e., Aspergillus) and the true yeasts (e.g., Candida, Kluyveromyces, Saccharomyces, Schizosaccharomyces, Pichia and Yarrowia). Examples of Basidiomycota include mushrooms, rusts and smuts. Representative groups of Chytridiomycota include e.g., Allomyces, Blastocladiella, Coelomomyces and aquatic fungi. Representative groups of Zygomycota include, e.g., Rhizopus and Mucor. Representative groups of Oomycota include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Non-limiting examples of mitosporic fungi include Aspergillus, Penicilliun, Candida and Alternaria.
  • The term “genome” as it applies to a fungal cells encompasses not only chromosomal DNA found within the nucleus, but organelle DNA found within subcellular components (e.g., mitochondrial, Woronin bodies) of the cell.
  • As used herein, an “isolated nucleic acid fragment” or “isolated nucleic acid molecule” or “genetic construct” will be used interchangeably and will mean a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.
  • A nucleic acid fragment is “hybridizable” to another nucleic acid fragment, such as a cDNA, genomic DNA, or RNA molecule, when a single-stranded form of the nucleic acid fragment can anneal to the other nucleic acid fragment under the appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well known and exemplified in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1989), particularly Chapter 11 and Table 11.1 therein (entirely incorporated herein by reference). The conditions of temperature and ionic strength determine the “stringency” of the hybridization. Stringency conditions can be adjusted to screen for moderately similar fragments (such as homologous sequences from distantly related organisms), to highly similar fragments (such as genes that duplicate functional enzymes from closely related organisms). Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6×SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2×SSC, 0.5% SDS at 45° C. for 30 min, and then repeated twice with 0.2×SSC, 0.5% SDS at 50° C. for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2×SSC, 0.5% SDS was increased to 60° C. Another preferred set of highly stringent conditions uses two final washes in 0.1×SSC, 0.1% SDS at 65° C. An additional set of stringent conditions include hybridization at 0.1×SSC, 0.1% SDS, 65° C. and washes with 2×SSC, 0.1% SDS followed by 0.1×SSC, 0.1% SDS, for example.
  • Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher Tm) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating Tm have been derived (see Sambrook et al., supra, 9.50-9.51). For hybridizations with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., supra, 11.7-11.8). In one embodiment the length for a hybridizable nucleic acid is at least about 10 nucleotides. Preferably a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides; more preferably at least about 20 nucleotides; and most preferably the length is at least about 30 nucleotides. Furthermore, the skilled artisan will recognize that the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the probe.
  • A “substantial portion” of an amino acid or nucleotide sequence is that portion comprising enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene specific oligonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., in situ hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a “substantial portion” of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence. The instant specification teaches the complete amino acid and nucleotide sequence encoding particular fungal proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.
  • The term “complementary” is used to describe the relationship between nucleotide bases that are capable of hybridizing to one another. For example, with respect to DNA, adenosine is complementary to thymine and cytosine is complementary to guanine.
  • The terms “homology” and “homologous” are used interchangeably herein. They refer to nucleic acid fragments wherein changes in one or more nucleotide bases do not affect the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype. These terms also refer to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially alter the functional properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.
  • Moreover, the skilled artisan recognizes that homologous nucleic acid sequences encompassed by this invention are also defined by their ability to hybridize, under moderately stringent conditions (e.g., 0.5×SSC, 0.1% SDS, 60° C.) with the sequences exemplified herein, or to any portion of the nucleotide sequences disclosed herein and which are functionally equivalent to any of the nucleic acid sequences disclosed herein.
  • “Codon degeneracy” refers to the nature in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.
  • “Chemically synthesized”, as related to a sequence of DNA, means that the component nucleotides were assembled in vitro. Manual chemical synthesis of DNA may be accomplished using well-established procedures or, automated chemical synthesis can be performed using one of a number of commercially available machines. “Synthetic genes” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments that are then enzymatically assembled to construct the entire gene. Accordingly, the genes can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell, where sequence information is available.
  • “Gene” refers to a nucleic acid fragment that expresses a specific protein, and that may refer to the coding region alone or may include regulatory sequences preceding (5′ non-coding sequences) and following (3′ non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, native genes introduced into a new location within the native host, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure. A “codon-optimized gene” is a gene having its frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell.
  • “Coding sequence” refers to a DNA sequence that codes for a specific amino acid sequence. “Suitable regulatory sequences” refer to nucleotide sequences located upstream (5′ non-coding sequences), within, or downstream (3′ non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites and stem-loop structures.
  • “Promoter” refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3′ to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed in most cell types at most times are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.
  • The terms “3′ non-coding sequences” and “transcription terminator” refer to DNA sequences located downstream of a coding sequence. This includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3′ end of the mRNA precursor. The 3′ region can influence the transcription, RNA processing or stability, or translation of the associated coding sequence.
  • “RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA” or “mRNA” refers to the RNA that is without introns and that can be translated into protein by the cell. “cDNA” refers to a double-stranded DNA that is complementary to, and derived from, mRNA. “Sense” RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell. “Antisense RNA” refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Pat. No. 5,107,065; PCT Publication No. WO 99/28508). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5′ non-coding sequence, 3′ non-coding sequence, or the coding sequence. “Functional RNA” refers to antisense RNA, ribozyme RNA, or other RNA that is not translated and yet has an effect on cellular processes.
  • The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.
  • The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragments of the invention. Expression may also refer to translation of mRNA into a polypeptide.
  • “Mature” protein refers to a post-translationally processed polypeptide, i.e., one from which any pre- or propeptides present in the primary translation product have been removed. “Precursor” protein refers to the primary product of translation of mRNA, i.e., with pre- and propeptides still present. Pre- and propeptides may be (but are not limited to) intracellular localization signals.
  • “Transformation” refers to the transfer of a nucleic acid molecule into a host organism, resulting in genetically stable inheritance. The nucleic acid molecule may be a plasmid that replicates autonomously, for example, or, it may integrate into the genome of the host organism. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” or “recombinant” or “transformed” organisms.
  • The terms “plasmid”, “vector” and “cassette” refer to an extra chromosomal element often carrying genes that are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3′ untranslated sequence into a cell. “Expression cassette” refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
  • The term “percent identity”, as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. “Identity” and “similarity” can be readily calculated by known methods, including but not limited to those described in: 1.) Computational Molecular Biology (Lesk, A. M., Ed.) Oxford University: N.Y. (1988); 2.) Biocomputing: Informatics and Genome Projects (Smith, D. W., Ed.) Academic: NY (1993); 3.) Computer Analysis of Sequence Data, Part I (Griffin, A. M., and Griffin, H. G., Eds.) Humania: NJ (1994); 4.) Sequence Analysis in Molecular Biology (von Heinje, G., Ed.) Academic (1987); and 5.) Sequence Analysis Primer (Gribskov, M. and Devereux, J., Eds.) Stockton: NY (1991).
  • Preferred methods to determine identity are designed to give the best match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Sequence alignments and percent identity calculations may be performed using the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wis.). Multiple alignment of the sequences is performed using the “Clustal method of alignment” which encompasses several varieties of the algorithm including the “Clustal V method of alignment” corresponding to the alignment method labeled Clustal V (described by Higgins and Sharp, CABIOS. 5:151-153 (1989); Higgins, D. G. et al., Comput. Appl. Biosci., 8:189-191 (1992)) and found in the MegAlign™ program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.). For multiple alignments, the default values correspond to GAP PENALTY=10 and GAP LENGTH PENALTY=10. Default parameters for pairwise alignments and calculation of percent identity of protein sequences using the Clustal method are KTUPLE=1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. For nucleic acids these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4 and DIAGONALS SAVED=4. After alignment of the sequences using the Clustal V program, it is possible to obtain a “percent identity” by viewing the “sequence distances” table in the same program. Additionally the “Clustal W method of alignment” is available and corresponds to the alignment method labeled Clustal W (described by Higgins and Sharp, CABIOS. 5:151-153 (1989); Higgins, D. G. et al., Comput. Appl. Biosci. 8:189-191(1992)) and found in the MegAlign™ v6.1 program of the LASERGENE bioinformatics computing suite (DNASTAR Inc.). Default parameters for multiple alignment (GAP PENALTY=10, GAP LENGTH PENALTY=0.2, Delay Divergen Seqs (%)=30, DNA Transition Weight=0.5, Protein Weight Matrix=Gonnet Series, DNA Weight Matrix=IUB). After alignment of the sequences using the Clustal W program, it is possible to obtain a “percent identity” by viewing the “sequence distances” table in the same program.
  • It is well understood by one skilled in the art that many levels of sequence identity are useful in identifying polypeptides, from other species, wherein such polypeptides have the same or similar function or activity. Useful examples of percent identities include, but are not limited to: 24%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, or any integer percentage from 24% to 100% may be useful in describing the present invention, such as 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids.
  • The term “motif” means a set of amino acids conserved at specific positions along an aligned sequence of evolutionarily related proteins. While amino acids at other positions can vary between homologous proteins, amino acids that are highly conserved at specific positions indicate amino acids that are essential in the structure, the stability, or the activity of a protein. Because they are identified by their high degree of conservation in aligned sequences of a family of protein homologues, they can be used as identifiers, or “signatures”, to determine if a protein with a newly determined sequence belongs to a previously identified protein family. For the purposes herein, the following Table describes motifs of the present invention which are indicative of a fungal protein having Δ12 desaturase activity or Δ15 desaturase activity, respectively.
  • TABLE 3
    Summary Of Fungal Desaturase Motifs
    Pro-
    tein
    SEQ
    ID
    Description Sequence NO.
    Fungal Δ12 G (I/L/V) W V (L/I) A H E C 1
    Desaturase G H (Q/G/L) (A/S) F S
    Motif “A”
    Fungal Δ12 G X W V X A H E C G H X X F S 2
    Desaturase
    Motif “B”
    Fungal Δ12 G (I/L/V) W V (L/I/V) (A/G) H E 3
    Desaturase (A/C) G H (Q/G/L) (A/S) (F/Y) S
    Motif “C”
    Fungal Δ12 G X W V X (A/G) H E (A/C) 4
    Desaturase G H X X (F/Y) S
    Motif “D”
    Fungal Δ12 G X W V X X H E X G H X X X S 5
    Desaturase
    Motif “E”
    Fungal Δ15 G (I/L/V/M/P) W I L (A/G/S) H E 46
    Desaturase (A/C) G H (G/S) A F S
    Motif “A”
    Fungal Δ15 G X W I L X H E (A/C) G H X A F S 47
    Desaturase
    Motif “B”
    Fungal Δ15 G X W I X X H E X G H X X X S 48
    Desaturase
    Motif “C”
  • The term “sequence analysis software” refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. “Sequence analysis software” may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to: 1.) the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wis.); 2.) BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol., 215:403-410 (1990)); 3.) DNASTAR (DNASTAR, Inc. Madison, Wis.); 4.) Sequencher (Gene Codes Corporation, Ann Arbor, Mich.); and 5.) the FASTA program incorporating the Smith-Waterman algorithm (W. R. Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Plenum: New York, N.Y.). Within the context of this application it will be understood that where sequence analysis software is used for analysis, that the results of the analysis will be based on the “default values” of the program referenced, unless otherwise specified. As used herein “default values” will mean any set of values or parameters that originally load with the software when first initialized.
  • Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1989) (hereinafter “Maniatis”); by Silhavy, T. J., Bennan, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience, Hoboken, N.J. (1987).
    • An Overview: Microbial Biosynthesis Of Fatty Acids And Triacylglycerols
  • In general, lipid accumulation in oleaginous microorganisms is triggered in response to the overall carbon to nitrogen ratio present in the growth medium. This process, leading to the de novo synthesis of free palmitate (16:0) in oleaginous microorganisms, is described in detail in PCT Publication No. WO 2004/101757. Palmitate is the precursor of longer-chain saturated and unsaturated fatty acid derivates, which are formed through the action of elongases and desaturases (FIG. 1).
  • TAGs (the primary storage unit for fatty acids) are formed by a series of reactions that involve: 1.) the esterification of one molecule of acyl-CoA to glycerol-3-phosphate via an acyltransferase to produce lysophosphatidic acid; 2.) the esterification of a second molecule of acyl-CoA via an acyltransferase to yield 1,2-diacylglycerol phosphate (commonly identified as phosphatidic acid); 3.) removal of a phosphate by phosphatidic acid phosphatase to yield 1,2-diacylglycerol (DAG); and 4.) the addition of a third fatty acid by the action of an acyltransferase to form TAG. A wide spectrum of fatty acids can be incorporated into TAGs, including saturated and unsaturated fatty acids and short-chain and long-chain fatty acids.
    • Biosynthesis Of Omega Fatty Acids
  • The metabolic process wherein oleic acid is converted to ω-3/ω-6 fatty acids involves elongation of the carbon chain through the addition of carbon atoms and desaturation of the molecule through the addition of double bonds. This requires a series of special desaturation and elongation enzymes present in the endoplasmic reticulim membrane. However, as seen in FIG. 1 and as described below, there are often multiple alternate pathways for production of a specific ω-3/ω-6 fatty acid.
  • Specifically, all pathways require the initial conversion of oleic acid to LA, the first of the ω-6 fatty acids, by a Δ12 desaturase. Then, using the “A6 desaturase/A6 elongase pathway”, ω-6 fatty acids are formed as follows: (1) LA is converted to GLA by a Δ6 desaturase; (2) GLA is converted to DGLA by a C18/20 elongase; and, (3) DGLA is converted to ARA by a Δ5 desaturase. Alternatively, the “Δ6 desaturase/Δ6 elongase pathway” can be utilized for formation of ω-3 fatty acids as follows: (1) LA is converted to ALA, the first of the ω-3 fatty acids, by a Δ15 desaturase; (2) ALA is converted to STA by a Δ6 desaturase; (3) STA is converted to ETA by a C18/20 elongase; (4) ETA is converted to EPA by a Δ5 desaturase; (5) EPA is converted to DPA by a C20/22 elongase; and, (6) DPA is converted to DHA by a Δ4 desaturase. Optionally, other ω-6 fatty acids may be converted to ω-3 fatty acids; for example, ETA and EPA are produced from DGLA and ARA, respectively, by Δ17 desaturase activity.
  • Alternate pathways for the biosynthesis of ω-3/ω-6 fatty acids utilize a Δ9 elongase and Δ8 desaturase. More specifically, LA and ALA may be converted to EDA and ETrA, respectively, by a Δ9 elongase; then, a Δ8 desaturase converts EDA to DGLA and/or ETrA to ETA.
  • It is contemplated that the particular functionalities required to be expressed in a specific host organism for production of ω-3/ω-6 fatty acids will depend on the host cell (and its native PUFA profile and/or desaturase/elongase profile), the availability of substrate, and the desired end product(s). One skilled in the art will be able to identify various candidate genes encoding each of the enzymes desired for ω-3/ω-6 fatty acid biosynthesis. Useful desaturase and elongase sequences may be derived from any source, e.g., isolated from a natural source (from bacteria, algae, fungi, plants, animals, etc.), produced via a semi-synthetic route or synthesized de novo. Although the particular source of the desaturase and elongase genes introduced into the host is not critical, considerations for choosing a specific polypeptide having desaturase or elongase activity include: 1.) the substrate specificity of the polypeptide; 2.) whether the polypeptide or a component thereof is a rate-limiting enzyme; 3.) whether the desaturase or elongase is essential for synthesis of a desired PUFA; and/or, 4.) co-factors required by the polypeptide. The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell (see PCT Publication No. WO 2004/101757 for additional details).
  • In additional embodiments, it will also be useful to consider the conversion efficiency of each particular desaturase and/or elongase. More specifically, since each enzyme rarely functions with 100% efficiency to convert substrate to product, the final lipid profile of un-purified oils produced in a host cell will typically be a mixture of various PUFAs consisting of the desired ω-3/ω-6 fatty acid, as well as various upstream intermediary PUFAs. Thus, each enzyme's conversion efficiency is also a variable to consider when optimizing biosynthesis of a desired fatty acid.
  • With each of the considerations above in mind, candidate genes having the appropriate desaturase and elongase activities (e.g., Δ6 desaturases, C18/20 elongases, Δ5 desaturases, Δ17 desaturases, Δ15 desaturases, Δ9 desaturases, Δ12 desaturases, C14/16 elongases, C16/18 elongases, Δ9 elongases, Δ8 desaturases, Δ4 desaturases and C20/22 elongases) can be identified according to publicly available literature (e.g., GenBank), the patent literature, and experimental analysis of organisms having the ability to produce PUFAs. These genes will be suitable for introduction into a specific host organism, to enable or enhance the organism's synthesis of PUFAs.
    • Identification Of Fungal Δ12 And Δ15 Desaturases
  • Public sources have long contained a variety of Δ12 desaturase sequences from fungal sources (e.g., the Mortierella alpina Δ12 desaturase [SEQ ID NO:59] isolated by Sakuradani, E., et al., Eur. J. Biochem., 261(3):812-820 (1999)); in contrast, however, the identication of Δ15 desaturases has been much more elusive to researchers. Although Δ15 desaturases from photosynthetic organisms (e.g., plants [PCT Publication No. WO 94/11516]) and Caenorhabditis elegans were available in the public literature, the first published disclosure of fungal Δ15 desaturases was not until PCT Publication No. WO 03/099216. Although WO 2003/099216 includes expression data to support the functional characterization of desaturases having Δ15 activity from Neurospora crassa and Aspergillus nidulans, no corresponding data is presented to support the putative annotation therein of the Botrytis cinerea desaturase as a “Δ15 desaturase”.
  • A Δ12 desaturase from Yarrowia lipolytica (PCT Publication No. WO 2004/104167; SEQ ID NO:89) was used as a query against a proprietary DuPont expressed sequence tag (EST) library of Fusarium moniliforme strain M-8114 (E.I. du Pont de Nemours and Co., Inc., Wilmington, Del.) as well as against public databases of the filamentous fungi Aspergillus nidulans, Magnaporthe grisea, Neurospora crassa and Fusarium graminearium. Remarkedly, these searches identified two homologs within each species of the filamentous fungi (i.e., “pairs of Δ12/Δ15 desaturase-like polypeptides”); and, the sequences from each species fell into one of two “sub-families” based on phylogenetic analyses (PCT Publications No. WO 2005/047480 and No. WO 2005/047485).
  • Since Yarrowia lipolytica was only able to synthesize 18:2 (but not 18:3) while each of the filamentous fungi described above could make both 18:2 and ALA, and since Yarrowia had a single Δ12 desaturase while each of the filamentous fungi had two homologs to the Yarrowia Δ12 desaturase, the Applicants postulated that one of the sub-families of desaturases in these organisms represented Δ12 desaturases and the other represented Δ15 desaturases. This hypothesis was confirmed by expression analysis of the two Fusarium moniliforme homologs, which positively characterized “Fm2” as a Δ12 desaturase (i.e., Fm.d12; SEQ ID NOs:41 and 49) while “Fm1” was characterized as a Δ15 desaturase additionally having some Δ12 desaturase activity (i.e., Fm.d15; SEQ ID NOs:39 and 50) (PCT Publications No. WO 2005/047480 and No. WO 2005/047485). Subsequent expression analysis also proved that one of the Δ12/Δ15 desaturase-like polypeptides in Fusarium graminearum and one of the Δ12/Δ15 desaturase-like polypeptides in Magnaporthe grisea encoded a Δ15 desaturase, additionally having some Δ12 desaturase activity (PCT Publication No. WO 2005/047480).
  • Identification Of Fungal Δ12 And Δ15 Desaturases Via Identification Of “Pairs” Of Δ12/Δ15 Desaturase-Like Polypeptides
  • Two additional Δ15 desaturases have recently been reported. Specifically, the Saccharomyces kluyveri Δ15 desaturase (GenBank Accession No. BAD11952; Sk.d15) was described in Oura et al. (Microbiol., 150:1983-1990 (2004)), while that from Mortierella alpina (GenBank Accession No. AB182163; Ma.d15) was described by Sakuradani et al. (Appl. Microbiol. Biotechnol., 66:648-654 (2005); PCT Publication No. WO 2006/019192). Since both sequences were identified in part based on their close homology to the previously identified S. kluyveri Δ12 desaturase (Sk.d12; GenBank Accession No. BAD08375; Watanabe et al., Biosci. Biotech. Biochem., 68(3):721-727 (2004)) and M. alpina Δ12 desaturase (Ma.d12; GenBank Accession No. BAA81754; Sakuradani et al., Eur. J. Biochem., 261(3):812-820 (1999)), respectively, followed by a determination of their functional activity, these two pairs of proteins provided additional examples of closely related fungal Δ12 and Δ15 desaturases similar to those of Fusarium moniliforme, Aspergillus nidulans, Magnaporthe grisea, Neurospora crassa and Fusarium graminearium (PCT Publications No. WO 2005/047480 and No. WO 2005/047485). This suggested that “pairs” of fungal Δ12/Δ15 desaturase-like polypeptide sequences may comprise one protein having Δ15 desaturase activity and one protein having Δ12 desaturase activity.
  • Accordingly similar “pairs” of Δ12/Δ15 desaturase-like polypeptides were analyzed in publicly available genomic databases from fungi. This search resulted in the identification of additional “pairs” of Δ12/Δ15 desaturase-like polypeptides in Kluyveromyces lactis, Candida albicans, C. guilliermondii, C. tropicalis, C. lusitaniae, Debaryomyces hansenii CBS767, Aspergillus fumigatus, A. oryzae and Chaetomium globosum. One member of each pair aligned more closely to the previously identified fungal Δ12 desaturases (i.e., Sk.d12, Nc.d12, An.d12) and the other more closely to fungal Δ15 desaturases (i.e., Sk.d15, Fm.d15), as shown in FIG. 2. Details concerning these previously characterized and putative desaturases are summarized in Table 4 below.
  • TABLE 4
    Previously Characterized And Putative Fungal Δ12 And Δ15 Desaturases
    Δ12 Desaturase Δ15 Desaturase
    Organism Abbreviation Reference Abbreviation Reference
    Fusarium Fm.d12 PCT Publication No. WO Fm.d15 PCT Publication No. WO
    moniliforme (SEQ ID NOs: 41 2005/047485; GenBank Accession (SEQ ID NOs: 39 2005/047480; GenBank Accession
    and 49) No. DQ272515 and 50) No. DQ272516
    Aspergillus An.d12 PCT Publication No. WO An.d15 PCT Publications No. WO
    nidulans (SEQ ID NO: 51) 2005/047485; Contig 1.15 (scaffold 1) (SEQ ID NO: 52) 2005/047480 and No. WO
    in the A. nidulans genome project; 2003/099216; Contig 1.122 (scaffold
    GenBank Accession No. XP_658641 9) in the A. nidulans genome project;
    GenBank Accession No. XP_664808
    Magnaporthe Mg.d12 PCT Publication No. WO Mg.d15 PCT Publication No. WO
    grisea (SEQ ID NO: 53) 2005/047485; Locus MG01985.1 in (SEQ ID NO: 54) 2005/047480; Locus MG08474.1 in
    contig 2.375 in the M. grisea genome contig 2.1597 in the M. grisea genome
    project; GenBank Accession No. project; GenBank XP_362963
    XP_365283
    Neurospora Nc.d12 PCT Publication No. WO Nc.d15 PCT Publications No. WO
    crassa (SEQ ID NO: 55) 2005/047485; GenBank Accession (SEQ ID NO: 56) 2005/047480 and No. WO
    No. XP_329856 2003/099216; GenBank Accession
    No. XP_330985
    Fusarium Fg.d12 PCT Publication No. WO Fg.d15 PCT Publication No. WO
    graminearium (SEQ ID NO: 57) 2005/047485; Contig 1.233 in the (SEQ ID NO: 58) 2005/047480; Contig 1.320 in the
    F. graminearium genome project; F. graminearium genome project;
    GenBank Accession No. EAA75859 GenBank Accession No. BAA33772.1
    (partial sequence)
    Mortierella Ma.d12 GenBank Accession No. BAA81754; Ma.d15 GenBank Accession No. AB182163;
    alpina (SEQ ID NO: 59) Sakuradani et al., Eur. J. Biochem., (SEQ ID NO: 60) Sakuradani et al., Appl. Microbiol.
    261(3): 812–820 (1999) Biotechnol., 66: 648–654 (2005); PCT
    Publication No. WO 2006/019192
    Saccharomyces Sk.d12 GenBank Accession No. BAD08375; Sk.d15 GenBank Accession No. BAD11952;
    kluyveri (SEQ ID NO: 61) Watanabe et al., Biosci. Biotech. (SEQ ID NO: 62) Oura et al., Microbiol., 150: 1983–1990
    Biochem., 68(3): 721–727 (2004) (2004)
    Kluyveromyces Kl.d12 GenBank Accession No. XP_455402; Kl.d15 GenBank Accession No. XP_451551;
    lactis NRRL Y- (SEQ ID NO: 63) Kainou, K. et al., Yeast, 23(8): 605–612 (SEQ ID NO: 64) Kainou, K. et al., Yeast, 23(8): 605–612
    1140 (2006) (2006)
    Candida albicans Ca.d12 GenBank Accession No. EAK94955; Ca.d15 GenBank Accession No. EAL03493;
    SC5314 (SEQ ID NO: 65) Murayama et al., Microbiol., (SEQ ID NO: 66) Murayama et al., Microbiol.,
    152(5): 1551–1558 (2006) 152(5): 1551–1558 (2006)
    Candida Cg.d12 DNA [1122100, 1123500] Cg.d15 DNA [680800, 682000] (complement):
    guilliermondii (SEQ ID NO: 67) (complement): Candida guilliermondii (SEQ ID NO: 68) Candida guilliermondii supercontig 1.4
    supercontig 1.3
    Candida Ct.d12 DNA [123300, 124400] (complement): Ct.d15 DNA [1709400, 1710700]
    tropicalis (SEQ ID NO: 69) Candida tropicalis supercontig 1.10 (SEQ ID NO: 70) (complement): Candida tropicalis
    supercontig 1.3
    Candida Cl.d12 DNA [738900, 740200] (complement): Cl.d15 DNA [2095200, 2096600]
    lusitaniae (SEQ ID NO: 71) Candida lusitaniae supercontig 1.2 (SEQ ID NO: 72) (complement): Candida lusitaniae
    supercontig 1.2
    Debaryomyces Dh.d12 GenBank Accession No. CAG90237 Dh.d15 GenBank Accession No. CAG88182
    hansenii CBS767 (SEQ ID NO: 73) (SEQ ID NO: 74)
    Aspergillus Af.d12 PCT Publication No. WO Af.d15 GenBank Accession No. EAL85733
    fumigatus (SEQ ID NO: 75) 2005/047485; GenBank Accession (SEQ ID NO: 76)
    No. EAL90585
    Aspergillus Ao.d12 GenBank Accession No. BAD04850 Ao.d15 GenBank Accession No. BAE66531
    oryzae (SEQ ID NO: 77) (SEQ ID NO: 78)
    Chaetomium Chg. d12 GenBank Accession No. EAQ83131 Chg. d15 GenBank Accession No. EAQ88866
    globosum CBS (SEQ ID NO: 79) (SEQ ID NO: 80)
    148.51
    Notes:
    All Candida genome sequences are sponsored by The Fungal Genome Initiative (FGI), Broad Institute of MIT and Harvard (Cambridge, MA). The Aspergillus nidulans genome project is sponsored by the Center for Genome Research (CGR), Cambridge, MA; the M. grisea genome project is sponsored by the CGR and International Rice Blast Genome Consortium; the F. graminearium genome project is sponsored by the CGR and the International Gibberella zeae Genomics Consortium (IGGR).
    As is well-known to one of skill in the art, the “nr” database (comprising all GenBank, EMBL, DDBJ and PDB sequences) contains some redundant accession numbers, as a result of the significant computational costs of maintaining a non-redundant database. For brevity, these redundancies are not included in the citations above. For example, GenBank Accession No. AB020033 (Mortierella alpina mRNA for Δ12 fatty acid desaturase, complete cds) includes the full nucleotide and protein sequence of a Δ12 fatty acid desaturase; the protein sequence of GenBank Accession No. AB020033 is 100% identical to that provided in GenBank Accession No. BAA81754. Similarly, some Δ12 desaturases have been isolated from various strains within a particular species (e.g., the M. alpina Δ12 desaturases from ATCC #32221, ATCC #16266 and strain IS-4, corresponding to GenBank Accession Nos. AAF08684, AAL13300 and BAA81754); sequences corresponding to these slight strain variations are not included above.
  • Given the teachings herein, one will be able to use similar methodology to identify other orthologous Δ12 desaturase and Δ15 desaturase proteins which are substantially identical to the instant desaturase sequences (i.e., Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and/or Chg.d15, corresponding to SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 39 [or 50], 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80, respectively). By “substantially identical” is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least about 70%, 80%, 90% or 95% homology to the selected polypeptides, or nucleic acid sequences encoding the amino acid sequence. For polypeptides, the length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids or most preferably at least 35 amino acids. For nucleic acids, the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably at least 110 nucleotides.
    • Identification Of Fungal Δ12 And Δ15 Desaturases Via Motifs
  • In additional embodiments herein, the Applicants have identified a means to readily distinguish fungal Δ12/Δ15 desaturase-like polypeptide sequences having Δ15 desaturase activity as opposed to Δ12 desaturase activity. Specifically, when an amino acid sequence alignment was analyzed that comprised Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and Chg.d15 (abbreviations provided above in Table 4), it became apparent that all of the 32 fungal Δ15 or Δ12 desaturases contained either an Ile or Val amino acid residue, respectively, at the position that is only three amino acid residues away from the conserved His Box I (“HE[C/A]GH”; SEQ ID NO:6) (Table 5). Furthermore, the amino acid region spanning from 6 residues upstream of the His Box I to 4 residues downstream of the His Box I (i.e., a region comprising a total of 15 amino acid residues) was also significantly conserved.
  • Although 7 different sequence variants exist within this region in the Δ12 desaturases (i.e., SEQ ID NOs:7, 8, 9, 10, 11, 12 and 13), a motif that was representative of all sixteen of the fungal Δ12 desaturases was identified as: G (I/L/V) W V (L/I) A H E C G H (Q/G/L) (A/S) F S (SEQ ID NO:1; “Fungal Δ12 Desaturase Motif A”). More broadly, this motif was defined as: G X W V X A H E C G H X X F S (SEQ ID NO:2; “Fungal Δ12 Desaturase Motif B”), while in a more preferred embodiment, this motif was defined as: G X W V X X H E X G H X X X S (SEQ ID NO:5; “Fungal Δ12 Desaturase Motif E”).
  • Similarly, although 9 different variants exist within the Δ15 desaturases (i.e., SEQ ID NOs:22, 23, 24, 25, 26, 27, 28, 29 and 30), a motif that was representative of all sixteen of the fungal Δ15 desaturases is: G (I/L/V/M/P) W I L (A/G/S) H E (A/C) G H (G/S) A F S (SEQ ID NO:46; “Fungal Δ15 Desaturase Motif A”). In a preferred embodiment, this motif was defined as: G X W I L X H E (A/C) G H X A F S (SEQ ID NO:47; “Fungal Δ15 Desaturase Motif B”), while in a more preferred embodiment, this motif was defined as: G X W I X X H E X G H X X X S (SEQ ID NO:48; “Fungal Δ15 Desaturase Motif C”).
  • TABLE 5
    Amino Acid Alignment Around The His Box I Of Fungal Δ12 And Δ15 Desaturases
    Figure US20070254299A1-20071101-C00001
    Figure US20070254299A1-20071101-C00002
    *Amino Acid Residue refers to the location of the first glycine within the conserved region around the His Box I (defined above), with respect to the full-length desaturase protein sequence. For example, the conserved region around the His Box I is located between amino acids 134-148 of the Candida albicans Δ12 desaturase (i.e., Ca.d12; SEQ ID NO: 65); thus, the amino acid residue corresponding to the initial glycine within the conserved region in this particularprotein is residue 134.
    **Shaded text highlights the His Box I.
  • Given this teaching it is apparent that the Ile and Val amino acid residues located three amino acid residues upstream from the first histidine in the conserved His Box I are a determinant of Δ15 and Δ12 desaturase specificity, respectively, in fungal Δ12/Δ15 desaturase-like polypeptides. It is therefore contemplated that any fungal Δ12/Δ15 desaturase-like polypeptide with Ile at the corresponding residue(s) (i.e., or the Fungal Δ15 Desaturase Motif A, B or C [SEQ ID NOs:46, 47 and 48, respectively]) will be a Δ15 desaturase and any fungal Δ12/Δ15 desaturase-like polypeptide with Val at the corresponding residue(s) (i.e., or the Fungal Δ12 Desaturase Motif A, B or E [SEQ ID NOs:1, 2 and 5, respectively]) will be a Δ12 desaturase. Thus, this single isoleucine/valine amino acid is expected to play a pivotal role in the determination of Δ12 or Δ15 desaturase activity.
  • This methodology will be particularly important as novel fungal Δ12/Δ15 desaturase-like polypeptide sequences are identified within species belonging to fungal groups from which a Δ15 desaturase has not previously been identified. Based on the teachings herein, it is expected that classification of any novel Δ12/Δ15 desaturase-like polypeptide as either a Δ12 desaturase or Δ15 desaturase by phylogenetic means alone will be possible. Prior to this teaching, identification of the Δ12 desaturase versus the Δ15 desaturase within the pair of Mortierella alpina Δ12/Δ15 desaturase-like polypeptides was possible only by experimentation (Sakuradani et al., Eur. J. Biochem., 261(3):812-820 (1999) and Appl. Microbiol. Biotechnol., 66:648-654 (2005)), since phylogentic analysis was not sufficient to distinguish enzymatic function.
  • Identification And Isolation Of Homologs
  • Any of the instant desaturase sequences (i.e., Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and/or Chg.d15, corresponding to SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 39 [or 50], 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80, respectively) or portions thereof may be used to search for Δ12 and Δ15 desaturase homologs in the same or other bacterial, algal, fungal or plant species using sequence analysis software. In general, such computer software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.
  • Alternatively, any of the instant desaturase sequences or portions thereof may also be employed as hybridization reagents for the identification of Δ12 desaturase and Δ15 desaturase homologs. The basic components of a nucleic acid hybridization test include a probe, a sample suspected of containing the gene or gene fragment of interest and a specific hybridization method. Probes of the present invention are typically single-stranded nucleic acid sequences that are complementary to the nucleic acid sequences to be detected. Probes are “hybridizable” to the nucleic acid sequence to be detected. Although the probe length can vary from 5 bases to tens of thousands of bases, typically a probe length of about 15 bases to about 30 bases is suitable. Only part of the probe molecule need be complementary to the nucleic acid sequence to be detected. In addition, the complementarity between the probe and the target sequence need not be perfect. Hybridization does occur between imperfectly complementary molecules with the result that a certain fraction of the bases in the hybridized region are not paired with the proper complementary base.
  • Hybridization methods are well defined. Typically the probe and sample must be mixed under conditions that will permit nucleic acid hybridization. This involves contacting the probe and sample in the presence of an inorganic or organic salt under the proper concentration and temperature conditions. The probe and sample nucleic acids must be in contact for a long enough time that any possible hybridization between the probe and sample nucleic acid may occur. The concentration of probe or target in the mixture will determine the time necessary for hybridization to occur. The higher the probe or target concentration, the shorter the hybridization incubation time needed. Optionally, a chaotropic agent may be added (e.g., guanidinium chloride, guanidinium thiocyanate, sodium thiocyanate, lithium tetrachloroacetate, sodium perchlorate, rubidium tetrachloroacetate, potassium iodide, cesium trifluoroacetate). If desired, one can add formamide to the hybridization mixture, typically 30-50% (v/v).
  • Various hybridization solutions can be employed. Typically, these comprise from about 20 to 60% volume, preferably 30%, of a polar organic solvent. A common hybridization solution employs about 30-50% v/v formamide, about 0.15 to 1 M sodium chloride, about 0.05 to 0.1 M buffers (e.g., sodium citrate, Tris-HCl, PIPES or HEPES (pH range about 6-9)), about 0.05 to 0.2% detergent (e.g., sodium dodecylsulfate), or between 0.5-20 mM EDTA, FICOLL (Pharmacia Inc.) (about 300-500 kdal), polyvinylpyrrolidone (about 250-500 kdal) and serum albumin. Also included in the typical hybridization solution will be unlabeled carrier nucleic acids from about 0.1 to 5 mg/mL, fragmented nucleic DNA (e.g., calf thymus or salmon sperm DNA, or yeast RNA), and optionally from about 0.5 to 2% wt/vol glycine. Other additives may also be included, such as volume exclusion agents that include a variety of polar water-soluble or swellable agents (e.g., polyethylene glycol), anionic polymers (e.g., polyacrylate or polymethylacrylate) and anionic saccharidic polymers (e.g., dextran sulfate).
  • Nucleic acid hybridization is adaptable to a variety of assay formats. One of the most suitable is the sandwich assay format. The sandwich assay is particularly adaptable to hybridization under non-denaturing conditions. A primary component of a sandwich-type assay is a solid support. The solid support has adsorbed to it or covalently coupled to it immobilized nucleic acid probe that is unlabeled and complementary to one portion of the sequence.
  • In additional embodiments, any of the Δ12 desaturase and/or Δ15 desaturase nucleic acid fragments of the instant invention (or any homologs identified thereof) may be used to isolate genes encoding homologous proteins from the same or other bacterial, algal, fungal or plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to: 1.) methods of nucleic acid hybridization; 2.) methods of DNA and RNA amplification, as exemplified by various uses of nucleic acid amplification technologies [e.g., polymerase chain reaction (PCR), Mullis et al., U.S. Pat. No. 4,683,202; ligase chain reaction (LCR), Tabor, S. et al., Proc. Acad. Sci. U.S.A., 82:1074 (1985); or strand displacement amplification (SDA), Walker, et al., Proc. Natl. Acad. Sci. U.S.A., 89:392 (1992)]; and 3.) methods of library construction and screening by complementation.
  • For example, genes encoding similar proteins or polypeptides to the Δ12 and/or Δ15 desaturases described herein could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired yeast or fungus using methodology well known to those skilled in the art (wherein those yeast or fungus producing LA or ALA [or LA and/or ALA-derivatives] would be preferred). Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis, supra). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan (e.g., random primers DNA labeling, nick translation or end-labeling techniques), or RNA probes using available in vitro transcription systems. In addition, specific primers can be designed and used to amplify a part of (or full-length of) the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full-length DNA fragments under conditions of appropriate stringency.
  • Typically, in PCR-type amplification techniques, the primers have different sequences and are not complementary to each other. Depending on the desired test conditions, the sequences of the primers should be designed to provide for both efficient and faithful replication of the target nucleic acid. Methods of PCR primer design are common and well known in the art (Thein and Wallace, “The use of oligonucleotides as specific hybridization probes in the Diagnosis of Genetic Disorders”, in Human Genetic Diseases: A Practical Approach, K. E. Davis Ed., (1986) pp 33-50, IRL: Herndon, Va.; and Rychlik, W., In Methods in Molecular Biology, White, B. A. Ed., (1993) Vol. 15, pp 31-39, PCR Protocols: Current Methods and Applications. Humania: Totowa, N.J.).
  • Generally two short segments of the instant sequences may be used in PCR protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. PCR may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3′ end of the mRNA precursor encoding microbial genes.
  • Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al., Proc. Acad. Sci. U.S.A., 85:8998 (1988)) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3′ or 5′ end. Primers oriented in the 3′ and 5′ directions can be designed from the instant sequences. Using commercially available 3′ RACE or 5′ RACE systems (Gibco/BRL, Gaithersburg, Md.), specific 3′ or 5′ cDNA fragments can be isolated (Ohara et al., Proc. Acad. Sci. U.S.A., 86:5673 (1989); Loh et al., Science, 243:217 (1989)).
  • It will be apparent that probes and/or primers corresponding to the nucleic acids of the invention (SEQ ID NOs:1, 2, 5, 46, 47 and/or 48) will be useful for the identification and isolation of Δ12 desaturase and/or Δ15 desaturase enzymes, respectively.
  • The validity of using the above methodologies for the identification of other Δ12 and Δ15 desaturases of fungal origin is well-supported herein. For example, the utility of Fungal Δ12 Desaturase Motif B (SEQ ID NO:2) as a means to identity other Δ12 desaturases was confirmed via homology searching using the motif as a query in a BLASTP program of analysis; specifically, the top results of the search included other known fungal Δ12 desaturases available in GenBank, all which shared the motif of SEQ ID NO:2 or a variant thereof (wherein the V residue was invariant): Accession No. CAG82952 (Yarrowia lipolytica; SEQ ID NO:89), Accession No. AAL13301 (Mortierella isabellina; SEQ ID NO:81), Accession No. AAP23194 (Aspergillus parasiticus; SEQ ID NO:85), Accession No. AAX20125 (Pichia pastoris; SEQ ID NO:83), Accession No. BAB69056 (Mucor circinelloides; “Mc.d12”; SEQ ID NO:92), Accession No. AAD55982 (Mucor rouxii; “Mr.d12”; SEQ ID NO:93), Accession No. AAT58363 (Rhizopus oryzae; “Ro.d12”; SEQ ID NO:94), Accession No. BAD51484 (Lentinula edodes; SEQ ID NO:90), Accession No. AAU12575 (Cryptococcus curvatus; “Cc.d12”; SEQ ID NO:86), Accession No. AAR20443 (Saprolegnia diclina; SEQ ID NO:88) and Accession No. AAP33789 (Aspergillus flavus; SEQ ID NO:95). Furthermore, four additional hypothetical fungal proteins were identified (having the Fungal Δ12 Desaturase Motif B or a variant thereof) that are hypothesized herein to encode Δ12 desaturases: Accession No. AAS53960 (Ashbya gossypii ATCC 10895; SEQ ID NO:84), Accession No. XP—757193 (Ustilago maydis 521; SEQ ID NO:91), Accession No. EAS31392 (Coccidioides immitis RS; SEQ ID NO:82) and Accession No. EAL21306 (Cryptococcus neoformans var. neoformans B-3501A; “Cn.d12”; SEQ ID NO:87). Based on analysis of the conserved region surrounding the His Box I of each of these additional known and putative Δ12 desaturase proteins, an additional fungal Δ12 desaturase motif was defined as: G (I/L/V) W V (L/I/V) (A/G) H E (A/C) G H (Q/G/L) (A/S) (F/Y) S (SEQ ID NO:3; “Fungal Δ12 Desaturase Motif C”). In a preferred embodiment, this motif was defined as: G X W V X (A/G) H E (A/C) G H X X (F/Y) S (SEQ ID NO:4; “Fungal Δ12 Desaturase Motif D”), while in a more preferred embodiment, this motif was defined as: G X W V X X H E X G H X X X S (SEQ ID NO:5; “Fungal Δ12 Desaturase Motif E”). The motifs of SEQ ID NOs:3, 4 and 5 are thus representative of all of the fungal Δ12 desaturases described in the present application (i.e., Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, as well as the known and putative Δ12 desaturases described above).
  • Analysis of select Δ12 desaturase and Δ15 desaturase proteins (i.e., Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Cc.d12, Mr.d12, Mc.d12, Ro.d12, Cn.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and Chg.d15, corresponding to SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 86, 93, 92, 94, 87, 39 [or 50], 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80, respectively) revealed that the Δ12 desaturase proteins shared between 27.3%-61.2% identity with the Δ15 desaturase proteins, according to the Clustal W (MegAlign™ program of DNASTAR software) method of alignment (FIG. 3). Within the twenty-one Δ12 desaturases the percent identity ranged from 24.0%-95%, while within the sixteen Δ15 desaturases the percent identity ranged from 31.8%-88.8%. Finally, the percent identity between the Δ12 desaturase and the Δ15 desaturase within the same organism ranged between 29.5%-61.0% identity.
  • It is within the context of the invention therefore to provide a method for identifying a fungal polypeptide having Δ12 desaturase activity from a pool of Δ12/Δ15 desaturase-like polypeptides comprising:
      • a) identifying a Δ12/Δ15 desaturase-like polypeptide of fungal origin; and,
      • b) confirming the presence of a Δ12 desaturase motif in the Δ12/Δ15 desaturase-like polypeptide, wherein the Δ12 desaturase motif is selected from the group consisting of SEQ ID NOs:3, 4 and 5, and wherein the presence of the Δ12 desaturase motif is indicative of Δ12 desaturase activity.
  • It will be expected that the Δ12/Δ15 desaturase-like polypeptide of fungal origin has either Δ12 or Δ15 desaturase activity and the Δ12/Δ15 desaturase-like polypeptide of fungal origin will have at least 27.3% identity with a known fungal Δ12 desaturase or Δ15 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix. Upon identification of a fungal polypeptide having Δ12 desaturase activity according to the methodology above, it will be expected that the Δ12 desaturase will have either “monofunctional Δ12 desaturase activity” (wherein the desaturase is only capable of using oleic acid as enzymatic substrate) or “bifunctional Δ12 desaturase activity” (wherein the desaturase prefers oleic acid as its enzymatic substrate but additionally has limited ability to use LA such that the enzyme is a “bifunctional” Δ12 desaturase). Additionally, it will be expected that the Δ12 desaturase identified above will have at least 24.0% identity with a known fungal Δ12 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.
  • Similarly it will be understood that the invention provides a method for identifying a fungal polypeptide having Δ15 desaturase activity from a pool of Δ12/Δ15 desaturase-like polypeptides comprising:
      • a) identifying a Δ12/Δ15 desaturase-like polypeptide of fungal origin; and,
      • b) confirming the presence of a Δ15 desaturase motif in the Δ12/Δ15 desaturase-like polypeptide, wherein the Δ15 desaturase motif is selected from the group consisting of SEQ ID NOs:46, 47 and 48, and wherein the presence of the Δ15 desaturase motif is indicative of Δ15 desaturase activity.
        It will be expected therefore that the Δ12/Δ15 desaturase-like polypeptide of fungal origin has either Δ12 or Δ15 desaturase activity and the Δ12/Δ15 desaturase-like polypeptide of fungal origin will have at least 27.3% identity with a known fungal Δ12 desaturase or Δ15 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix. Upon identification of a fungal polypeptide having Δ15 desaturase activity according to the methodology above, it will be expected that the Δ15 desaturase will have either “monofunctional Δ15 desaturase activity” (wherein the desaturase is only capable of using LA as enzymatic substrate) or “bifunctional Δ15 desaturase activity” (wherein the desaturase prefers LA as its enzymatic substrate but additionally has limited ability to use oleic acid such that the enzyme is a “bifunctional” Δ15 desaturase). Additionally, it will be expected that the Δ15 desaturase identified above will have at least 31.8% identity with a known fungal Δ15 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.
    Modification Of Fungal Δ12 And Δ15 Desaturase Activity And Specificity
  • The present analysis teaches that mutation(s) that result in a Ile-to-Val change three amino acid residues upstream from the first histidine in the conserved His Box I of a bifunctional fungal Δ15 desaturase-like polypeptide will alter enzyme specificity towards Δ12 desaturation (thereby producing a mutant desaturase having improved Δ12 substrate conversion); and, conversely, those mutations that result in a Val-to-Ile change in the same position will alter enzyme specificity towards Δ15 desaturation (thereby producing a mutant desaturase having improved Δ15 substrate conversion).
  • Mutant variants based on the Fusarium moniliforme bifunctional homologs, i.e., Fm.d12 (characterized as a Δ12 desaturase with a trace level of Δ15 desaturase activity) and Fm.d15 (characterized as a primarily a Δ15 desaturase, additionally having some Δ12 desaturase activity), were constructed. Specifically, the native Val at position 151 of Fm.d12 was changed to Ile by site-specific mutation (i.e., V151I mutation), while the native Ile at position 102 of Fm.d15 was similarly changed to Val by site-specific mutation (i.e., I1102V mutation). Fatty acid composition within a Δ12 desaturase-disrupted strain of Yarrowia lipolytica transformed with plasmids expressing the mutant desaturases showed that the I102V mutation in Fm.d15 resulted in improved Δ12 desaturation, poorer Δ15 desaturation and a ratio of Δ15 substrate conversion to Δ12 substrate conversion of ca. 46-55% compared to the wild type enzyme. Conversely, the V151I mutation in Fm.d12 resulted in poorer Δ12 desaturation, improved Δ15 desaturation and ca. 381-401% improvement in the ratio of Δ15 substrate conversion to Δ12 substrate conversion compared to the wild type enzyme. The experimental results clearly confirmed that the Ile or Val amino acid residue, respectively, that is only three amino acid residues upstream of the conserved His Box I is a determinant of Δ12 or Δ15 specificity in the Δ12 and Δ15 desaturases of fungi.
  • Similarly, a V118I mutation in the bifunctional Yl.d12 desaturase improves its Δ15/Δ12 specificity.
  • In contrast, a I119V mutation in the monofunctional Sk.d15 desaturase was found to reduce Δ15 substrate conversion by ca. 17%. No Δ12 desaturase activity was detectable.
  • Therefore, it is within the context of the present invention to provide a method for increasing the ability of a bifunctional fungal Δ15 desaturase enzyme to act on a Δ12 desaturase substrate comprising:
      • a) providing a nucleic acid molecule encoding a polypeptide having bifunctional Δ15 desaturase activity and comprising a Δ15 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:46, 47 and 48, wherein each of the motif sequences comprises an isoleucine at amino acid residue 4; and,
      • b) altering the nucleic acid molecule of (a) such that it encodes a mutant polypeptide comprising a mutant Δ15 desaturase motif of (a) wherein the isoleucine at amino acid residue 4 is replaced with valine, wherein the mutant polypeptide has an increased ability to act on a Δ12 desaturase substrate.
  • Conversely the invention describes a method for increasing the ability of a bifunctional fungal Δ12 desaturase enzyme to act on a Δ15 desaturase substrate comprising:
      • a) providing a nucleic acid molecule encoding a polypeptide having bifunctional Δ12 desaturase activity and comprising a Δ12 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4 and 5, wherein each of the motif sequences comprises a valine at amino acid residue 4; and,
      • b) altering the nucleic acid molecule of (a) such that it encodes a mutant polypeptide comprising a mutant Δ12 desaturase motif of (a) wherein the valine at amino acid residue 4 is replaced with isoleucine, wherein the mutant polypeptide has an increased ability to act on a Δ15 desaturase substrate.
  • Although the techniques described herein made use of site-directed mutagenesis to alter the Fusarium moniliforme Δ12 and Δ15 desaturase, the Yarrowia lipolytica Δ12 desaturase and the Saccharomyces kluyveri Δ15 desaturase catalytic activity and specificity, it is well known in the art that in vitro mutagenesis and selection, chemical mutagenesis, “gene shuffling” methods or other means can be employed to obtain mutations of naturally occurring desaturase genes. This would permit production of various polypeptides having altered Δ12 and/or Δ15 desaturase activity, that possessed a Val-to-Ile mutation or a Ile-to-Val mutation, respectively, three amino acid residues upstream from the first histidine in the conserved His Box I (SEQ ID NO:6).
    • Methods For Production Of Various ω-3 And/Or ω-6 Fatty Acids
  • It is expected that introduction of chimeric genes encoding the Δ12 desaturases and Δ15 desaturases described herein (i.e., wildtype enzymes, mutant enzymes, codon-optimized enzymes or homologs thereof), under the control of the appropriate promoters will result in increased production of LA and ALA in the transformed host organism, respectively. As such, the present invention encompasses a method for the direct production of PUFAs comprising exposing a fatty acid substrate (i.e., oleic acid or LA) to the desaturase enzymes described herein (e.g., Ca.d12 or Kl.d15), such that the substrate is converted to the desired fatty acid product (i.e., LA or ALA).
  • Specifically the methods described here contemplate production of α-linolenic acid comprising the steps of:
      • a.) providing a host cell comprising:
        • i.) an isolated nucleic acid fragment encoding a polypeptide having Δ15 desaturase activity and comprising a Δ15 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:46, 47 and 48; and,
        • ii.) a source of linoleic acid;
      • b.) growing the host cell of step (a) under conditions wherein the nucleic acid fragment encoding the polypeptide is expressed and the linoleic acid is converted to α-linolenic acid; and,
      • c.) optionally recovering the α-linolenic acid of step (b).
  • In the alternative, linoleic acid may be made in a process comprising the steps of:
      • a.) providing a host cell comprising:
        • i.) an isolated nucleic acid fragment encoding a polypeptide having Δ12 desaturase activity and comprising a Δ12 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4 and 5; and,
        • ii.) a source of oleic acid;
      • b.) growing the host cell of step (a) under conditions wherein the nucleic acid fragment encoding the polypeptide is expressed and the oleic acid is converted to linoleic acid; and,
      • c.) optionally recovering the linoleic acid of step (b).
  • Alternatively, each PUFA gene and its corresponding enzyme product described herein can be used indirectly for the production of ω-3/ω-6 PUFAs (see PCT Publications No. WO 2005/047480 and No. WO2005/047485). Indirect production of ω-3/ω-6 PUFAs occurs wherein the fatty acid substrate is converted indirectly into the desired fatty acid product, via means of an intermediate step(s) or pathway intermediate(s). Thus, it is contemplated that the Δ12 desaturases and/or the Δ15 desaturases described herein (i.e., wildtype enzymes, mutant enzymes, codon-optimized enzymes or homologs thereof) may be expressed in conjunction with additional genes encoding enzymes of the PUFA biosynthetic pathway to result in higher levels of production of longer-chain ω-3/ω-6 fatty acids (e.g., ARA, EPA and DHA). The particular genes included within a particular expression cassette will depend on the host cell (and its PUFA profile and/or desaturase/elongase profile), the availability of substrate and the desired end product(s).
  • In alternative embodiments, it may be useful to disrupt a host organism's native Δ12 desaturase or Δ15 desaturase, based on the complete sequences described herein, the complement of those complete sequences, substantial portions of those sequences, codon-optimized desaturases derived therefrom and those sequences that are substantially homologous thereto. For example, the targeted disruption of the Δ15 desaturase in a host organism produces a mutant strain that is unable to synthesize ALA. This mutant strain could be useful for the production of “pure” ω-6 fatty acids (without co-synthesis of ω-3 fatty acids).
  • In preferred embodiments for the production of linoleic acid nucleic acids encoding the following desaturase polypeptides may be used:
      • a.) a polypeptide selected from the group consisting of the following GenBank Accession Nos: XP—455402 (Kluyveromyces lactis [SEQ ID NO:63]), EAK94955 (Candida albicans [SEQ ID NO:65]), CAG90237 (Debaryomyces hansenii CBS767 [SEQ ID NO:73]), EAL90585 (Aspergillus fumigatus [SEQ ID NO:75]), BAD04850 (Aspergillus oryzae [SEQ ID NO:77]), EAQ83131 (Chaetomium globosum [SEQ ID NO:79]), EAS31392 (Coccidioides immitis RS [SEQ ID NO:82]), AAS53960 (Ashbya gossypii ATCC 10895 [SEQ ID NO:84]), XP—757193 (Ustilago maydis 521 [SEQ ID NO:91]) and EAL 21306 (Cryptococcus neoformans var. neoformans B-3501A [SEQ ID NO:87]); and,
      • b.) a polypeptide whose amino acid sequence is selected from the group consisting of the following genomic sequence ORFs:
        • i.) [1122100, 1123500] (complement) within Candida guilliermondii supercontig 1.3 [SEQ ID NO:67];
        • ii.) [123300, 124400] (complement) within Candida tropicalis supercontig 1.10 [SEQ ID NO:69]; and
        • iii.) [738900, 740200] (complement) within Candida lusitaniae supercontig 1.2 [SEQ ID NO:71].
  • Similarly In preferred embodiments for the production of α-linolenic acid nucleic acids encoding the following desaturase polypeptides may be used:
      • a.) a polypeptide selected from the group consisting of the following GenBank Accession Nos: XP—451551 (Kluyveromyces lactis [SEQ ID NO:64]), EAL03493 (Candida albicans [SEQ ID NO:66]), CAG88182 (Debaryomyces hansenii CBS767 [SEQ ID NO:74]), EAL85733 (Aspergillus fumigatus [SEQ ID NO:76]), BAE66531 (Aspergillus oryzae [SEQ ID NO:78]) and EAQ88866 (Chaetomium globosum [SEQ ID NO:80]); and,
      • b.) a polypeptide whose amino acid sequence is selected from the group consisting of the following genomic sequence ORFs:
        • i.) [680800, 682000] (complement) within Candida guilliermondii supercontig 1.4 [SEQ ID NO:68];
        • ii.) [1709400, 1710700] (complement) within Candida tropicalis supercontig 1.3 [SEQ ID NO:70]; and,
        • iii.) [2095200, 2096600] (complement) within Candida lusitaniae supercontig 1.2 [SEQ ID NO:72].
    Expression Systems, Cassettes And Vectors
  • The genes and gene products of the instant sequences described herein may be expressed in heterologous host cells. Expression in recombinant hosts may be useful for the production of various PUFA pathway intermediates, or for the modulation of PUFA pathways already existing in the host for the synthesis of new products heretofore not possible using the host.
  • Expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of any of the gene products of the instant sequences. These chimeric genes could then be introduced into appropriate host cells via transformation to provide high-level expression of the encoded enzymes.
  • Vectors or DNA cassettes useful for the transformation of suitable host cells are well known in the art. The specific choice of sequences present in the construct is dependent upon the desired expression products (supra), the nature of the host cell and the proposed means of separating transformed cells versus non-transformed cells. Typically, however, the vector or cassette contains sequences directing transcription and translation of the relevant gene(s), a selectable marker and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5′ of the gene that controls transcriptional initiation (e.g., a promoter) and a region 3′ of the DNA fragment that controls transcriptional termination (i.e., a terminator). It is most preferred when both control regions are derived from genes from the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.
  • Initiation control regions or promoters which are useful to drive expression of the instant ORFs in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of directing expression of these genes in the selected host cell is suitable for the present invention. Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest. Stable expression can be achieved by the use of a constituitive promoter operably linked to the gene of interest. As an example, when the host cell is yeast, transcriptional and translational regions functional in yeast cells are provided, particularly from the host species (e.g., see PCT Publication No. WO 2006/052870 for preferred transcriptional initiation regulatory regions for use in Yarrowia lipolytica). Any one of a number of regulatory sequences can be used, depending upon whether constitutive or induced transcription is desired, the efficiency of the promoter in expressing the ORF of interest, the ease of construction and the like.
  • The termination region can be derived from the 3′ region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known and function satisfactorily in a variety of hosts (when utilized both in the same and different genera and species from where they were derived). The termination region usually is selected more as a matter of convenience rather than because of any particular property. Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary; however, it is most preferred if included.
  • As one of skill in the art is aware, merely inserting a gene into a cloning vector does not ensure that it will be successfully expressed at the level needed. In response to the need for a high expression rate, many specialized expression vectors have been created by manipulating a number of different genetic elements that control aspects of transcription, translation, protein stability, oxygen limitation and secretion from the host cell. More specifically, some of the molecular features that have been manipulated to control gene expression include: 1.) the nature of the relevant transcriptional promoter and terminator sequences; 2.) the number of copies of the cloned gene and whether the gene is plasmid-borne or integrated into the genome of the host cell; 3.) the final cellular location of the synthesized foreign protein; 4.) the efficiency of translation and correct folding of the protein in the host organism; 5.) the intrinsic stability of the mRNA and protein of the cloned gene within the host cell; and, 6.) the codon usage within the cloned gene, such that its frequency approaches the frequency of preferred codon usage of the host cell. Each of these types of modifications are encompassed in the present invention, as means to further optimize expression of the Δ12 and Δ15 desaturases described herein.
  • For example, codon-optimized genes encoding desaturases that are substantially identical to Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12, Chg.d12, Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and/or Chg.d15 (i.e., SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 39 [or 50], 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80, respectively) could be utilized as a means to increase expression of the heterologous genes in an alternate host (see, e.g., PCT Publication No. WO 2004/101757 for details concerning means to identify host-preferred codons and optimize codon usage of heterologous proteins in Yarrowia lipolytica).
    • Transformation Of Host Cells
  • Once the DNA encoding a polypeptide suitable for expression in an appropriate host cell has been obtained, it is placed in a plasmid vector capable of autonomous replication in the host cell, or it is directly integrated into the genome of the host cell. Integration of expression cassettes can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination with the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.
  • Where two or more genes are expressed from separate replicating vectors, it is desirable that each vector has a different means of selection and should lack homology to the other construct(s) to maintain stable expression and prevent reassortment of elements among constructs. Judicious choice of regulatory regions, selection means and method of propagation of the introduced construct(s) can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.
  • Constructs comprising the gene of interest may be introduced into a host cell by any standard technique. These techniques include transformation (e.g., lithium acetate transformation [Methods in Enzymology, 194:186-187 (1991)]), protoplast fusion, biolistic impact, electroporation, microinjection, or any other method that introduces the gene of interest into the host cell.
  • For convenience, a host cell that has been manipulated by any method to take up a DNA sequence (e.g., an expression cassette) will be referred to as “transformed” or “recombinant” herein. The transformed host will have at least one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified, or is present on an extrachromosomal element having multiple copy numbers. The transformed host cell can be identified by various selection techniques, as described in PCT Publications No. WO 2004/101757, No. WO 2005/003310 and No. WO 2006/052870.
  • Following transformation, substrates suitable for the instant Δ12 and/or Δ15 desaturases (and, optionally other PUFA enzymes that are co-expressed within the host cell) may be produced by the host either naturally or transgenically, or they may be provided exogenously.
    • Metabolic Engineering Of ω-3 And/Or ω-6 Fatty Acid Biosynthesis
  • Knowledge of the sequences of the present Δ12 and Δ15 desaturases will be useful for manipulating ω-3 and/or ω-6 fatty acid biosynthesis in various host cells. This may require metabolic engineering directly within the PUFA biosynthetic pathway or additional manipulation of pathways that contribute carbon to the PUFA biosynthetic pathway. Methods useful for up-regulating desirable biochemical pathways and down-regulating undesirable biochemical pathways are well known to those skilled in the art. For example, biochemical pathways competing with the ω-3 and/or ω-6 fatty acid biosynthetic pathways for energy or carbon, or native PUFA biosynthetic pathway enzymes that interfere with production of a particular PUFA end-product, may be eliminated by gene disruption or down-regulated by other means (e.g., antisense mRNA).
  • Detailed discussion of manipulations within the PUFA biosynthetic pathway as a means to increase ARA, EPA or DHA (and associated techniques thereof) are presented in PCT Publication No. WO 2006/055322 [U.S. Patent Publication No. 2006-0094092-A1], PCT Publication No. WO 2006/052870 [U.S. Patent Publication No. 2006-0115881-A1] and PCT Publication No. WO 2006/052871 [U.S. Patent Publication No. 2006-0110806-A1], respectively, as are desirable manipulations in the TAG biosynthetic pathway and the TAG degradation pathway (and associated techniques thereof).
    • Preferred Hosts For Recombinant Expression Of Δ12 And Δ15 Desaturases
  • Host cells for expression of the instant genes and nucleic acid fragments may include microbial hosts that grow on a variety of feedstocks, including simple or complex carbohydrates, fatty acids, organic acids, oils, alcohols, and/or hydrocarbons over a wide range of temperature and pH values. Based on the needs of the Applicants' Assignee, the genes described in the instant invention were initially isolated for expression in an oleaginous yeast (and in particular Yarrowia lipolytica); however, it is contemplated that because transcription, translation and the protein biosynthetic apparatus are highly conserved, any bacteria, yeast, algae and/or fungus will be a suitable host for expression of the present nucleic acid fragments.
  • Preferred hosts are oleaginous organisms, such as oleaginous yeast. These oleaginous organisms are naturally capable of oil synthesis and accumulation, wherein the oil can comprise greater than about 25% of the cellular dry weight, more preferably greater than about 30% of the cellular dry weight, and most preferably greater than about 40% of the cellular dry weight. Genera typically identified as oleaginous yeast include, but are not limited to: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces. More specifically, illustrative oil-synthesizing yeast include: Rhodosporidium toruloides, Lipomyces starkeyii, L. lipoferus, Candida revkaufi, C. pulcherrima, C. tropicalis, C. utilis, Trichosporon pullans, T. cutaneum, Rhodotorula glutinus, R. graminis and Yarrowia lipolytica (formerly classified as Candida lipolytica).
  • Most preferred is the oleaginous yeast Yarrowia lipolytica; and, in a further embodiment, most preferred are the Y. lipolytica strains designated as ATCC #76982, ATCC #20362, ATCC #8862, ATCC #18944 and/or LGAM S(7)1 (Papanikolaou S., and Aggelis G., Bioresour. Technol., 82(1):43-9 (2002)).
  • Specific teachings applicable for engineering GLA, ARA, EPA and DHA in Y. lipolytica are provided in U.S. patent application Ser. No. 11/198975 (PCT Publication No. WO 2006/033723), Ser. No. 11/264784 (PCT Publication No. WO 2006/055322), Ser. No. 11/265761 (PCT Publication No. WO 2006/052870) and Ser. No. 11/264737 (PCT Publication No. WO 02006/052871), respectively. Detailed means for the synthesis and transformation of expression vectors comprising Δ12 and Δ15 desaturases in oleaginous yeast (i.e., Yarrowia lipolytica) are provided in PCT Publications No. WO 2005/047480 and No. WO 2005/047485. The preferred method of expressing genes in this yeast is by integration of linear DNA into the genome of the host; and, integration into multiple locations within the genome can be particularly useful when high level expression of genes are desired [e.g., in the Ura3 locus (GenBank Accession No. AJ306421), the Leu2 gene locus (GenBank Accession No. AF260230), the Lys5 gene locus (GenBank Accession No. M34929), the Aco2 gene locus (GenBank Accession No. AJ001300), the Pox3 gene locus (Pox3: GenBank Accession No. XP—503244; or, Aco3: GenBank Accession No. AJ001301), the Δ12 desaturase gene locus (PCT Publication No. WO 2004/104167), the Lip1 gene locus (GenBank Accession No. Z50020) and/or the Lip2 gene locus (GenBank Accession No. AJ012632)].
  • Preferred selection methods for use in Yarrowia lipolytica are resistance to kanamycin, hygromycin and the amino glycoside G418, as well as ability to grow on media lacking uracil, leucine, lysine, tryptophan or histidine. In alternate embodiments, 5-fluoroorotic acid (5-fluorouracil-6-carboxylic acid monohydrate; “5-FOA”) is used for selection of yeast Ura− mutants. The compound is toxic to yeast cells that possess a functioning URA3 gene encoding orotidine 5′-monophosphate decarboxylase (OMP decarboxylase); thus, based on this toxicity, 5-FOA is especially useful for the selection and identification of Ura− mutant yeast strains (Bartel, P. L. and Fields, S., Yeast 2-Hybrid System, Oxford University: New York, v. 7, pp 109-147, 1997).
  • Other preferred microbial hosts include oleaginous bacteria, algae and other fungi; and, within this broad group of microbial hosts, of particular interest are microorganisms that synthesize ω-3/ω-6 fatty acids. Thus, for example, transformation of Mortierella alpina (which is commercially used for production of ARA) with any of the present Δ15 desaturase genes under the control of inducible or regulated promoters could yield a transformant organism capable of synthesizing EPA. Furthermore, one could improve the ratio of ω-3 to ω-6 fatty acids in this genetically engineered organism by transforming those strains having a disruption or mutation in their native Δ12 desaturase (e.g., by introducing any of the present Δ15 desaturases into the locus of the native Δ12 gene, using means well known in the art). The method of transformation of M. alpina is described by Mackenzie et al. (Appl. Environ. Microbiol., 66:4655 (2000)). Similarly, methods for transformation of Thraustochytriales microorganisms are disclosed in U.S. Pat. No. 7,001,772.
  • In alternate preferred embodiments, the present invention provides a variety of plant hosts for transformation with the Δ12 and Δ15 desaturases described herein. Plants so transformed can be monocotyledonous plants or dicotyledonous plants, and preferably they belong to a class of plants identified as oleaginous (e.g., oilseed plants). Examples of preferred oilseed plant hosts include, but are not limited to: soybean (Glycine and Soja sp.), corn (Zea mays), flax (Linum sp.), rapeseed (Brassica sp.), primrose, canola, maize, safflower (Carthamus sp.) and sunflower (Helianthus sp.). Means for overexpression of the instant Δ12 and Δ15 desaturases in oilseed plants (e.g., construction of expression cassettes, transformation, selection, etc.) are described in PCT Publications No. WO 2005/047479 and No. WO 2005/047480.
  • No matter what particular host is selected for expression of the Δ12 and Δ15 desaturases described herein, multiple transformants must be screened in order to obtain a strain displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA blots (Southern, J. Mol. Biol., 98:503 (1975)), Northern analysis of mRNA expression (Kroczek, J. Chromatogr. Biomed. Appl., 618 (1-2):133-145 (1993)), Western and/or Elisa analyses of protein expression, phenotypic analysis or GC analysis of the PUFA products.
    • Fermentation Processes For Omega Fatty Acid Production In Microbes
  • The transformed microbial host cell is grown under conditions that optimize expression of chimeric desaturase genes and produce the greatest and most economical yield of desired PUFAs. In general, media conditions that may be optimized include the type and amount of carbon source, the type and amount of nitrogen source, the carbon-to-nitrogen ratio, the amount of different mineral ions, the oxygen level, growth temperature, pH, length of the biomass production phase, length of the oil accumulation phase and the time and method of cell harvest. Yarrowia lipolytica are generally grown in complex media (e.g., yeast extract-peptone-dextrose broth (YPD)) or a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes (e.g., Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Mich.)).
  • Fermentation media in the present invention must contain a suitable carbon source. Suitable carbon sources are taught in PCT Publication No. WO 2005/047480. Although it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing sources, preferred carbon sources are sugars, glycerol and/or fatty acids. Most preferred is glucose and/or fatty acids containing between 10-22 carbons.
  • Nitrogen may be supplied from an inorganic (e.g., (NH4)2SO4) or organic (e.g., urea or glutamate) source. In addition to appropriate carbon and nitrogen sources, the fermentation media must also contain suitable minerals, salts, cofactors, buffers, vitamins and other components known to those skilled in the art suitable for the growth of the oleaginous host and promotion of the enzymatic pathways necessary for PUFA production. Particular attention is given to several metal ions (e.g., Fe+2, Cu+2, Mn+2, Co+2, Zn+2, Mg+2) that promote synthesis of lipids and PUFAs (Nakahara, T. et al., Ind. Appl. Single Cell Oils, D. J. Kyle and R. Colin, eds. pp 61-97 (1992)).
  • Preferred growth media in the present invention are common commercially prepared media, such as Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Mich.). Other defined or synthetic growth media may also be used and the appropriate medium for growth of the transformant host cells will be known by one skilled in the art of microbiology or fermentation science. A suitable pH range for the fermentation is typically between about pH 4.0 to pH 8.0, wherein pH 5.5 to pH 7.5 is preferred as the range for the initial growth conditions. The fermentation may be conducted under aerobic or anaerobic conditions, wherein microaerobic conditions are preferred.
  • Typically, accumulation of high levels of PUFAs in oleaginous yeast cells requires a two-stage process, since the metabolic state must be “balanced” between growth and synthesis/storage of fats. Thus, most preferably, a two-stage fermentation process is necessary for the production of PUFAs in Yarrowia lipolytica. This approach is described in PCT Publication No. WO 2004/101757, as are various suitable fermentation process designs (i.e., batch, fed-batch and continuous) and considerations during growth.
    • EXAMPLES
  • The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
    • General Methods
  • Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by: 1.) Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1989) (Maniatis); 2.) T. J. Silhavy, M. L. Bennan, and L. W. Enquist, Experiments with Gene Fusions; Cold Spring Harbor Laboratory: Cold Spring Harbor, N.Y. (1984); and 3.) Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience, Hoboken, N.J. (1987).
  • Materials and methods suitable for the maintenance and growth of microbial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, Eds), American Society for Microbiology: Washington, D.C. (1994); or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, 2nd ed., Sinauer Associates: Sunderland, Mass. (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of microbial cells were obtained from Aldrich Chemicals (Milwaukee, Wis.), DIFCO Laboratories (Detroit, Mich.), GIBCO/BRL (Gaithersburg, Md.), or Sigma Chemical Company (St. Louis, Mo.), unless otherwise specified. E. coli (XL1-Blue) competent cells were purchased from the Stratagene Company (San Diego, Calif.). E. coli strains were typically grown at 37° C. on Luria Bertani (LB) plates.
  • General molecular cloning was performed according to standard methods (Sambrook et al., supra).
  • DNA sequence was generated on an ABI Automatic sequencer using dye terminator technology (U.S. Pat. No. 5,366,860; EP 272,007) using a combination of vector and insert-specific primers. Sequence editing was performed in Sequencher (Gene Codes Corporation, Ann Arbor, Mich.). All sequences represent coverage at least two times in both directions. Comparisons of genetic sequences were accomplished using DNASTAR software (DNASTAR, Inc., Madison, Wis.).
  • Percent identity between desaturase-related proteins were performed by multiple sequence alignment by the slow-accurate method Clustal W method using the MegAlign™ program of LASERGENE (Windows 32 MegAlign™5.06 1993-2003; DNASTAR Inc.). The parameters included GAP PENALTY=10, GAP LENGTH PENALTY=0.1, Protein Weight Matrix of Gonnet 250 series, and Delay Divergent Seqs(%) of 30%.
  • The meaning of abbreviations is as follows: “sec” means second(s), “min” means minute(s), “h” means hour(s), “d” means day(s), “μL” means microliter(s), “mL” means milliliter(s), “L” means liter(s), “μM” means micromolar, “mM” means millimolar, “M” means molar, “mmol” means millimole(s), “pmole” mean micromole(s), “g” means gram(s), “μg” means microgram(s), “ng” means nanogram(s), “U” means unit(s), “bp” means base pair(s), and “kB” means kilobase(s).
    • Yarrowia lipolytica Plasmids
  • The synthesis of the Yarrowia expression vector identified herein as pY35 was described in PCT Publication No. WO 2005/047485. The vector comprised the Fusarium monilforme Δ12 desaturase (i.e., Fm.d12 or Fm2) under the control of the Yarrowia lipolytica translation elongation factor-1 α (TEF) promoter (Muller, S., et al., Yeast 14:1267-1283 (1998); GenBank Accession No. AF054508) and a terminator comprising ˜100 bp of the 3′ region of the Yarrowia Xprgene (GenBank Accession No. M17741) [i.e., a TEF::Fm.d12::XPR chimeric gene].
  • The synthesis of the Yarrowia expression vector identified herein as pY34 was described in PCT Publication No. WO 2005/047480. The vector comprised the Fusarium moniliforme bifunctional Δ15 desaturase (i.e., Fm.d15 or Fm1) under the control of the Yarrowia glyceraldehyde phosphate dehydrogenase promoter (GPD; PCT Publication No. WO 2005/003310) [i.e., a GPD::Fm.d15::XPR chimeric gene].
  • Both pY34 and pY35 additionally contained: the ARS18 Yarrowia autonomous replication sequence; a ColE1 plasmid origin of replication; an ampicillin resistance gene (AmpR) for selection in E. coli; the E. coli ‘f1’ replication origin; and the Yarrowia LEU2 gene for selection in Yarrowia.
    • Yarrowia lipolytica Strains
  • Yarrowia lipolytica strains ATCC #20362, #76982 and #90812 were purchased from the American Type Culture Collection (Rockville, Md.).
  • Two separate Δ12 desaturase-disrupted [Δ12 knockout (KO)] strains of Yarrowia lipolytica ATCC #76982 were utilized herein: strain Q-d12D and strain L38. Both strains will be generically referred to as a “d12KO” strain and are phenotypically identical. Strain “Q-d12D” was previously described in PCT Publication No. WO 2004/104167; briefly, this d12KO strain was derived from Y. lipolytica #76982, following a Δ12 desaturase knockout created via homologous recombination-mediated replacement of the Δ12 desaturase gene with a targeting cassette comprising a truncated and disrupted version of the wildtype Δ12 desaturase. Strain “L38” is a Δ12 desaturase-disrupted strain of Yarrowia lipolytica similar to strain Q-d12D (supra). It will be described in Example 1, infra.
    • Transformation And Cultivation Of Yarrowia lipolytica
  • Y. lipolytica strains were usually grown at 28° C. on YPD agar (1% yeast extract, 2% bactopeptone, 2% glucose, 2% agar).
  • For selection of transformants, minimal medium (“MM”) was generally used; the composition of liquid MM is as follows: 0.17% yeast nitrogen base (DIFCO Laboratories, Detroit, Mich.) without ammonium sulfate or amino acids, 2% glucose, 0.1% proline, pH 6.1), whereas MM plates additionally contained 20 g/L agar.
    • Fatty Acid Analysis Of Yarrowia lipolytica
  • For fatty acid analysis, cells were collected by centrifugation and lipids were extracted as described in Bligh, E. G. & Dyer, W. J. (Can. J. Biochem. Physiol., 37:911-917 (1959)). Fatty acid methyl esters were prepared by transesterification of the lipid extract with sodium methoxide (Roughan, G. and Nishida I., Arch Biochem Biophys., 276(1):38-46 (1990)) and subsequently analyzed with a Hewlett-Packard 6890 GC fitted with a 30-m X 0.25 mm (i.d.) HP-INNOWAX (Hewlett-Packard) column. The oven temperature was from 170° C. (25 min hold) to 185° C. at 3.5° C./min.
  • For direct base transesterification, Yarrowia culture (3 mL) was harvested, washed once in distilled water, and dried under vacuum in a Speed-Vac for 5-10 min. Sodium methoxide (100 μl of 1%) was added to the sample, and then the sample was vortexed and rocked for 20 min. After adding 3 drops of 1 M NaCl and 400 μl hexane, the sample was vortexed and spun. The upper layer was removed and analyzed by GC as described above.
    • Example 1 Description Of Δ12 Knockout Yarrowia Strain L38
  • Strain L38 is a Δ12 desaturase-disrupted strain of Yarrowia lipolytica similar to the d12KO strain described as Q-d12D (PCT Publication No. WO 2004/10416). It was also derived from Y. lipolytica ATCC #76982 following disruption of its only native Δ12 desaturase gene by replacement with a disrupted version via homologous recombination.
    • Selection Method Theory
  • The methodology used to create the d12KO strain identified herein as L38 relied on site-specific recombinase systems. Briefly, the site-specific recombination system consists of two elements: (1) a recombination site having a characteristic DNA sequence [e.g., LoxP]; and, (2) a recombinase enzyme that binds to the DNA sequence specifically and catalyzes recombination (i.e., excision) between DNA sequences when two or more of the recombination sites are oriented in the same direction at a given interval on the same DNA molecule [e.g., Cre]. For the purposes herein, an integration construct was created comprising a target gene that was desirable to insert into the host genome (i.e., a first selection marker [i.e., Leu2]) that was flanked by recombination sites. Following transformation and selection of the transformants, the first selection marker was excised from the chromosome by the introduction of a replicating plasmid carrying a second selection marker (i.e., sulfonylurea resistance [AHAS]) and a recombinase suitable to recognize the site-specific recombination sites introduced into the genome (i.e., Cre). Upon selection of those transformants carrying the second marker, the replicating plasmid was then cured from the host in the absence of selection and excision of the first selection marker from the cured strain's host genome was confirmed by loss of Leu prototrophy. This produced a transformant that possessed neither the first nor second selection marker, and thus the cured strain was available for another round of transformation using the first selection marker. Additional details concerning site-specific recombinase based methodology for use in Yarrowia lipolytica is described in PCT Publication No. WO 2006/052870.
  • The second selection marker gene utilized was a native Yarrowia lipolytica acetohydroxyacid synthase (AHAS or acetolactate synthase; E.C. 4.1.3.18; GenBank Accession No. XM—501277) containing a single amino acid change (W497L) that confers sulfonyl urea herbicide resistance (SUR; described in PCT Publication No. WO 2006/052870). AHAS is the first common enzyme in the pathway for the biosynthesis of branched-chain amino acids and it is the target of the sulfonylurea and imidazolinone herbicides.
    • Experimental Methodology
  • Yarrowia lipolytica ATCC #76982 was transformed with SphI and Asci linearized plasmid pY137. The sequence of plasmid pY137 (labeled as pY137.YID12ko.Leu2 in FIG. 4A) is disclosed as SEQ ID NO:101 and pY137 Is described in the table below.
  • TABLE 6
    Description of pY137 (SEQ ID NO: 101)
    RE Sites And
    Nucleotides Within Description Of Fragment And Chimeric Gene
    SEQ ID NO: 101 Components
    PacI-Bg/II Contains LoxP::Leu2::LoxP, comprising:
    [digestion with LoxP (28–61 bp)
    PacI-Sa/I releases Yarrowia LEU2 gene (68–2228 bp) (GenBank
    LoxP::Leu2] Accession No. AF260230)
    LoxP (2308–2341)
    Bg/II-AscI Contains 3′ portion of Yarrowia lipolytica Δ12
    desaturase ORF (2357–2950 bp) that corresponds to
    661–1254 bp of GenBank Accession No.
    XM_500707)
    AscI-SphI Contains ColE1 plasmid origin of replication
    (3003–3883), ampicillin resistance gene (AmpR;
    3941–4801) for selection in E. coli, E. coli f1 origin
    of replication (5009–5409)
    SphI-PacI Contains 5′ portion of Yarrowia lipolytica Δ12
    desaturase ORF (5662–6262 bp) that corresponds to
    1–601 bp of GenBank Accession No. XM_500707)
  • Eleven LEU prototrophic pY137 transformants were analyzed by GC and four were identified as Δ12 knockout (d12KO) strains by the absence of detectable 18:2 (LA) upon GC analysis. One of these was designated strain L37.
  • The LEU2 gene in d12KO strain L37 was excised by transient expression of Cre recombinase under the control of Yarrowia glycerol-3-phosphate acyltransferase (GPAT) promoter. Specifically, strain L37 was transformed with plasmid pY117. The mutated Yarrowia AHAS enzyme in plasmid pY117 conferred SUR, which was used as a positive screening marker.
  • Plasmid pY117 was derived from plasmid pY116 (described in U.S. patent application Ser. No. 11/635258) by inserting the mutant AHAS gene flanked by PacI-SwaI sites into PacI-SwaI digested pY116 thereby replacing the LEU selectable marker with the sulfonylurea marker. Plasmid pY117 (SEQ ID NO:102) is represented in FIG. 4B (labeled therein as pY117.Cre.AHASw497L) and is described in Table 7 below.
  • TABLE 7
    Description of pY117 (SEQ ID NO: 102)
    RE Sites And
    Nucleotides Within Description Of Fragment And Chimeric Gene
    SEQ ID NO: 102 Components
    BsiWI-Eco RI Contains ColE1 plasmid origin of replication
    (448–1328), ampicillin resistance gene (AmpR;
    1328–2258, complementary) for selection in E. coli,
    and E. coli f1 origin of replication (2438–2838)
    Eco RI-PacI Yarrowia autonomous replication sequence (ARS18;
    GenBank Accession No. A17608) (3157–4461 bp)
    PacI-SwaI Contains Yarrowia lipolytica AHAS gene
    (corresponding to 27040–30026 bp [complementary]
    in Genbank Accession No. CR382129) comprising a
    W497L mutation (3157–4461 bp)
    Swa I/BsiWI Contains GPAT::Cre::XPR2 comprising:
    [digestion with GPAT: Yarrowia lipolytica GPAT promoter
    SwaI-NotI releases (PCT Publication No. WO 2006/031937)
    GPAT::Cre] (7498–8535 bp)
    Cre: Enterobacteria phage P1 Cre ORF for
    recombinase protein (GenBank Accession
    No. X03453) (8537–9570 bp) except for single
    base change (T4G) resulting in a single
    amino acid change (S2A) to create a NcoI site
    for cloning convenience
    XPR: ~170 bp of the 3′ region of the Yarrowia
    Xpr gene (GenBank Accession No. M17741)
  • L37 transformed by pY117 were plated on minimal plates containing Leu and 280 μg/mL sulfonyurea (chlorimuron ethyl, E. I. duPont de Nemours & Co., Inc., Wilmington, Del.). To cure the strains of pY117, two SUR colonies were used to inoculate 3 mL YPD. After overnight growth at 30° C., 100 μl of 1:250,000 diluted cultures were plated on YPD plates. After overnight growth at 30° C., 6 single colonies were streaked on both YPD and MM plates. All grew on YPD but not on MM plates, confirming their Leu auxotrophy. One of these was designated as strain L38.
    • Example 2 Identification Of Fungal Sequences Encoding Δ15 Desaturases
  • “Pairs” of Δ12/Δ15 desaturase-like polypeptides have previously been identified in the following filamentous fungi: Fusarium moniliforme, Fusarium graminearum, Magneporthe grisea, Neurospora crassa, Aspergillus nidulans, Mortirerella alpina and Saccharomyces kluveromyces. In each case, one protein was subsequently determined (or predicted) to possess Δ12 desaturase activity while the other protein was determined to possess Δ15 desaturase activity (PCT Publication No. WO 2005/047480; PCT Publication No. WO 2005/047485; Sakuradani et al., Appl. Microbiol. Biotechnol., 66:648-654 (2005); Oura, T. and Kajiwara, S., Microbiology (Reading, Engl.), 150(6):1983-1990 (2004); Sakuradani, E., et al., Eur. J. Biochem., 261(3):812-820 (1999); Watanabe, K., et al., Biosci. Biotechnol. Biochem., 68(3):721-727 (2004)). More specifically, the following proteins were previously characterized as Δ15 desaturases: Fm.d15 (SEQ ID NOs:39 and 50), Fg.d15 (SEQ ID NO:58), Mg.d15 (SEQ ID NO:54), Nc.d15 (SEQ ID NO:56), An.d15 (SEQ ID NO:52), Ma.d15 (SEQ ID NO:60) and Sk.d15 (SEQ ID NO:62); and, the following proteins were previously characterized as, or predicted to be, Δ12 desaturases: Fm.d12 (SEQ ID NOs:41 and 49), Fg.d12 (SEQ ID NO:57), Mg.d12 (SEQ ID NO:53), Nc.d12 (SEQ ID NO:55), An.d12 (SEQ ID NO:51), Ma.d12 (SEQ ID NO:59) and Sk.d12 (SEQ ID NO:61) (see Table 4, supra, for additional details).
  • Publically available sequences from other fungal species were searched to identify similar “pairs” of Δ12/Δ15 desaturase-like polypeptides as a means to identify novel Δ15 desaturases. Specifically, “pairs” of Δ12/Δ15 desaturase-like polypeptides were identified by performing standard BLAST searches against public databases (e.g., NCBI) using known fungal Δ12 desaturases, such as the Fusarium moniliforme and Yarrowia lipolytica Δ12 desaturases (SEQ ID NOs:41 [or 49] and 89, respectively).
  • Following the identification of nine different “pairs” of Δ12/Δ15 desaturase-like polypeptides, phylogenetic analysis of the sequences was performed using the Clustal W method (slow/accurate Gonnet) by DNASTAR MegAlign™6.1 (FIG. 2). Desaturases whose functions were biochemically characterized in published literature other than PCT Publications No. WO 2005/047485 or No. WO 2005/047480 are identified with a black star (i.e., *).
  • As shown in FIG. 2, this phylogenetic analysis confirmed that one member of each “pair” of Δ12/Δ15 desaturase-like polypeptides was more closely related to a known fungal Δ15 desaturase (i.e., Sk.d15, Fm.d15), while the other was more closely related to a known fungal Δ12 desaturase (i.e., Sk.d12, Nc.d12, An.d12). This enabled the Applicants to differentiate one protein as a putative Δ15 desaturase (i.e., d15) and the other as a putative Δ12 desaturase (i.e., .d12) within each “pair” of Δ12/Δ15 desaturase-like polypeptides as indicated in Table 8 below in the column labeled as “ORF Designation”. Additional details concerning each “pair” of Δ12/Δ15 desaturase-like polypeptides are also provided in Table 8, including the putative function of the protein as annotated in public sources (i.e., GenBank).
  • TABLE 8
    “Pairs” Of Fungal Δ12/Δ15 Desaturase-Like Polypeptides
    SEQ
    ORF ID
    Designation Organism Locus NO Annotation
    Ca.d12 Candida GenBank 65 Δ12-like;
    albicans Accession No. Ode 1
    SC5314 EAK94955
    Ca.d15 Candida GenBank 66 Likely Δ12
    albicans Accession No. fatty acid
    SC5314 EAL03493 desaturase
    Cg.d12 Candida DNA [1122100, 67 —
    guilliermondii 1123500]
    (complement):
    Candida
    guilliermondii
    supercontig 1.3
    Cg.d15 Candida DNA [680800, 68 —
    guilliermondii 682000]
    (complement):
    Candida
    guilliermondii
    supercontig 1.4
    Cl.d12 Candida DNA [738900, 71 —
    lusitaniae 740200]
    (complement):
    Candida
    lusitaniae
    supercontig 1.2
    Cl.d15 Candida DNA [2095200, 72 —
    lusitaniae 2096600]
    (complement):
    Candida
    lusitaniae
    supercontig 1.2
    Ct.d12 Candida DNA [123300, 69 —
    tropicalis 124400]
    (complement):
    Candida
    tropicalis
    supercontig 1.10
    Ct.d15 Candida DNA [1709400, 70 —
    tropicalis 1710700]
    (complement):
    Candida
    tropicalis
    supercontig 1.3
    Dh.d12 Debaryomyces GenBank 73 Unnamed
    hansenii Accession No. protein
    CBS767 CAG90237 product
    Dh.d15 Debaryomyces GenBank 74 Unnamed
    hansenii Accession No. protein
    CBS767 CAG88182 product
    Kl.d12 Kluyveromyces GenBank 63 Unnamed
    lactis NRRL Accession No. protein
    Y-1140 XP_455402 product
    Kl.d15 Kluyveromyces GenBank 64 Unnamed
    lactis NRRL Accession No. protein
    Y-1140 XP_451551 product
    Af.d12 Aspergillus GenBank 75 Oleate Δ12
    fumigatus Accession No. desaturase
    EAL90585
    Af.d15 Aspergillus GenBank 76 Oleate Δ12
    fumigatus Accession No. desaturase
    EAL85733
    Ao.d12 Aspergillus GenBank 77 Oleate Δ12
    oryzae Accession No. desaturase
    BAD04850
    Ao.d15 Aspergillus GenBank 78 Unnamed
    oryzae Accession No. protein
    BAE66531 product; Fatty
    acid
    desaturase
    Chg.d12 Chaetomium GenBank 79 Hypothetical
    globosum CBS Accession No. protein
    148.51 EAQ83131 CHGG10949;
    Fatty acid
    desaturase
    Chg.d15 Chaetomium GenBank 80 Hypothetical
    globosum CBS Accession No. protein
    148.51 EAQ88866 CHGG05485;
    Fatty acid
    desaturase
    Note:
    All Candida genome sequences were sponsored by The Fungal Genome Initiative (FGI), Broad Institute of MIT and Harvard (Cambridge, MA).
    • Confirmation Of Predicted Fungal Δ15 Desaturase Activity By Analysis Of Fatty Acid Composition
  • Prior to functional characterization of the putative Δ15 desaturases by over-expression in an alternate host, two of the yeast strains were analyzed to confirm the presence of ALA, i.e., the fatty acid product of the putative Δ15 desaturase. Specifically, Kluyveromyces lactis NRRL-Y-1140 (designated “Kl Y12651” herein) and Debaromyces hansenii CBS767 (designated “Dh Y7426” herein) were obtained from the Agriculture Research Service (ARS) Culture Collection (National Center for Agricultural Utilization Research, Peoria, Ill.). Additionally, Saccharomyces kluyveri NRRL Y-12651 (designated “Sk Y12651” herein) was also obtained from the ARS Culture Collection as a means to confirm Oura et al.'s identification of a Δ15 desaturase within that strain (Microbiol., 150:1983-1990 (2004)).
  • Each yeast strain was grown for 2 days on YPD plates and the fatty acid composition was determined by analyzing a loop full of cells, as described in the General Methods. All three strains were confirmed to make a significant amount of the Δ15 desaturation product, ALA. More specifically, the fatty acid profile of each strain is shown below in Table 9. Fatty acids are identified as 16:0 (palmitate), 16:1 (palmitoleic acid), 18:0, 18:1 (oleic acid), 18:2 (LA) and 18:3 (ALA) and the composition of each is presented as a % of the total fatty acids. “Δ12% SC” was calculated according to the following formula: ([18:2+18:3]/[18:1+18:2+18:3])*100 and represents percent substrate conversion to 18:2. “Δ15% SC” was calculated according to the following formula: ([18:3]/[18:2+18:3])*100 and represents percent substrate conversion to ALA.
  • TABLE 9
    Fatty Acid Composition (% Total Fatty Acids) Of Yeast Strains
    Δ12 Δ15
    Yeast Species 16:0 16:1 18:0 18:1 18:2 ALA % SC % SC
    Sk Y12651 14 28 2 28 16 11 50 41
    Kl Y1140 12 22 2 14 31 18 77 37
    Dh Y7426 15 2 3 43 22 15 46 41
    • Functional Characterization Of Predicted Fungal Δ15 Desaturases By Expression In Yarrowia lipolytica
  • To experimentally confirm the activity of Kl.d15 (SEQ ID NO:64) and Dh.d15 (SEQ ID NO:74) as Δ15 desaturases, and to comparatively evaluate the function of these ORFs with respect to Sk.d15 (SEQ ID NO:62), all three ORFs were subsequently expressed in wild-type (WT) and Δ12 desaturase knockout (Δ12d KO) strains of Yarrowia lipolytica ATCC #76982.
  • First, genomic DNA from all three strains was extracted by the YeaStar Genomic DNA Kit™ (Zymo Research Corporation, Orange, Calif.). For this, 1.5 mL of yeast cultures were harvested by spinning. Supernatant was removed and 120 μl of YD Digestion Buffer and 5 μl of R-Zymolyase™ added. Each pellet was resuspended by vortexing and incubated at 37° C. for 60 min. Then, 120 μl of YD Lysis Buffer was added and mixed by gentle vortexing. Lysates were centrifuged in a table-top centrifuge at >10,000 rpm for 2 min and the supernatant loaded onto the Zymo-spin III column and centrifuged at >10,000 rpm for 1 min. The column was washed by 300 μl of DNA Wash Buffer and centrifuged for 1 min at 10,000 rpm. Another 300 μl of DNA Wash Buffer was added to repeat the wash and centrifuged for 1 min. The Zymo-spin III column was transferred to a new 1.5 mL centrifuge tube and the genomic DNAs were eluted with 60 μl of water.
  • Next, the isolated genomic DNAs were used to clone the predicted Δ15 desaturase ORFs. Since each ORF lacked an intron, the genomic DNA was used for cloning the entire ORF by PCR using the following upper primer and lower primer combinations:
  • TABLE 10
    Primers Used for Amplification of Predicted Δ15 Desaturase ORFs
    ORF Upper Primer Lower Primer
    Kl.d15 Primer 513 Primer 514
    (SEQ ID NO: 31) (SEQ ID NO: 32)
    Sk.d15 Primer 519 Primer 520
    (SEQ ID NO: 33) (SEQ ID NO: 34)
    Dh.d15 Primer 521 Primer 522
    (SEQ ID NO: 35) (SEQ ID NO: 36)
    • The primers were designed to allow direct cloning of the ORFs without use of restriction sites using in-fusion cloning (Clontech Laboratories, Inc., Mountain View, Calif.).
  • PCR was performed using standard conditions in a 25 μl total volume containing: 100 ng genomic DNA, 200 μM each deoxyribonucleotide triphosphate, 10 pmole of each primer, 2.5 μl 10× PfuUltra™ high-fidelity reaction buffer and 1 μl PfuUltra™ high-fidelity DNA polymerase (Stratagene, San Diego, Calif.). Amplification was carried out via initial denaturation at 95° C. for 3 min, followed by 30 cycles of the following: 95° C. for 1 min, 55° C. for 30 sec and 72° C. for 1 min. A final extension cycle of 72° C. for 10 min was carried out, followed by reaction termination at 4° C. PCR products were run on an agarose gel and products of the expected length were obtained, gel purified, and cloned by the in-fusion method (Clontech, Catalog No. PT3650-2) into plasmid pY35 linearized with NcoI/NotI digestion (PCT Publication No. WO 2005/047485).
  • The in-fusion reaction was transformed into E. coli XL1-Blue competent cells (Stratagene) and the cells were plated on LB/Amp selection plates. Correct transformants were screened by digesting miniprep DNA with SalI/NcoI and then performing agarose gel electrophoresis for product analysis.
  • The resultant plasmids comprising the K. lactis, D. hansenii and S. kluyveri ORFs (i.e., Kl.d15, Dh.d15, and Sk.d15, respectively) were designated “pY104 Kld15”, “pY106 Dhd15” and “pY107 Skd15”, respectively. Kl.d15 and Dh.d15 in plasmids pY104 Kld15 and pY106 Dhd15, respectively, were sequenced and confirmed to be identical to the public sequences (i.e., GenBank Accession No. XP—451551 and No. CAG88182, corresponding to SEQ ID NOs:64 and 74, respectively). Surprisingly, however, ORF Sk.d15 in plasmid pY107 Skd15 had 29 bp substitutions (97.7% identity) that resulted in 5 amino acid substitutions (98.8% identity), when compared to the public sequence (i.e., GenBank Accession No. BAD11952; SEQ ID NO:62). The differences presumably arose from strain differences. The nucleotide sequence of ORF Sk.d15 in plasmid pY107 Skd15 is provided herein as SEQ ID NO:103, while the amino acid sequence of ORF Sk.d15 in plasmid pY107 Skd15 is provided herein as SEQ ID NO:37.
  • Plasmids pY104 Kld15, pY106 Dhd15 and pY107 Skd15 were then transformed into wild type (WT) Y. lipolytica ATCC #76982 and the d12KO strain referred to as “Q-d12D”(General Methods; PCT Publication No. WO 2004/104167). Additionally, plasmid pY34 (PCT Publication No. WO 2005/047480) was used as a positive control, comprising the Fusarium moniliforme Δ15 desaturase (i.e., Fm.d15 [SEQ ID NOs:39 and 50], which additionally possessed some Δ12 desaturase activity). Plasmids pY34 and pY35 shared the same vector background to allow direct comparison of expression results.
  • One strain from each transformation was selected and grown in duplicate in 3 mL MM at 30° C. for 2 days before determining the fatty acid composition, as described in the General Methods. The average fatty acid composition of the transformants is shown in Table 11. Fatty acids are identified as 16:0 (palmitate), 16:1 (palmitoleic acid), 18:0, 18:1 (oleic acid), 18:2 (LA) and 18:3 (ALA) and the composition of each is presented as a % of the total fatty acids. “Δ12% SC” was calculated according to the following formula: ([18:2+18:3]/[18:1+18:2+18:3])*100 and represents percent substrate conversion to 18:2. “Δ15% SC” was calculated according to the following formula: ([18:3]/[18:2+18:3])*100 and represents percent substrate conversion to ALA.
  • TABLE 11
    Fatty Acid Composition (% Total Fatty Acids) In Yarrowia Transformants
    Host Δ12 % Δ15 %
    strain Plasmid 16:0 16:1 18:0 18:1 18:2 ALA SC SC
    WT pY34 Fm.d15 5.8 8.8 2.0 46.7 9.3 17.7 36.6 65.7
    WT pY104 Kld15 7.2 8.6 2.6 44.5 25.1 0.8 36.8 3.1
    WT pY106 Dhd15 7.0 8.7 2.6 42.7 28.1 0.2 39.8 0.6
    WT pY107 Skd15 6.9 8.8 2.8 44.9 23.3 2.7 36.7 10.4
    d12KO pY34 Fm.d15 5.2 9.3 2.4 63.8 0.5 9.1 13.1 95.0
    d12KO pY104 Kld15 4.3 7.7 2.2 70.1 0.0 0.0 0.0 0.0
    d12KO pY106 Dhd15 4.3 7.8 2.1 70.0 0.0 0.0 0.0 0.0
    d12KO pY107 Skd15 4.9 9.3 2.7 72.9 0.0 0.0 0.0 0.0
  • In WT cells, all transformants resulted in the presence of a new fatty acid methyl ester with a retention time that was identical to that for ALA. Thus, both Kl.d15 (SEQ ID NO:64) and Dh.d15 (SEQ ID NO:74) were shown to positively encode proteins having Δ15 desaturase activity. Additionally, Sk.d15 (SEQ ID NO:37) was also confirmed to have Δ15 desaturase activity when expressed in Yarrowia lipolytica. The amount of ALA varied from 0.2 to 2.7% (of total fatty acids); the relatively low level of ALA, compared to the levels seen in the source organisms (Table 9, wherein the amount of ALA varied from 11 to 18%) likely reflects differences in growth conditions and codon usage of the heterologous genes that were not codon oprtimized for expression in Yarrowia.
  • In the d12KO strain, ALA was observed only with Fm.d15. This was not unexpected, since Fm.d15 is a bifunctional Δ15 desaturase having primarily Δ15 desaturase activity and some Δ12 desaturase activity. In contrast, none of the d12KO transformants expressing Kl.d15, Dh.d15 or Sk.d15 possessed Δ12 desaturase activity in addition to Δ15 desaturase activity; thus, these desaturases can not be characterized as bifunctional Δ15 desaturases but should instead be classified as monofunctional Δ15 desaturases.
    • Example 3 Amino Acids Motifs For Identification Of Fungal Δ12 And Δ15 Desaturases
  • Comparison of the different fungal Δ12/Δ15 desaturase-like polypeptides (i.e., including both known and putative Δ12 and Δ15 desaturase sequences) from sixteen different fungal species (Table 4, supra) enabled the identification of regions of significant homology between the genes, such as the 15 amino acids surrounding and including the conserved His Box I (“HE[C/A]GH”; SEQ ID NO:6). More specifically, a total of 7 different sequence variants within this region (i.e., from 6 residues upstream of the His Box I to 4 residues downstream of the His Box I) were identified within the Δ12 desaturases (i.e., SEQ ID NOs:7, 8, 9, 10, 11, 12 and 13), while a total of 9 different sequence variants within this region were identified within the Δ15 desaturases (i.e., SEQ ID NOs:22, 23, 24, 25, 26, 27, 28, 29 and 30). These conserved sequences are summarized below in Tables 12 and 13 (wherein the shaded portion of the sequence corresponds to the His Box I), and led to the identification of SEQ ID NOs:1 and 2 as motifs that were representative of the fungal Δ12 desaturases and the identification of SEQ ID NOs:46, 47 and 48 as motifs that were representative of the fungal Δ15 desaturases.
  • TABLE 12
    Amino Acid Alignment Around The His Box I Of Fungal
    Δ12/Δ15 Desaturase-Like Polypeptides Identified As Δ12 Desaturases
    Figure US20070254299A1-20071101-C00003
  • TABLE 13
    Amino Acid Alignment Around The His Box I Of Fungal
    Δ12/Δ15 Desaturase-Like Polypeptides Identified As Δ15 Desaturases
    Figure US20070254299A1-20071101-C00004

    The most significant residue within SEQ ID NOs:1, 2, 46, 47 and 48 is the invariant Val or Ile, respectively, which is located three amino acid residues upstream from the first histidine in the conserved His Box I. This amino acid residue was hypothesized to be a determinant of Δ12 and Δ15 desaturase specificity, respectively, in fungal Δ12/Δ15 desaturase-like polypeptides.
  • Following the identification of the Δ15 and Δ12 desaturase fungal motifs, above, the Fungal Δ12 Desaturase Motif of SEQ ID NO:2 was used as a means to identity other fungal Δ12 desaturases using the BLASTP program of analysis (Basic Local Alignment Search Tool; Altschul, S. F., et al., J. Mol. Biol., 215:403-410 (1993) and Nucleic Acids Res., 25:3389-3402 (1997)), with hits limited to fungal organisms. These searches resulted in the identification of the following known and putative Δ12 desaturases, all of which comprised the fungal Δ12 desaturase fungal motif of SEQ ID NO:2, or a variant thereof (see Table 14, infra); some additional hits were drawn to those Δ12 and Δ15 desaturases previously described in Table 4. It is important to note that none of the organisms in Table 14 possessed a “pair” of Δ12/Δ15 desaturase-like polypeptide sequences and thus either lack Δ15 desaturase or their Δ15 desaturase is yet to be identified. Significantly, all of the additional known and putative Δ12 desaturases identified below in Table 14 share an invariant Val residue which is located three amino acid residues upstream from the first histidine in the conserved His Box I, thus lending support that this amino acid is a determinant of Δ12 desaturase specificity in fungal desaturases.
  • TABLE 14
    Additional Δ12 Desaturases Comprising Fungal Δ12 Desaturase Motif “B” (SEQ ID NO: 2)
    Or A Variant Thereof
    Figure US20070254299A1-20071101-C00005
    Figure US20070254299A1-20071101-C00006
    Figure US20070254299A1-20071101-C00007
    Figure US20070254299A1-20071101-C00008
    *Amino Acid Residue refers to the location of the first glycine within the conserved region around the His Box I, with respect to the full-length desaturase protein sequence. For example, the conserved region around the His Box I is located between amino acids 106-120 of the Mortierella isabellina Δ12 desaturase; thus, the amino acid residue corresponding to the initial glycine within the conserved region in this particular protein is residue 106.
    **Shaded text highlights the His Box I.
  • Based on the residues that were variant with respect to Fungal Δ12 Desaturase Motif “B” (shown in bold text in Table 14), a third Fungal Δ12 Desaturase Motif “C” motif was defined as: G (I/L/V) W V (L/I/V) (A/G) H E (A/C) G H (Q/G/L) (A/S) (F/Y) S (SEQ ID NO:3). Since Motif “C” is representative of all of the fungal Δ12 desaturases described in Table 14, in addition to Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12 and Chg.d12 (i.e., SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77 and 79, respectively), this motif is preferred (relative to either SEQ ID NO:1 or SEQ ID NO:2) for the identification of fungal polypeptides having Δ12 desaturase activity, wherein the presence of Fungal Δ12 Desaturase Motif “C” motif is indicative of Δ12 desaturase activity. More broadly, a motif indicative of Δ12 desaturase activity was defined as: G X W V X (A/G) H E (A/C) G H X X (F/Y) S (SEQ ID NO:4; “Fungal Δ12 Desaturase Motif D”), while even more broadly, this motif was defined as: G X W V X X H E X G H X X X S (SEQ ID NO:5; “Fungal Δ12 Desaturase Motif E”).
  • The desaturase proteins identified above as Cc.d12 (SEQ ID NO:86), Ro.d12 (SEQ ID NO:94), Mc.d12 (SEQ ID NO:92), Mr.d12 (SEQ ID NO:93) and Cn.d12 (SEQ ID NO:87), in addition to the Δ15 desaturases identified as Fm.d15, An.d15, Mg.d15, Nc.d15, Fg.d15, Ma.d15, Sk.d15, Kl.d15, Ca.d15, Cg.d15, Ct.d15, Cl.d15, Dh.d15, Af.d15, Ao.d15 and/or Chg.d15 (i.e., SEQ ID NOs:39 [or 50], 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78 and 80, respectively) and the Δ12 desaturases identified as Fm.d12, An.d12, Mg.d12, Nc.d12, Fg.d12, Ma.d12, Sk.d12, Kl.d12, Ca.d12, Cg.d12, Ct.d12, Cl.d12, Dh.d12, Af.d12, Ao.d12 and Chg.d12 (i.e., SEQ ID NOs:41 [or 49], 51, 53, 55, 57, 59, 61, 63, 65, 57, 59, 71, 73, 75, 77 and 79, respectively) were then aligned using the method of Clustal W (slow, accurate, Gonnet option; Thompson et al., Nucleic Acids Res., 22:4673-4680 (1994)) of the MegAlign™ program of DNASTAR software. This resulted in creation of FIG. 3, where percent similarity is shown in the large upper triangle of the Figure while percent divergence is shown in the large lower triangle.
  • The percent identities revealed by this method allowed determination of: 1.) the percent identity between each of the fungal Δ12 and Δ15 desaturases (of putative and known function); 2.) the percent identity among the putative and known fungal Δ12 desaturase proteins; and 3.) the percent identity among the putative and known fungal Δ15 desaturase proteins. Specifically, comparison of the fungal Δ12 desaturases (putative and confirmed) to the fungal Δ15 desaturases (putative and confirmed) determined that the sequences collectively shared between 27.3%-61.2% identity; minimum identity was between Chg.d12 and Nc.d15, while the maximum identity was between Cl.d12 and Cg.d15 (61.2% identity), Kl.d12 and Cg.d15 (61.2% identity), and Sk.d12 and Cg.d15 (61.2% identity). Within the twenty-one Δ12 desaturases, the percent identity ranged from 24.0% to 95%; minimum identity was between Chg.d12 and Mr.d12, while maximum identity was between Fm.d12 and Fg.d12. Similarly, within the sixteen Δ15 desaturases, the percent identity ranged from 31.8% to 88.8%; minimum identity was between Fg.d15 and Ma.d15, while maximum identity was between Fg.d15 and Fm.d15. Boxes in FIG. 3 corresponding to the specific maximum and minimum interspecies percent identities described above are outlined in bold.
  • The percent identity between the Δ12 desaturase and the Δ15 desaturase within the same organism ranged between 29.5%-61.0% identity (shown as individual gray highlighted boxes in FIG. 3).
    • Example 4 Method Of Altering Δ12/Δ15 Desaturase Specificity Of Bifunctional Fungal Desaturases
  • Based on the Applicant's observation that a single amino acid was sufficient to distinguish all known and putative fungal Δ12 desaturases from all known and putative fungal Δ15 desaturases (Tables 12, 13 and 14, supra), the work described below was undertaken as a means to confirm the desaturase specificity conveyed by this diagnostic Val or Ile amino acid residue located three amino acid residues upstream from the first histidine in the conserved His Box I. More specifically, the present Example demonstrates that a Val-to-Ile mutation within the Fungal Δ12 Desaturase Motif (SEQ ID NO:3, 4 or 5) of a bifunctional Δ12 desaturase or a Ile-to-Val mutation within the Fungal Δ15 Desaturase Motif (SEQ ID NO:46, 47 or 48) of a bifunctional Δ15 desaturase is an effective means to alter the Δ12/Δ15 specificity of fungal Δ12 and Δ15 desaturases, respectively.
    • Site-Directed Mutagenesis Within Fm.d12 And Fm.d15
  • The Δ12 desaturase (Fm.d12; SEQ ID NOs:40 and 41 [or 49] herein) and Δ15 desaturase (Fm.d15; SEQ ID NOs:38 and 39 [or 50] herein) from Fusarium monoliforme have been well-characterized in PCT Publications No. WO 2005/047485 and No. WO 2005/047480, respectively. Briefly, wild type Fm.d12 is a bifunctional Δ12 desaturase having only a trace level of Δ15 desaturase activity, while wild type Fm.d15 is a bifunctional Δ15 desaturase, wherein the polypeptide prefers LA as its enzymatic substrate but additionally has some ability to utilize oleic acid as substrate. The activity of these wildtype enzymes were compared to mutant enzymes, created via site-directed mutagenesis. Specifically, single nucleotide base pair changes resulting in single amino acid substitutions of V-to-I in Fm.d12 and I-to-V in Fm.d15 were engineered. Then, both mutant enzymes were evaluated according to: 1.) their Δ12 activity; 2.) their Δ15 activity; and 3.) the ratio of Δ15 to Δ12 substrate conversion.
  • Site directed mutagenesis was carried out using Stratagene's QuikChange® XL Site-Directed Mutagenesis kit, per the manufacturer's instructions. Nucleotide ‘G’ at position 451 of Fm.d12 was changed to ‘A’, resulting in a V-to-I substitution at amino acid residue 151 (i.e., a V151I mutation). Plasmid pY35 (comprising a TEF::Fm.d12 chimeric gene) was used as the template with sense and antisense mutant primers 515 and 516 (SEQ ID NOs:42 and 43), respectively. Similarly, nucleotide ‘A’ at position 304 of Fm.d15 was changed to ‘G’, resulting in an I-to-V substitution at amino acid residue 102 (i.e., a I102V mutation). Plasmid pY34 (comprising a GPD::Fm.d15 chimeric gene) was used as the template with sense and antisense mutant primers 517 and 518 (SEQ ID NOs:44 and 45), respectively.
  • QuickChange reactions were transformed into E. coli GOLD XL competent cells (BRL, Bethesda, Md.). Ten transformants each were sequenced; of those mutants, clone pY34M #1 was identified as a Fm.d12 mutant containing only a V151I mutation, while clone pY35M #20 was identified as a Fm.d15 mutant containing only a I102V mutation.
    • Analysis Of Lipid Composition In Transformant Y. lipolytica Over-Expressing Mutant Fm.d12 And Fm.d15 Desaturases
  • Plasmids pY34M #1 and pY35M #20 were transformed into wild type (WT) transformed into wild type (WT) Y. lipolytica ATCC #76982 and the d12KO strain referred to as “Q-d12D”(General Methods; PCT Publication No. WO 2004/104167) using standard lithium acetate methods and plated onto MM selection plates. After 3-4 days selection on MM plates, four colonies from each transformation were streaked onto fresh MM plates. After incubation at 30° C. overnight, cells from each plate were used to inoculate 3 mL MM liquid medium and grown on a shaker at 30° C. for 2 days. As controls, wild type (WT) and d12KO Yarrowia lipolytica ATCC #76982 strains transformed with parental plasmids pY34 and pY35 were also similarly grown. The cells were collected by centrifugation, total lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC as described in the General Methods.
  • Fatty acid composition of the single culture of each WT was compared to that of the average of 4 independent transformants of each mutation (“Experiment #1”). Alternatively, the experimental work described above was repeated in “Experiment 2”; and, fatty acid composition of duplicate cultures of both WT were compared to that of duplicate cultures of a single transformant out of the original four independent transformants of each mutation.
  • The results of the two experiments are combined in Table 15. Fatty acid composition as % of the total fatty acids is shown for each strain. Fatty acids are identified as 16:0 (palmitate), 16:1 (palmitoleic acid), 18:0, 18:1 (oleic acid), 18:2 (LA) and 18:3 (ALA). In the column titled “Desaturase”, the amino acid residue of the mutant enzyme is specified. The number in bracket following the enzyme description indicates the number of samples tested. “Δ12% SC” was calculated according to the following formula: ([18:2+18:3]/[18:1+18:2+18:3])*100 and represents percent substrate conversion (“SC”) to 18:2. “Δ15% SC” was calculated according to the following formula: ([18:3]/[18:2+18:3])*100 and represents percent substrate conversion to ALA. Δ15/Δ12 SC is calculated as Δ15% SC/Δ12% SC; Δ12/Δ15 SC is calculated as Δ12% SC/Δ15% SC; A15/Δ12SC % WT is calculated as ([Δ15/Δ12 SC of the mutant enzyme]/[Δ15/Δ12 SC of the wild type enzyme])*100; and Δ12/Δ15 SC % WT is calculated as ([Δ12/Δ15 SC of the mutant enzyme]/[Δ12/Δ15 SC of the wild type enzyme])*100.
  • TABLE 15
    Effect Of Site Directed Mutations On Δ12/Δ15 Desaturation Specificity In Bifunctional
    Fusarium moniliforme Δ12 And Δ15 Desaturases
    Δ15/ Δ12/
    Δ15/ Δ12 Δ12/ Δ15
    Experiment % % % % % % Δ12 % Δ15 % Δ12 SC Δ15 SC
    No. Host Desaturase 16:0 16:1 18:0 18:1 18:2 ALA SC SC SC % WT SC % WT
    1 WT Fm.d15 WT (1) 8 9 7 43 7 20.1 39 74.8 1.9 0.5
    1 WT Fm.d15 I102V (4) 8 9 7 34 13 23.2 52 64.1 1.2 64 0.8 156
    2 WT Fm.d15 WT (2) 6 9 2 47 9 17.7 37 65.7 1.8 0.6
    2 WT Fm.d15 I102V (2) 7 9 3 43 16 14.3 42 47.1 1.1 63 0.9 159
    1 d12KO Fm.d15 WT (1) 7 9 10 53 1 12.6 20 95.1 4.8 0.2
    1 d12KO Fm.d15 I102V (4) 7 9 8 50 5 14.4 28 73.6 2.6 55 0.4 182
    2 d12KO Fm.d15 WT (2) 5 9 2 64 0 9.1 13 95.0 7.2 0.1
    2 d12KO Fm.d15 I102V (2) 5 7 2 59 5 7.8 18 59.7 3.3 46 0.3 219
    1 WT Fm.d12 WT (1) 12 4 11 12 57 0.4 82 0.8 0.0 108.3
    1 WT Fm.d12 V151I (4) 11 5 8 17 55 1.8 77 3.1 0.0 433 25.0 23
    2 WT Fm.d12 WT (2) 10 4 3 15 64 0.6 81 0.9 0.0 95.1
    2 WT Fm.d12 V151I (2) 10 4 3 20 55 1.8 74 3.1 0.0 394 24.1 25
    1 d12KO Fm.d12 WT (1) 11 4 9 21 51 0.4 71 0.8 0.0 84.2
    1 d12KO Fm.d12 V151I (4) 10 4 9 23 49 1.6 69 3.3 0.0 401 21.0 25
    2 d12KO Fm.d12 WT (2) 9 4 2 22 56 0.5 72 0.9 0.0 80.5
    2 d12KO Fm.d12 V151I (2) 9 5 2 27 51 1.6 66 3.1 0.05 381 21.2 26
  • Results showed that I102V mutation in Fm.d15 resulted in a mutant enzyme with improved Δ12 desaturation and poorer Δ15 desaturation. Specifically, in the Δ12 desaturase-disrupted strain, the I102V mutant had a ratio of Δ15/Δ12 SC of 46% (Experiment 2) to 55% (Experiment 1), as compared to the wild type enzyme. Conversely, the V151I mutation in Fm.d12 resulted in poorer Δ12 desaturation and improved Δ15 desaturation. Specifically, in the Δ12 desaturase-disrupted strain, the V151I mutant had a 381% (Experiment 2) to 401% (Experiment 1) improvement in Δ15/Δ12 SC, as compared to the wild type enzyme. This showed that the catalytic activity and specificity of the Fusarium monoliforme desaturases can be improved by the mutations.
  • Thus, in summary, the present work demonstrated that an Ile-to-Val mutation within the Fungal Δ15 Desaturase Motif (SEQ ID NO:46, 47 or 48) in the Δ15 desaturase of Fusarium moniliforme (i.e., a I102V mutation in the Δ15 desaturase having bifunctional Δ15 desaturase activity) decreased the enzyme's Δ15/Δ12 specificity. In contrast, a Val-to-Ile mutation within the Fungal Δ12 Desaturase Motif (SEQ ID NO:3, 4 or 5) in the Δ12 desaturase of Fusarium moniliforme (i.e., a V151I mutation in the Δ12 desaturase having bifunctional Δ12 desaturase activity) increased the enzyme's Δ15/Δ12 specificity.
  • Modification of Δ12/Δ15 desaturase-like polypeptides having Δ12 and/or Δ15 desaturase activity could be achieved using the methodology described in the present Example in e.g., An.d12 (SEQ ID NO:51), Mg.d12 (SEQ ID NO:53), Nc.d12 (SEQ ID NO:55), Fg.d12 (SEQ ID NO:57), Ma.d12 (SEQ ID NO:59), Sk.d12 (SEQ ID NO:61), Kl.d12 (SEQ ID NO:63), Ca.d12 (SEQ ID NO:65), Cg.d12 (SEQ ID NO:67), Ct.d12 (SEQ ID NO:69), Cl.d12 (SEQ ID NO:71), Dh.d12 (SEQ ID NO:73), Af.d12 (SEQ ID NO:75), Ao.d12 (SEQ ID NO:77), Chg.d12 (SEQ ID NO:79), An.d15 (SEQ ID NO:52), Mg.d15 (SEQ ID NO:54), Nc.d15 (SEQ ID NO:56), Fg.d15 (SEQ ID NO:58), Ma.d15 (SEQ ID NO:60), Sk.d15 (SEQ ID NO:62), Kl.d15 (SEQ ID NO:64), Ca.d15 (SEQ ID NO:66), Cg.d15 (SEQ ID NO:68), Ct.d15 (SEQ ID NO:70), Cl.d15 (SEQ ID NO:72), Dh.d15 (SEQ ID NO:74), Af.d15 (SEQ ID NO:76), Ao.d15 (SEQ ID NO:78), Chg.d15 (SEQ ID NO:80), Ro.d12 (SEQ ID NO:94), Cc.d12 (SEQ ID NO:86), Mc.d12 (SEQ ID NO:92), Mr.d12 (SEQ ID NO:93) and/or Cn.d12 (SEQ ID NO:87), or wildtype enzymes, mutant enzymes, codon-optimized enzymes or homologs thereof.
    • Example 5 Method Of Altering Δ12/Δ15 Desaturase Specificity Of Monofunctional Fungal Desaturases
  • Based on the Applicant's demonstration that a Val-to-Ile mutation within the Fungal Δ12 Desaturase Motif (SEQ ID NO:3, 4 or 5) of a desaturase having bifunctional Δ12 desaturase activity increased the enzyme's Δ15/Δ12 specificity, while a Ile-to-Val mutation within the Fungal Δ15 Desaturase Motif (SEQ ID NO:46, 47 or 48) of a desaturase having bifunctional Δ15 desaturase activity decreased the enzyme's Δ15/Δ12 specificity, comparable mutations were made in the present Example in monofunctional fungal Δ12 and Δ15 desaturases. Specifically, the Applicant made the corresponding mutations in the monofunctional Δ15 desaturase (Sk.d15) from Saccharomyces kluyveri and the apparently monofunctional Δ12 desaturase (Yl.d12) from Yarrowia lipolytica. Both mutant enzymes were compared to their parent controls with respect to: 1.) their Δ12 activity; 2.) their Δ15 activity; and 3.) the ratio of Δ15 to Δ12 substrate conversion.
    • Site-Directed Mutagenesis in Sk.d15
  • Plasmid pY107 Skd15, comprising a TEF::Sk.d12 chimeric gene, described in Example 2, was used as the template with sense and antisense mutant primers 631 and 632 (SEQ ID NOs:96 and 97), respectively, for site-directed mutagenesis using Stratagene's QuikChange® XL Site-Directed Mutagenesis kit, per the manufacturer's instructions. These primers were designed to change nucleotide ‘A’ at position 355 of Sk.d15 ORF to ‘G’ (i.e., a A355G mutation) resulting in an I-to-V substitution at amino acid residue 119 (i.e., a I119V mutation).
  • The QuickChange reaction was transformed into E. coli GOLD XL competent cells (BRL, Bethesda, Md.). Several transformants were sequenced. Plasmid pY123 #5 was identified as a Sk.d15 mutant containing only the desired A355G mutation resulting in a I119V mutation. To ensure that there were no mutations in the unsequenced portion of pY123 #5, the sequenced region of pY123 #5 between SphI and NcoI was isolated and used to replace the corresponding sequence of the parent pY107. This resulted in plasmid pY125 that contained Sk.d15 with I119V as the sole mutation.
    • Site-Directed Mutagenesis in Yl.d12
  • Plasmid pY28 comprising a GPD::Yl.d12 chimeric gene, is derived from plasmid pY34 (described in PCT Publication No. WO 2005/047480). Plasmid pY28 is described in Table 16 and its 9099 bp sequence disclosed in SEQ ID NO:98.
  • TABLE 16
    Description of Plasmid pY28 (SEQ ID NO: 98)
    RE Sites
    And
    Nucleotides
    Within SEQ
    ID NO: 98 Description Of Fragment And Chimeric Gene Components
    SalI/NcoI Yarrowia lipolytica GPD promoter (WO 2005/003310;
    (1–971) GenBank Accession No. XM_501515) (corresponding to
    825835–826763 bp in GenBank Accession No. CR382129,
    except for a single bp change (C826238T) made to destroy
    the NcoI for cloning convenience, a single A insertion at
    position 826161 and a 37 bp direct repeat of nucleotides
    825884–825922)
    NcoI/NotI Yarrowia lipolytica Δ12 desaturase (WO 2004/104167;
    (971–2234) GenBank Accession No. CR382128) (SEQ ID NO: X)
    NotI (2234)- Lip1: Lip1 terminator sequence from Yarrowia Lip1 gene
    2561 (GenBank Accession No. Z50020)
    2562–2635 ~100 bp of the 3′ region of the Yarrowia Xpr gene
    (GenBank Accession No. M17741)
    2636-Sal1 E. coli/Yarrowia shuttle vector backbone, including:
    (1) E. coli replication origin, ‘ColE1’ (2878–3758)
    E. coli replication origin, ‘f1’ (4868–5268)
    Yarrowia autonomous replication sequence (ARS18)
    sequence (5587–6864)
    Yarrowia LEU2 gene for selection in Yarrowia
    (6873–1) (GenBank Accession No. AF260230)
  • Plasmid pY6 was derived from plasmid pY28 by removal of the Yl.d12 ORF. It served as an empty vector control.
  • Plasmid pY28 was used as the template with sense and antisense mutant primers 633 and 634 (SEQ ID NOs:99 and 100), respectively, for site-directed mutagenesis using Stratagene's QuikChange® XL Site-Directed Mutagenesis kit, per the manufacturer's instructions. These primers were designed to change nucleotide ‘G’ at position 352 of the Yl.d12 ORF to ‘A’ (i.e., a G352A mutation) resulting in a V-to-I substitution at amino acid residue 118 (i.e., a V118I mutation).
  • The QuickChange reaction was transformed into E. coli GOLD XL competent cells (BRL, Bethesda, Md.). Several transformants were sequenced to identify mutant enzymes. Plasmid pY124 #7 was identified as a Yl.d12 desaturase mutant containing only the desired G352A mutation resulting in a V118I mutation. In addition, plasmid pY124 #9 was also identified with an inadvertent Yl.d12 desaturase mutant containing a G352T mutation resulting in a V118F mutation.
  • To ensure that there were no mutations in the unsequenced portion of the Yl.d12 mutants, the mutant Yl.d12 ORFs were isolated from pY124 #7 and pY124 #9, and used to replace the Yl.d12 WT ORF in the parental plasmid pY28 resulting in plasmids pY128 (Yl.d12 V118I mutant) and pY127 (Yl.d12 V118F mutant), respectively.
    • Analysis Of Lipid Composition In Transformant Y. lipolytica Over-Expressing Mutant Sk.d15 and Yl.d12 Desaturases
  • Experiment 1: Plasmids pY5-13 (vector control) (Damude et al., Proc. Nat. Acad. Sci. U.S.A., 103:9446 (2006)), pY107 (Sk.d15 WT), pY125 (Sk.d15 I119V mutant), pY28 (Yl.d12 WT), pY128 (Yl.d12 V118I mutant) and pY127 (Yl.d12 V118F mutant) were transformed into wild type (WT) Y. lipolytica ATCC #76982 and the d12KO strain referred to as “Q-d12D”(General Methods; PCT Publication No. WO 2004/104167), using standard lithium acetate methods and plated onto MM selection plates. After 3-4 days selection on MM plates, three colonies from each transformation were streaked onto fresh MM plates. After incubation at 30° C. overnight, cells from each plate were used to inoculate 3 mL MM liquid medium and grown on a shaker at 30° C. for 2 days. The cells were collected by centrifugation, total lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC as described in the General Methods.
  • Experiment 2: Plasmid pY129, comprising a Y. lipolytica GPD promoter and the Mortierella alpina Δ12 desaturase (Ma.d12; GenBank Accession No. AF417244) was created as follows. First, the Ma.d12 ORF was cloned by PCR from a M. alpina cDNA library with 5′ NcoI and 3′ NotI. The encoded Δ12 desaturase protein was identical to the sequence in GenBank Accession No. AF417244, except for a H392Q mutation. Then, the NcoI/NotI fragment carrying the Ma.d12 ORF was used to replace the NcoI/NotI fragment carrying the Yl.d12 ORF in plasmid pY28, resulting in plasmid pY129 comprising a chimeric GPD::Ma.d12 ORF gene.
  • Plasmids pY6 (empty vector control), pY28 (Yl.d12 WT), pY128 (Yl.d12 V118I mutant), pY127 (Yl.d12 V118F mutant), and pY129 (Ma.d12 WT) were transformed into wild type (WT) Y. lipolytica ATCC #76982 and the d12KO strain referred to as “L38”(Example 1) using standard lithium acetate methods and plated onto MM selection plates.
  • After 3-4 days selection on MM plates, four transformant colonies from each transformation were streaked onto fresh MM plates. After incubation at room temperature for 3 days, cells from each plate were used to separately inoculate three 3 mL MM liquid medium and grown on a shaker at 30° C. for 2 days. Each culture (2 mL) was collected by centrifugation, total lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC as described in the General Methods.
  • Tables 17 and 18 show fatty acid composition (% of the total fatty acids) with standard deviation (“SD”) in experiments 1 and 2, respectively. Fatty acids are identified as 16:0 (palmitate), 16:1 (palmitoleic acid), 18:0, 18:1 (oleic acid), 18:2 (c9, 12) (LA) and 18:3 (c9, 12, 15) (ALA). In the column titled “Desaturase”, the amino acid residue of the mutant enzyme is specified. “Δ12% SC” was calculated according to the following formula: ([18:2+18:3]/[18:1+18:2+18:3])*100 and represents percent substrate conversion (“SC”) to 18:2. “Δ15% SC” was calculated according to the following formula: ([18:3]/[18:2+18:3])*100 and represents percent substrate conversion to ALA. Δ15/Δ12 SC is calculated as Δ15% SC/Δ12% SC. Fatty acid composition in Table 17 is the average of triplicate cultures of all samples, except WT host transformed with pY124, which was the average of duplicate cultures. Fatty acid composition in Table 18 is the average of quadruplicate cultures of all samples, except the d12KO host transformed with pY28, which was the average of triplicate cultures.
  • TABLE 17
    Fatty Acid Composition (% Total Fatty Acids) In Yarrowia Transformants (Experiment 1)
    Host % % % % % % Δ12 % Δ15 % Δ15/Δ12
    strain Plasmid Desaturase 16:0 16:1 18:0 18:1 LA ALA SC SC SC
    WT pY5-13 Vector control avg 10.3 10.5 5.8 39.8 30.4 0.000 43.3 0.0
    SD 0.3 0.2 0.3 0.6 0.4 0.0 0.6 0.0
    WT pY28 Yld12 WT avg 11.2 6.7 6.2 25.2 46.3 0.977 65.2 2.1 0.03
    SD 0.2 0.1 0.4 0.4 0.6 0.1 0.6 0.2 0.00
    WT pY127 Yld12 V118F mutant avg 10.5 9.5 6.6 39.0 30.3 0.063 43.8 0.2 0.00
    SD 0.8 1.3 1.1 1.5 1.2 0.1 1.9 0.3 0.01
    WT pY128 Yld12 V118I mutant avg 10.1 7.5 6.3 28.7 39.7 2.976 59.7 6.7 0.11
    SD
    WT pY107 Skd15 WT avg 9.8 9.6 5.7 43.4 20.9 6.588 38.8 24.0 0.62
    SD 0.2 0.2 0.2 0.4 0.5 0.2 0.5 0.9 0.03
    WT pY125 Skd15 I119V mutant avg 9.5 9.4 5.4 42.7 22.9 5.652 40.1 19.8 0.49
    SD 0.4 0.1 0.3 0.5 0.6 0.1 0.8 0.2 0.01
    d12KO pY5-13 Vector control avg 8.6 11.5 5.2 70.9 0.0 0.000 0.0 0.0
    SD 0.5 0.1 0.7 0.2 0.0 0.0 0.0 0.0
    d12KO pY28 Yld12 WT avg 10.5 6.6 6.1 32.8 38.8 1.104 54.8 2.8 0.05
    SD 0.1 0.1 0.0 0.3 0.3 0.1 0.4 0.2 0.00
    d12KO pY127 Yld12 V118F mutant avg 7.8 12.1 4.3 69.7 0.000 0.000 0.0 0.0
    SD 0.0 0.3 0.5 0.5 0.0 0.0 0.0 0.0
    d12KO pY128 Yld12 V118I mutant avg 10.1 6.9 5.7 35.9 33.0 4.738 51.2 12.6 0.25
    SD 0.1 0.1 0.1 0.2 0.2 0.1 0.3 0.2 0.00
    d12KO pY107 Skd15 WT avg 7.7 10.3 4.2 71.9 0.000 0.000 0.00 0.00
    SD 0.3 0.4 0.4 0.9 0.0 0.0 0.00 0.00
    d12KO pY125 Skd15 I119V mutant avg 7.7 9.9 4.5 72.0 0.000 0.000 0.00 0.00
    SD 0.3 0.3 0.4 0.6 0.0 0.0 0.00 0.00
  • TABLE 18
    Fatty Acid Composition (% Total Fatty Acids) In Yarrowia Transformants (Experiment 2)
    % % % % % % Δ12 % Δ15 % Δ15/Δ12
    Host Plasmid Desaturase 16:0 16:1 18:0 18:1 LA ALA SC SC SC
    WT pY6 empty vector avg 10.1 9.4 2.4 28.4 36.90 0.00 56.5 0.0
    SD 0.2 0.3 0.1 1.1 1.8 0.0
    WT pY28 Yl D12d WT avg 10.5 5.1 2.0 14.4 51.30 1.90 78.7 3.6 0.045
    SD 0.0 0.5 0.3 1.7 3.0 0.2
    WT pY127 Yld12 V118F mutant avg 11.0 9.8 2.2 22.9 45.70 0.10 66.7 0.2 0.003
    SD 1.0 1.2 0.4 5.1 8.8 0.1
    WT pY128 Yld12 V118I mutant avg 10.4 4.9 1.4 12.2 50.80 9.70 83.2 16.0 0.193
    SD 0.2 0.1 0.1 0.4 0.2 0.2
    WT pY129 Ma D12d avg 10.9 6.1 2.2 12.8 54.60 0.80 81.2 1.4 0.018
    SD 0.3 0.8 0.8 1.5 3.7 0.5
    d12KO pY6 empty vector avg 6.7 10.8 2.1 71.4 0.000 0.000 0.0
    SD 0.3 0.3 0.3 1.2 0.0 0.0 0.0
    d12KO pY28 Yl D12d WT avg 9.8 7.1 2.3 27.9 44.97 1.14 62.3 2.5 0.040
    SD 0.1 0.0 0.3 1.0 1.3 0.0 1.5 0.0
    d12KO pY127 Yld12 V118F mutant avg 5.8 12.5 1.4 70.0 0.000 0.000 0.0
    SD 0.4 0.9 0.2 0.9 0.0 0.0 0.0
    d12KO pY128 Yld12 V118I mutant avg 9.3 7.2 1.9 31.3 37.10 6.35 58.2 14.6 0.251
    SD 0.3 0.1 0.1 0.6 0.8 0.4 1.1 0.5
    d12KO pY129 Ma D12d avg 11.6 6.0 3.5 22.9 49.53 1.15 68.9 2.3 0.033
    SD 0.2 0.1 0.2 0.5 0.8 0.0 0.8 0.0
  • Results in Table 17 showed that the I119V mutation in the monofunctional Δ15 (ω3) desaturase of Saccharomyces kluyveri reduced Δ15 desaturase conversion efficiency (SC) by ca. 17% without detectable Δ12 desaturase activity.
  • Results in Tables 17 and 18 showed that WT and d12KO Yarrowia transformed with empty vector lack detectable ALA. Thus, expression of the native chromosomal Yl.d12 gene results in an apparently monofunctional Δ12 desaturase, i.e., without detectable Δ15 desaturase activity. However, WT and d12KO Yarrowia transformed with pY28 (Yl.d12 WT) showed traces of ALA, as confirmed by GC-MS. Thus, plasmid-based expression of the Yl.d12 ORF under control of the GPD promoter in Yarrowia resulted in a bifunctional Δ12 desaturase, i.e., with trace Δ15 desaturase activity. It is likely that overexpression of Yl.d12 desaturase confers or reveals Δ12/Δ15 bifunctional desaturase activity to an apparently monofunctional Δ12 desaturase enzyme. Applicants postulate that all fungal Δ12 desaturases that appear monofunctional in their native species are bifunctional when so overexpressed. This postulate is also supported by the expression of the Mortierella alpina Δ12 desaturase (GenBank Accession No. AF417244) that appears monofunctional under its native promoter (Sakuradani, E. et al., European J. Biochem., 261(3):812-820 (1999)) and bifunctional when overexpressed in Y. lipolytica under the control of the Y. lipolytica GPD promoter in plasmid pY129 (Table 18).
  • Nevertheless, results in Tables 17 and 18 showed that, as expected, transformants of plasmid pY128 carrying Yl.d12 V118I mutant demonstrated improved Δ15/Δ12 SC compared to transformants carrying the parental control plasmid, pY28. For example, d12KO transformant carrying plasmid pY128 showed 6.3 fold improvement in Δ15/Δ12 specificity (Δ15/Δ12 SC) over that of pY28 (Table 18). Thus, this result with the Yl.d12 V118I mutant is qualitatively similar to that of the Fm.d12 V151I mutant (Example 4), which showed ca. 4 fold improvement in Δ15/Δ12 specificity.
  • Results showed no Δ12 desaturase activity in the d12KO strain transformed with plasmid pY127 carrying the Yl.d12 V118F mutant; thus, residue 118 of Yl.d12 desaturase is important for enzyme activity.
  • Modification of Δ12/Δ15 desaturase-like polypeptides having Δ12 and/or Δ15 desaturase activity could be achieved using the methodology described in the present Example in e.g., An.d12 (SEQ ID NO:51), Mg.d12 (SEQ ID NO:53), Nc.d12 (SEQ ID NO:55), Fg.d12 (SEQ ID NO:57), Ma.d12 (SEQ ID NO:59), Sk.d12 (SEQ ID NO:61), Kl.d12 (SEQ ID NO:63), Ca.d12 (SEQ ID NO:65), Cg.d12 (SEQ ID NO:67), Ct.d12 (SEQ ID NO:69), Cl.d12 (SEQ ID NO:71), Dh.d12 (SEQ ID NO:73), Af.d12 (SEQ ID NO:75), Ao.d12 (SEQ ID NO:77), Chg.d12 (SEQ ID NO:79), An.d15 (SEQ ID NO:52), Mg.d15 (SEQ ID NO:54), Nc.d15 (SEQ ID NO:56), Fg.d15 (SEQ ID NO:58), Ma.d15 (SEQ ID NO:60), Kl.d15 (SEQ ID NO:64), Ca.d15 (SEQ ID NO:66), Cg.d15 (SEQ ID NO:68), Ct.d15 (SEQ ID NO:70), Cl.d15 (SEQ ID NO:72), Dh.d15 (SEQ ID NO:74), Af.d15 (SEQ ID NO:76), Ao.d15 (SEQ ID NO:78), Chg.d15 (SEQ ID NO:80), Ro.d12 (SEQ ID NO:94), Cc.d12 (SEQ ID NO:86), Mc.d12 (SEQ ID NO:92), Mr.d12 (SEQ ID NO:93) and/or Cn.d12 (SEQ ID NO:87), or wild type enzymes, mutant enzymes, codon-optimized enzymes or homologs thereof.

Claims (42)

1. A fungal Δ12 desaturase motif having an amino acid sequence as set forth in SEQ ID NO:5.
2. The motif of claim 1 having an amino acid sequence as set forth in SEQ ID NO:4.
3. The motif of claim 1 having an amino acid sequence as set forth in SEQ ID NO:3.
4. A fungal Δ15 desaturase motif having an amino acid sequence as set forth in SEQ ID NO:48.
5. The motif of claim 4 having an amino acid sequence as set forth in SEQ ID NO:47.
6. The motif of claim 4 having an amino acid sequence as set forth in SEQ ID NO:46.
7. A nucleic acid molecule encoding the fungal Δ12 desaturase motif of claim 1.
8. A nucleic acid molecule encoding the fungal Δ15 desaturase motif of claim 4.
9. A method for identifying a fungal polypeptide having Δ12 desaturase activity from a pool of Δ12/Δ15 desaturase-like polypeptides comprising:
a) identifying a fungal Δ12/Δ15 desaturase-like polypeptide; and,
b) confirming the presence of a Δ12 desaturase motif in the Δ12/Δ15 desaturase-like polypeptide, wherein the Δ12 desaturase motif is selected from the group consisting of SEQ ID NOs:3, 4 and 5, and wherein the presence of the Δ12 desaturase motif is indicative of Δ12 desaturase activity.
10. The method of claim 9 wherein the fungal Δ12/Δ15 desaturase-like polypeptide has either Δ12 desaturase activity or Δ15 desaturase activity.
11. The method of claim 9 wherein the fungal Δ12/Δ15 desaturase-like polypeptide has at least 27.3% identity with a known fungal Δ15 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.
12. The method of claim 9 wherein the fungal Δ12/Δ15 polypeptide has at least 24.0% identity with a known fungal Δ12 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.
13. A method for identifying a fungal polypeptide having Δ15 desaturase activity from a pool of Δ12/Δ15 desaturase-like polypeptides comprising:
a) identifying a fungal Δ12/Δ15 desaturase-like polypeptide; and
b) confirming the presence of a Δ15 desaturase motif in the Δ12/Δ15 desaturase-like polypeptide, wherein the Δ15 desaturase motif is selected from the group consisting of SEQ ID NOs:46, 47 and 48, and wherein the presence of the Δ15 desaturase motif is indicative of Δ15 desaturase activity.
14. The method of claim 13 wherein the fungal Δ12/Δ15 desaturase-like polypeptide has either Δ12 or Δ15 desaturase activity.
15. The method of claim 13 wherein the fungal Δ12/Δ15 desaturase-like polypeptide has at least 31.8% identity with a known fungal Δ15 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.
16. The method of claim 13 wherein the fungal Δ12/Δ15 desaturase-like polypeptide of fungal origin has at least 27.3% identity with a known fungal Δ12 desaturase based on the Clustal W method of alignment, using the default parameters of GAP PENALTY=10, GAP LENGTH PENALTY=0.1, and Gonnet 250 series of protein weight matrix.
17. An isolated fungal polypeptide having Δ 12 desaturase activity isolated by the method of claim 9, excluding those Δ12 desaturase polypeptides isolated from species selected from the following: Saccharomyces kluyveri, Mortierella alpina, Fusarium graminearum, Fusarium moniliforme, Magnaporthe grisea, Neurospora crassa, Aspergillus nidulans, Mortierella isabellina, Pichia pastoris, Aspergillus parasiticus, Cryptococcus curvatus, Saprolegnia diclina, Yarrowia lipolytica, Lentinula edodes, Mucor circinelloides, Mucor rouxii, Rhizopus oryzae, Botrytis cinerea and Aspergillus flavus.
18. An isolated fungal polypeptide having Δ15 desaturase activity isolated by the method of claim 13, excluding those Δ15 desaturase polypeptides isolated from species selected from the following: Saccharomyces kluyveri, Mortierella alpina, Aspergillus nidulans, Neurospora crassa, Fusarium graminearum, Fusarium moniliforme and Magnaporthe grisea.
19. A method of obtaining a nucleic acid fragment encoding a Δ12 desaturase enzyme comprising:
a) probing a fungal genomic library with an isolated nucleic acid molecule encoding a Fungal Δ12 Desaturase Motif selected from the group consisting of SEQ ID NOs:3, 4 and 5;
b) identifying a DNA clone that hybridizes with the isolated nucleic acid molecule encoding a Fungal Δ12 Desaturase Motif of step (a); and,
c) sequencing the genomic fragment that comprises the clone identified in step (b);
wherein the sequenced genomic fragment encodes a Δ12 desaturase enzyme.
20. A method of obtaining a nucleic acid fragment encoding a Δ12 desaturase enzyme comprising:
a) providing a fungal genomic library;
b) synthesizing at least one oligonucleotide primer corresponding to a portion of an isolated nucleic acid molecule encoding a Fungal Δ12 Desaturase Motif selected from the group consisting of SEQ ID NOs:3, 4 and 5; and,
c) performing primer directed amplification on the genomic library of (a) with the primers of (b) to obtain amplification products wherein the amplification products encode a portion of an amino acid sequence encoding a Δ12 desaturase enzyme.
21. A method of obtaining a nucleic acid fragment encoding a Δ15 desaturase enzyme comprising:
a) probing a fungal genomic library with an isolated nucleic acid molecule encoding a Fungal Δ15 Desaturase Motif selected from the group consisting of SEQ ID NOs:46, 47 and 48;
b) identifying a DNA clone that hybridizes with the isolated nucleic acid molecule encoding a Fungal Δ15 Desaturase Motif of step (a); and,
c) sequencing the genomic fragment that comprises the clone identified in step (b) wherein the sequenced genomic fragment encodes a Δ15 desaturase enzyme.
22. A method of obtaining a nucleic acid fragment encoding a Δ15 desaturase enzyme comprising:
a) providing a fungal genomic library;
b) synthesizing at least one oligonucleotide primer corresponding to a portion of an isolated nucleic acid molecule encoding a Fungal Δ15 Desaturase Motif selected from the group consisting of SEQ ID NOs:46, 47 and 48; and,
c) performing primer directed amplification on the genomic library of (a) with the primers of (b) to obtain amplification products wherein the amplification products encode a portion of an amino acid sequence encoding a Δ15 desaturase enzyme.
23. An isolated fungal nucleic acid molecule encoding a polypeptide having Δ12 desaturase activity isolated by the method of either of claims 19 or 20, excluding nucleic acid molecules having Δ12 desaturase activity isolated from species selected from the following: Saccharomyces kluyveri, Mortierella alpina, Fusarium graminearum, Fusarium moniliforme, Magnaporthe grisea, Neurospora crassa, Aspergillus nidulans, Mortierella isabellina, Pichia pastoris, Aspergillus parasiticus, Cryptococcus curvatus, Saprolegnia diclina, Yarrowia lipolytica, Lentinula edodes, Mucor circinelloides, Mucor rouxii, Rhizopus oryzae, Botrytis cinerea and Aspergillus flavus.
24. An isolated fungal nucleic acid molecule encoding a polypeptide having Δ15 desaturase activity isolated by the method of either of claims 21 or 22 excluding nucleic acid molecules having Δ15 desaturase activity isolated from species selected from the following: Saccharomyces kluyveri, Mortierella alpina, Aspergillus nidulans, Neurospora crassa, Fusarium graminearum, Fusarium moniliforme and Magnaporthe grisea.
25. A method for increasing the ability of a bifunctional fungal Δ15 desaturase enzyme to act on a Δ12 desaturase substrate comprising:
a) providing a nucleic acid molecule encoding a polypeptide having bifunctional Δ15 desaturase activity and comprising a Δ15 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:46, 47 and 48, wherein each of the motif sequences comprises an isoleucine at amino acid residue 4; and,
b) altering the nucleic acid molecule of (a) such that it encodes a mutant polypeptide comprising a mutant Δ15 desaturase motif of (a) wherein the isoleucine at amino acid residue 4 is replaced with valine, wherein the mutant polypeptide has an increased ability to act on a Δ12 desaturase substrate.
26. A method for increasing the ability of a bifunctional fungal Δ12 desaturase enzyme to act on a Δ15 desaturase substrate comprising:
a) providing a nucleic acid molecule encoding a polypeptide having bifunctional Δ12 desaturase activity and comprising a Δ12 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4 and 5, wherein each of the motif sequences comprises a valine at amino acid residue 4; and,
b) altering the nucleic acid molecule of (a) such that it encodes a mutant polypeptide comprising a mutant Δ12 desaturase motif of (a) wherein the valine at amino acid residue 4 is replaced with isoleucine, wherein the mutant polypeptide has an increased ability to act on a Δ15 desaturase substrate.
27. A method for the production of linoleic acid comprising:
a) providing a host cell comprising:
i) an isolated nucleic acid fragment encoding a polypeptide having Δ12 desaturase activity and comprising a Δ12 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:3, 4 and 5; and,
ii) a source of oleic acid;
b) growing the host cell of step (a) under conditions wherein the nucleic acid fragment encoding the desaturase polypeptide is expressed and the oleic acid is converted to linoleic acid; and,
c.) optionally recovering the linoleic acid of step (b).
28. A method according to claim 27 wherein the isolated nucleic acid fragment encoding the desaturase polypeptide is selected from the group consisting of:
a.) a polypeptide selected from the group consisting of: SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:91 and SEQ ID NO:87; and,
b.) a polypeptide whose amino acid sequence is selected from the group consisting of the following genomic sequence ORFs:
i.) [SEQ ID NO:67];
ii.) [SEQ ID NO:69]; and
iii.) [SEQ ID NO:71].
29. A method for the production of α-linolenic acid comprising:
a.) providing a host cell comprising:
i.) an isolated nucleic acid fragment encoding a polypeptide having Δ15 desaturase activity and comprising a Δ15 desaturase motif having an amino acid sequence selected from the group consisting of SEQ ID NOs:46, 47 and 48; and,
ii.) a source of linoleic acid;
b.) growing the host cell of step (a) under conditions wherein the nucleic acid fragment encoding the desaturase polypeptide is expressed and the linoleic acid is converted to α-linolenic acid; and,
c.) optionally recovering the α-linolenic acid of step (b).
30. A method according to claim 29 wherein the isolated nucleic acid fragment encoding the desaturase polypeptide is selected from the group consisting of:
a.) a polypeptide selected from the group consisting of SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78 and SEQ ID NO:80; and,
b.) a polypeptide whose amino acid sequence is selected from the group consisting of the following genomic sequence ORFs:
i.) [SEQ ID NO:68];
ii.) [SEQ ID NO:70]; and,
iii.) [SEQ ID NO:72].
31. A method according to claim 29 wherein the desaturase polypeptide having Δ15 desaturase activity binds both oleic acid and linoleic acid as enzymatic substrates.
32. A method according to either of claims 27 or 29 wherein the host cell is an oleaginous yeast.
33. A method according to claim 32 wherein the oleaginous yeast is selected from the group consisting of: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces.
34. A method according to claim 33 wherein the Yarrowia is selected from the group consisting of: Yarrowia lipolytica ATCC #20362, Yarrowia lipolytica ATCC #8862, Yarrowia lipolytica ATCC #18944, Yarrowia lipolytica ATCC #76982 and Yarrowia lipolytica LGAM S(7)1.
35. A method for identifying a polynucleotide sequence encoding a fungal polypeptide having Δ15 desaturase activity comprising:
a) providing at least one polynucleotide sequence encoding a Δ15 desaturase motif selected from the group consisting of SEQ ID NOs:46, 47 and 48, on a computer-readable format;
b) comparing, on the computer-readable format, the at least one polynucleotide sequence of (a) with at least one polynucleotide sequence from at least one fungal genome; and,
c) identifying a fungal sequence comprising the at least one polynucleotide sequence encoding a Δ15 desaturase motif;
wherein the fungal sequence of (c) comprising the at least one polynucleotide sequences encoding a Δ15 desaturase motif encodes a Δ15 desaturase polypeptide having Δ15 desaturase activity.
36. A method according to claim 35 wherein the at least one polynucleotide sequence from at least one fungal genome are comprised of sequences encoding fungal Δ12/Δ15 desaturase-like polypeptides.
37. A method for identifying an amino acid sequence of a fungal polypeptide having Δ15 desaturase activity comprising:
a) providing at least one amino acid sequence of a Δ15 desaturase motif selected from the group consisting of SEQ ID NOs:46, 47 and 48, on a computer-readable format;
b) comparing, on the computer-readable format, the at least one amino acid sequence of (a) with at least one amino acid sequence from at least one fungal genome;
c) identifying a fungal sequence comprising the at least one amino acid sequence of a Δ15 desaturase motif;
wherein the fungal sequence of (c) comprising the at least one amino acid sequence of a Δ15 desaturase motif defines a Δ15 desaturase polypeptide having Δ15 desaturase activity.
38. A method according to claim 37 wherein the at least one amino acid sequence from at least one fungal genome are comprised of sequences defining fungal Δ12/Δ15 desaturase-like polypeptides.
39. A method for identifying a polynucleotide sequence encoding a fungal polypeptide having Δ12 desaturase activity comprising:
a) providing at least one polynucleotide sequence encoding a Δ12 desaturase motif selected from the group consisting of SEQ ID NOs:3, 4 and 5, on a computer-readable format;
b) comparing, on the computer-readable format, the at least one polynucleotide sequence of (a) with at least one polynucleotide sequence from at least one fungal genome; and,
c) identifying a fungal sequence comprising the at least one polynucleotide sequence encoding a Δ12 desaturase motif;
wherein the fungal sequence of (c) comprising the at least one polynucleotide sequences encoding a Δ12 desaturase motif encodes a Δ12 desaturase polypeptide having Δ12 desaturase activity.
40. A method according to claim 39 wherein the at least one polynucleotide sequence from at least one fungal genome are comprised of sequences encoding fungal Δ12/Δ15 desaturase-like polypeptides.
41. A method for identifying an amino acid sequence of a fungal polypeptide having Δ12 desaturase activity comprising:
a) providing at least one amino acid sequence of a Δ12 desaturase motif selected from the group consisting of SEQ ID NOs:3, 4 and 5, on a computer-readable format;
b) comparing, on the computer-readable format, the at least one amino acid sequence of (a) with at least one amino acid sequence from at least one fungal genome;
c) identifying a fungal sequence comprising the at least one amino acid sequence of a Δ12 desaturase motif;
wherein the fungal sequence of (c) comprising the at least one amino acid sequence of a Δ12 desaturase motif defines a Δ12 desaturase polypeptide having Δ12 desaturase activity.
42. A method according to claim 41 wherein the at least one amino acid sequence of at least one fungal genome are comprised of sequences defining fungal Δ12/Δ15 desaturase-like polypeptides.
US11/740,298 2006-05-01 2007-04-26 Fungal delta 12 desaturase and delta 15 desaturase motifs Abandoned US20070254299A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/740,298 US20070254299A1 (en) 2006-05-01 2007-04-26 Fungal delta 12 desaturase and delta 15 desaturase motifs
US12/396,845 US9057083B2 (en) 2006-05-01 2009-03-03 Fungal Δ-12 desaturase and Δ-15 desaturase motifs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79663706P 2006-05-01 2006-05-01
US11/740,298 US20070254299A1 (en) 2006-05-01 2007-04-26 Fungal delta 12 desaturase and delta 15 desaturase motifs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/396,845 Division US9057083B2 (en) 2006-05-01 2009-03-03 Fungal Δ-12 desaturase and Δ-15 desaturase motifs

Publications (1)

Publication Number Publication Date
US20070254299A1 true US20070254299A1 (en) 2007-11-01

Family

ID=38657554

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/740,298 Abandoned US20070254299A1 (en) 2006-05-01 2007-04-26 Fungal delta 12 desaturase and delta 15 desaturase motifs
US12/396,845 Expired - Fee Related US9057083B2 (en) 2006-05-01 2009-03-03 Fungal Δ-12 desaturase and Δ-15 desaturase motifs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/396,845 Expired - Fee Related US9057083B2 (en) 2006-05-01 2009-03-03 Fungal Δ-12 desaturase and Δ-15 desaturase motifs

Country Status (3)

Country Link
US (2) US20070254299A1 (en)
EP (1) EP2013335A2 (en)
WO (1) WO2007133425A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297713A1 (en) * 2006-12-07 2010-11-25 E. I. Du Pont De Nemours And Company Mutant delta-8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids
US8722910B2 (en) 2009-07-10 2014-05-13 Evolva Ag Diyne compositions
WO2014100061A1 (en) 2012-12-21 2014-06-26 E. I. Du Pont De Nemours And Company Down-regulation of a polynucleotide encoding a sou2 sorbitol utilization protein to modify lipid production in microbial cells
CN104894146A (en) * 2015-05-26 2015-09-09 昆明理工大学 Novel application of delta12-fatty acid desaturase gene
AU2009286755B2 (en) * 2008-08-26 2015-10-22 Basf Plant Science Gmbh Nucleic acids encoding desaturases and modified plant oil

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185184A2 (en) 2012-06-15 2013-12-19 Commonwealth Scientific And Industrial Research Organisation Production of long chain polyunsaturated fatty acids in plant cells
WO2015001505A2 (en) 2013-07-05 2015-01-08 Basf Plant Science Company Gmbh Gene expression or activity enhancing elements
EP3083949B1 (en) 2013-12-17 2020-02-12 BASF Plant Science Company GmbH Methods for conversion of the substrate specificity of desaturases
WO2015196250A1 (en) 2014-06-27 2015-12-30 Commonwealth Scientific And Industrial Research Organisation Lipid comprising docosapentaenoic acid
JP6726619B2 (en) 2013-12-18 2020-07-22 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション Lipids containing long-chain polyunsaturated fatty acids
WO2015184277A1 (en) 2014-05-29 2015-12-03 Novogy, Inc. Increasing lipid production and optimizing lipid composition

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952544A (en) * 1991-12-04 1999-09-14 E. I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US6342658B1 (en) * 1995-12-14 2002-01-29 Cargill, Incorporated Fatty acid desaturases and mutant sequences thereof
US20030196217A1 (en) * 2002-01-30 2003-10-16 Pradip Mukerji Desaturase genes, enzymes encoded thereby, and uses thereof
US20060156435A1 (en) * 2002-05-22 2006-07-13 Monsanto Technology, Llc Fatty acid desaturases from fungi
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
US7189559B2 (en) * 2004-11-04 2007-03-13 E. I. Du Pont De Nemours And Company Mortierella alpina lysophosphatidic acid acyltransferase homolog for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms
US7192762B2 (en) * 2004-11-04 2007-03-20 E. I. Du Pont De Nemours And Company Mortierella alpina glycerol-3-phosphate o-acyltransferase for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms
US7198937B2 (en) * 2004-11-04 2007-04-03 E. I. Du Pont De Nemours And Company Mortierella alpina diacylglycerol acyltransferase for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms
US7202356B2 (en) * 2003-11-14 2007-04-10 E. I. Du Pont De Nemours And Company Fructose-bisphosphate aldolase regulatory sequences for gene expression in oleaginous yeast

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7238482B2 (en) 2003-05-07 2007-07-03 E. I. Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
US7504259B2 (en) 2003-11-12 2009-03-17 E. I. Du Pont De Nemours And Company Δ12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast
CA2542574C (en) 2003-11-12 2014-03-18 E. I. Du Pont De Nemours And Company Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous plants and yeast
CA2559360A1 (en) 2004-02-27 2005-09-09 Basf Plant Science Gmbh Method for producing c18, c20 and c22 polyunsaturated fatty acids in transgenic plants
JP4587451B2 (en) 2004-08-20 2010-11-24 サントリーホールディングス株式会社 Polypeptide having ω3 fatty acid desaturation activity, polynucleotide encoding the polypeptide, and use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952544A (en) * 1991-12-04 1999-09-14 E. I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US6342658B1 (en) * 1995-12-14 2002-01-29 Cargill, Incorporated Fatty acid desaturases and mutant sequences thereof
US20030196217A1 (en) * 2002-01-30 2003-10-16 Pradip Mukerji Desaturase genes, enzymes encoded thereby, and uses thereof
US20060156435A1 (en) * 2002-05-22 2006-07-13 Monsanto Technology, Llc Fatty acid desaturases from fungi
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
US7202356B2 (en) * 2003-11-14 2007-04-10 E. I. Du Pont De Nemours And Company Fructose-bisphosphate aldolase regulatory sequences for gene expression in oleaginous yeast
US7189559B2 (en) * 2004-11-04 2007-03-13 E. I. Du Pont De Nemours And Company Mortierella alpina lysophosphatidic acid acyltransferase homolog for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms
US7192762B2 (en) * 2004-11-04 2007-03-20 E. I. Du Pont De Nemours And Company Mortierella alpina glycerol-3-phosphate o-acyltransferase for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms
US7198937B2 (en) * 2004-11-04 2007-04-03 E. I. Du Pont De Nemours And Company Mortierella alpina diacylglycerol acyltransferase for alteration of polyunsaturated fatty acids and oil content in oleaginous organisms

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297713A1 (en) * 2006-12-07 2010-11-25 E. I. Du Pont De Nemours And Company Mutant delta-8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids
US8026089B2 (en) 2006-12-07 2011-09-27 E.I. Du Pont De Nemours And Company Mutant Δ8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids
AU2009286755B2 (en) * 2008-08-26 2015-10-22 Basf Plant Science Gmbh Nucleic acids encoding desaturases and modified plant oil
US8722910B2 (en) 2009-07-10 2014-05-13 Evolva Ag Diyne compositions
WO2014100061A1 (en) 2012-12-21 2014-06-26 E. I. Du Pont De Nemours And Company Down-regulation of a polynucleotide encoding a sou2 sorbitol utilization protein to modify lipid production in microbial cells
CN104894146A (en) * 2015-05-26 2015-09-09 昆明理工大学 Novel application of delta12-fatty acid desaturase gene

Also Published As

Publication number Publication date
US9057083B2 (en) 2015-06-16
WO2007133425A3 (en) 2008-05-15
WO2007133425A2 (en) 2007-11-22
US20090186362A1 (en) 2009-07-23
EP2013335A2 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
US7678560B2 (en) Δ 5 desaturase and its use in making polyunsaturated fatty acids
US9057083B2 (en) Fungal Δ-12 desaturase and Δ-15 desaturase motifs
US7695950B2 (en) Δ5 desaturase and its use in making polyunsaturated fatty acids
US8241884B2 (en) Δ17 desaturase and its use in making polyunsaturated fatty acids
US8119784B2 (en) Delta-4 desaturase and its use in making polyunsaturated fatty acids
US7465793B2 (en) Synthetic Δ17 desaturase derived from Phytophthora ramourum and its use in making polyunsaturated fatty acids
WO2008073271A1 (en) Mutant delta8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids
US7923223B2 (en) Δ-9 desaturase and its use in making polyunsaturated fatty acids
US8148121B2 (en) Δ6 desaturases and their use in making polyunsaturated fatty acids

Legal Events

Date Code Title Description
AS Assignment

Owner name: E. I. DU PONT DE NEMOURS AND COMPANY, DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YADAV, NARENDRA S.;ZHANG, HONGXIANG;REEL/FRAME:019406/0345

Effective date: 20070524

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION